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  2Abstract 
This thesis explores the use of early MRI in prognosis and diagnosis in patients 
presenting with a clinically isolated syndrome (CIS) characteristic of demyelination. 
This has been investigated in a cohort recruited within 3 months of CIS onset between 
1995 and 2004 and followed up clinically and with MRI (planned at 3 months, 1,3 
and 5 years).   
 
Current MRI criteria are highly specific for the development of clinically definite 
multiple sclerosis (CDMS) but have limited sensitivity and are complex. Presented is 
the evaluation of simplified MRI criteria in my London CIS cohort and in a 
multicentre CIS cohort. Results from the presented studies show that the MRI criteria 
can be simplified (dissemination in space: 2 or more lesions in separate but 
characteristic locations, dissemination in time: an early new T2 lesion) and still 
maintain high specificity, with improved sensitivity and accuracy.  
 
The prognostic role of early MRI was investigated in the optic neuritis (ON) 
subgroup, as 80% of my cohort presented with ON and some studies have suggested 
that such a presentation is associated with more benign disease. Whereas baseline 
lesion number significantly predicted conversion to CDMS and increased disability at 
5 years, other MRI parameters, namely baseline lesion location (periventricular 
lesions increasing the hazard of CDMS and spinal cord and infratentorial lesions 
increasing the odds of greater disability at 5 years) and lesion activity (new T2 lesion 
at 3 month follow-up), were stronger predictors. No non-conventional MRI 
parameters (spectroscopy, magnetisation transfer ratio or atrophy measures) had a 
significant prognostic role.  
 
Overall early MRI findings can aid diagnosis and help identify the CIS patients at 
greatest risk of conversion to CDMS and subsequent disability, which in turn can help 
direct treatment and clinical follow-up in specialist MS clinics. 
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1. Introduction 
Multiple sclerosis is an inflammatory, autoimmune disorder of the CNS causing 
disability in young adults.  It is thought to be a T cell-mediated autoimmune disease 
precipitated by as yet unidentified environmental triggers in a genetically susceptible 
person. Macrophages, B cells and autoantibodies to myelin antigens [1] some of 
which have high affinity, are also involved but whether their presence is a result of the 
destruction or causal is not clear.  Previously thought to be a disease of white matter 
with loss of myelin only, recent work has shown extensive grey matter involvement 
and loss of axons.   
 
1.1 Aetiology of multiple sclerosis 
1.1.1 Genetics 
The role of genetic susceptibility is apparent from work such as the Canadian 
Collaborative Study.  Results have shown that family members of MS patients have 
greater disease risk than the general population: monozygotic twins have about 30% 
concordance compared with about 5% in dizygotic twins.  The risk of MS in offspring 
of two parents with the disease is significantly higher than for offspring with only one 
parent (30.5% vs 2.5%) [2].  Full siblings have roughly twice the risk of disease than 
half siblings (3.5% vs 1.9%) and adopted individuals the same risk as the general 
population. In families with two or more first degree relatives with MS the disease 
subtype shows concordance between siblings (but not parent-child) but clinical 
severity was not concordant [3]. These studies indicate that familial aggregation of 
MS is due to sharing of genes rather than environment.   
 
MS susceptibility is polygenic and associated with normal polymorphisms rather than 
genetic mutations.  As in other autoimmune diseases, MHC shows the strongest 
association, and varies with different populations.  The extended HLA-DR15 
haplotype, particularly the HLA DRB1*1501 allele, has been closely associated with 
MS in Caucasian patients of northern European heritage [4-6], whereas HLA 
DPB1*0501 has been associated with the optical-spinal variant in Japan [6].   
However the strong linkage disequilibrium occurring in the MHC region makes it 
  17hard to determine whether these alleles or others linked to them are the major 
candidates. 
 
Apart from being associated with a younger age of onset [7, 8], the DR15 haplotype 
has not been shown to affect phenotype, and no association has been found with 
disease course, type or outcome.  
 
 
1.1.2 Epidemiology 
MS affects twice as many females as it does males, and over time this difference 
appears to be expanding with a disproportionate increase in incidence in women over 
the last hundred years [9].  The reason for female predominance in autoimmune 
disease is not understood.  Androgens tend to be immunosuppressive [10] whereas 
oestradiol has been shown to enhance the secretion of γIFN from CD4
+ T cells in 
vitro  [11], thus sex hormones may influence the susceptibility to autoreactivity. 
However no overwhelming evidence has been provided to support this.   
 
Disease risk varies geographically.  The comparison of prevalence studies from 
different areas is limited by variation in population demographics, regional medical 
services and survey diagnostic criteria.  A geographical relation of the disease was 
proposed by Kurtzke who observed a variation in disease frequency with latitude and 
described high risk countries with frequency greater than 80/100,000 [12] (northern 
Europe, northern United States, southern Canada, New Zealand and southern 
Australia), medium risk with frequency 30-80/100,000 (southern Europe, South 
America and the rest of Australia) and low risk with frequency less than 30/100,000 
(Africa and Asia) [13], see Figure 1.1.   
 
  18Figure 1.1 World distribution of multiple sclerosis 
 
 
The risk of MS is low in distinct ethnic and racial groups such as African blacks, New 
Zealand Maoris, Chinese, Japanese and Amerindians.  Thus European colonisation 
may partly explain these high risk areas with white Caucasians at greater risk than 
ethnic and racial groups sharing the same environment but different gene pool.  Sicily 
and Sardinia have high incidences that do not match regions of similar latitude [14] 
which may be due to unusually high frequency of rare HLA alleles. Thus the 
geographic distribution of MS may reflect the migration of genetically susceptible 
alleles. 
 
However a clear relationship has been observed between increasing latitude and 
increasing prevalence in Australia, with prevalence increasing from 12 per 100,000 in 
Northern Queenstown to 76 per 100,000 in Hobart, Tasmania [15] with no substantial 
differences in the distribution of individual countries of origin of the migrant 
population. This evidence, along with immigration studies, supports an environmental 
role.  Although immigrants from low to high risk areas retain the low risk of their 
country of origin [16], their children have similar risk to children born in that country 
[17].  Migration within the USA from high to low risk areas gave migrants an 
intermediate risk [18]. Such rapid changes in risk over a single generation implicate 
environmental factors in MS aetiology.  The age of migration was important.   
Younger children migrating developed the high risk of the destination country 
  19whereas older teenagers retained the low risk of the country of origin indicating that 
risk of disease is established in the first two decades in life [19].   
 
There is likely to be a long latency between exposure to environmental agents and 
symptom onset making determination of causal factors difficult. Possible factors in 
the aetiology of MS include exposure to sunlight, and studies suggest an inverse 
correlation between sunlight exposure and disease risk [20].  More recently mortality 
from MS was negatively associated with exposure to sunlight [21], and greater levels 
of actinic skin damage were associated with decreased risk of MS [22].  Vitamin D 
receptors are present on activated T cells and the most potent vitamin D metabolite 
inhibits IL2, thus interfering with T cell expansion and potentially autoreactivity [23]. 
Vitamin D enters cell nuclei bound to the receptor and acts on the promoter region of 
certain genes via a vitamin D response element (VDRE), of which there are several 
providing a spectrum of binding affinities for vitamin D. A functioning VDRE has 
recently been identified next to the HLA DRB1 gene, and has been shown to be 
highly conserved in the HLA DRB1*1501 haplotype but not so among non-MS 
associated haplotypes. This study implies direct interactions between vitamin D (a 
strong candidate in determining MS risk) and HLA DRB1 (the main susceptibility 
locus for MS) [24].   
 
Other putative causal agents include infections or vaccinations, however no consistent 
association has been found for any virus or vaccination in MS aetiology.  Epstein Barr 
virus (EBV) has long been touted as a causative agent, and a recent meta-analysis of 
14 studies confirmed it as a risk factor for MS [25].  About 90% of healthy adults 
have evidence of persistent EBV infection compared with nearly 100% of MS adult 
patients.  T cells from MS patients show a stronger immune response to EBV nuclear 
antigen compared to seropositive controls [26].  The virus, mostly quiescent in B 
cells, sheds periodically and could explain the relapsing-remitting pattern of the 
disease.  EBV contains a pentapeptide sequence homologous to myelin basic protein, 
providing a substrate for molecular mimicry (although this is not unique to EBV). 
Chlamydia pneumoniae [27] and human herpes virus 6 [28] are recent yet 
unsubstantiated candidates.  
 
  20The evidence is confusing, but it is clear that MS aetiology is multifactorial with 
environmental factor(s) acting at a population level and genes determining relative 
familial risk.   
  
1.2 Pathology 
MS is a disease of myelin and axonal loss in the central nervous system.  It is most 
conspicuous in white matter but grey matter involvement has recently become evident 
[29].  There is little information on the pathological changes that occur early in the 
disease, apart from aggressive variants of MS, or on the events preceding the 
destructive inflammatory infiltration.    
 
1.2.1 White matter 
The hallmark of MS pathology is the white matter plaque. Acute white matter lesions, 
found during the relapsing-remitting phase of the disease, tend to be centred around a 
venule and contain blood-borne inflammatory cells: T cells, predominantly CD8
+, and 
activated macrophages (see Figure 1.2) [30].  There is evidence of breakdown of the 
blood brain barrier within acute lesions, believed to be the primary and obligatory 
event in lesion pathogenesis [31].  Inflammatory cells and mediators target myelin-
maintaining, mature oligodendrocytes resulting in complete demyelination. Other 
cells are caught ‘in the cross-fire’ and a variable degree of axonal transection and loss 
is observed.  Macrophages phagocytose myelin debris (appearing laden with lipid on 
histology) and remyelination may then follow.   
 
Figure 1.2 Microscopic appearance of an acute lesion, (i) centred around a venule (red arrow), (ii) 
with lipid laden macrophages in the lesion and at the interface (blue arrows) and (iii) numerous 
perivenous and parenchymal (red arrows) inflammatory cells. Images from University of 
California, San Francisco, MS microscopic pathology. 
(i) (ii) (iii)
 
 
  21Remyelination is patient-dependent. Whereas in most patients it is limited to the edge 
of lesions, in a small percentage it occurs extensively [32]. It is also stage-dependent, 
occurring more frequently early in the disease [33]. Remyelination requires 
recruitment, differentiation and maturation of multipotent progenitor cells, which rely 
on intrinsic factors, intact signalling systems between axons and progenitor cells 
(which in turn require axonal integrity) and a suitable microenvironment. A fault in 
any area would prevent remyelination [33]. For example, myelin debris inhibits 
differentiation and maturation of oligodendrocyte progenitor cells [34], explaining the 
observation that remyelination is more frequent in lesions rich in macrophages [35]. 
Remyelinated plaques have lower myelin density than normal white matter due to 
their disproportionately thin sheaths, explaining their ‘shadow plaque’ appearance 
(see Figure 1.3). 
 
Figure 1.3 Shadow plaques. Section of brain 
stained with luxol fast blue showing areas of 
demyelination (green arrows) and areas of 
remyelination (red arrows) so called shadow 
plaques. Image from Nature Reviews 
Neurosciences, Multiple Sclerosis Pathology 
Recent work looking at a large number of brain biopsies and autopsies from patients 
in the early stage of the disease concluded that there are 4 patterns of acute active 
demyelination:  
pattern I:   T cell and macrophage dominant 
pattern II:   as above but with antibody and complement (most frequent) 
pattern  III:    less inflammation but distal oligodendrocyte pathology and 
apoptosis 
pattern  IV:    rare and seen exclusively in primary progressive MS, again 
suggestive of oligodendrocyte pathology  
 
  22The study concluded that MS was a pathologically heterogeneous condition, with 
individual patients showing only one of the 4 patterns of acute, active plaques 
throughout their disease course [36]. Contrary to this however, Barnett et al 
concluded that the pathology is stage-dependent and that the primary event is 
oligodendrocyte apoptosis with microglial activation and T cell infiltration occurring 
secondary to this [37], however use of steroids for treatment of the acute lesion in 
question may have affected the findings.    
 
In the progressive phase, acute demyelinating lesions are rare.  Most lesions are 
inactive, with astrocytosis and glial scars (see Figure 1.4).  Some pre-existing plaques 
remain chronically active, with a less inflammatory infiltrate forming a ‘smouldering 
rim’ of T cells and activated (resident) microglia.  Active demyelination in chronic 
active plaques is less than in acute plaques with only a few microglia containing 
myelin degradation products. 
Figure 1.4 Microscopic appearance of chronic demyelinated lesions (i) with very little perivenous
inflammation (ii) and astrocytes stained for GFAP (glial fibrillary acidic protein). Images from 
University of California, San Francisco, MS microscopic pathology. 
 
Non lesion white matter, or normal appearing white matter (NAWM), previously 
thought to escape the disease process, has been shown to be highly abnormal in 
autopsy studies [38].  Autopsy studies reveal diffuse inflammation throughout the 
tissue, predominantly CD8
+ T cells and activated microglia, and diffuse axonal injury 
[39]. This pronounced inflammation is not proportional to lesion load, and processes 
other than Wallerian degeneration may be implicated.   
 
1.2.2 Grey matter  
Grey matter involvement, including cortex, deep grey matter and spinal cord, has 
become apparent with more sophisticated immunohistochemical staining techniques. 
  23Its involvement is likely to play a role in cognitive function and disability. Kidd et al 
described 3 main types of cortical lesions [40]: 
 
Type I: juxtacortical involving both grey and white matter (most common type) 
Type II: transcortical confined to the cortex 
Type III: large superficial, subpial lesions 
 
Cortical lesions tend to be sharply demarcated with less lymphocytic infiltration and 
axonal damage than in white matter plaques [40-42]. Some inflammation is observed 
however, notably T cells, plasma cells and microglial activation, as well as transected 
axons and dendrites [41]. Apoptotic loss of neurons are also observed in demyelinated 
cortex [41].  A particular loss of synapses (by nearly 50%) has been reported and this 
loss of dendritic arborisation has been implicated as an important feature of MS 
cortical pathology [43]. Compared to white matter lesions where only about 40% of 
lesions show remyelination, 95% of cortical lesions appear remyelinated, and 
investigation of the normal appearing grey matter revealed evidence of remyelination 
[44], suggesting that cortical lesions are still underestimated. 
 
Grey matter involvement was seen in 88% of chronic MS cases in one study, 
involving on average 16% of the cortex [44].  Cortical lesions are not restricted to the 
progressive phase of the disease and are also observed in early MS, with 37% of 262 
early MS biopsies showing cortical demyelination [42]. 
 
1.2.3 Axonal loss 
Axonal loss has only recently been acknowledged and is thought to contribute to the 
persistent neurological deficits acquired during the progressive phase of the disease.  
Axonal damage has been demonstrated in acute lesions [45], and to a lesser degree in 
the margin and centre of chronic active lesions [46].  Smaller diameter axons seem to 
be more sensitive to damage.  Although axonal transection is not observed in normal 
appearing white matter there is substantial loss of axons in normal appearing white 
matter tracts.  An average axonal loss of 53% in normal appearing corpus callosum 
[47], and reductions in axonal density of 19-42% in lateral corticospinal tracts [48, 
49] was demonstrated in post mortem specimens from MS patients with various 
degrees of functional impairment.  Axonal loss occurs early in the disease, and one 
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of acute axonal damage) were five times denser in acute plaques isolated from 
patients within a year of disease onset than those with disease duration greater than 
10yrs [50].  In a post-mortem study of a patient with a 9 month history of MS, 22% 
axonal loss in descending tracts distal to a terminal brainstem lesion was reported, 
with preservation of other tracts [51].  In this and other studies, myelin staining was 
grossly normal since empty tubes of myelin can persist for some time following 
axonal degeneration, and the white matter can appear normal both pathologically and 
with conventional MRI.   
 
The observation of axonal transection in active lesions points to involvement of 
inflammatory mediators such as proteolytic enzymes, excitotoxins, cytokines and free 
radicals in the destructive process. For example, nitric oxide (NO) and inducible NO 
synthase are found in high levels in acute lesions [52]. NO impairs mitochondrial 
function leading to cellular energy depletion [53]. Another mechanism of axonal 
injury involves the redistribution (across a longer length of axolemma rather than just 
at the nodes of Ranvier) and change in subtype of sodium channels on demyelinated 
axons, demonstrated in acute lesions [54].   The diffuse distribution of channels can 
still support action potential conduction but generates greater energy requirements and 
causes considerably more sodium influx per impulse than in the myelinated state. 
Such persistent sodium influx may then drive reverse Na
+/Ca
2+ exchange culminating 
in the accumulation of calcium and cell death.   
 
As axonal loss is observed in chronic lesions and in patients on immune suppression 
with cessation of clinical and radiological relapses [55], mechanisms independent of 
inflammation may be responsible for ongoing axonal loss. Animal studies have shown 
that oligodendrocytes and some myelin-associated proteins contribute to long-term 
axonal viability thus demyelination may compromise axons [56, 57].  Axonal death 
may lead to degeneration of proximal and distal neurons, with the loss of pre- and 
post-synaptic trophic signals.  Mitochondrial DNA damage acquired in the acute 
inflammatory phase [58] may lead to their production of reactive oxygen species [59] 
creating a cycle of decline in energy metabolism resulting in axonal degeneration 
delayed from the acute inflammatory event.   
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progression.  To overcome axonal loss in the early phase of the disease there is 
evidence of compensatory cortical adaptation with reorganisation of functional 
pathways [60].  Permanent disability of the progressive phase may develop when a 
threshold of axonal loss is reached and the CNS compensatory resources are 
exhausted.    
 
 
1.3 Clinical course and diagnosis 
1.3.1 Presentation 
Eighty five percent of MS patients present with an acute or subacute episode of 
neurological disturbance characteristic of demyelination, known as a clinically 
isolated syndrome (CIS). This completely or partially resolves, and is followed 
months or years later by a second episode, and a diagnosis of relapsing remitting (RR) 
MS. In the remaining 15%, rather than recovering from the first presentation, the 
clinical picture is one of slow progression, so called primary progressive (PP)MS. 
PPMS usually presents as a progressive spinal cord syndrome, but progressive 
cerebellar syndromes, visual loss or dementia are occasionally seen.   
 
In some patients presenting with a CIS, it will remain a monophasic illness, but 50 to 
68% convert to CDMS by 20 years [61-63]. 
 
Peak age of symptom onset in MS is 30 years, typically between 15 and 50. Onset 
after 60 is unusual. Patients with PPMS tend to be older. Twice as many females are 
affected than males, with a higher ratio of males in PPMS. Lesions occur anywhere in 
the CNS, but certain ‘clinically eloquent’ locations, such as the optic nerve, brainstem 
and spinal cord, give rise to symptoms. The most frequent monofocal presentation is 
with long-tract symptoms and signs (46%), followed by optic neuritis (21%) and 
brainstem syndrome (10%) such as internuclear ophthalmoplegia.  Twenty three 
percent present with multifocal abnormalities [64].   
 
PPMS and RRMS differ in their age of onset, gender and clinical course. MRI 
findings, which will be discussed later, are also remarkably different, with PPMS 
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patients. 
 
 
1.3.2 Clinical course 
In the early phase of RRMS, relapses are followed by remission, with complete or 
partial recovery of symptoms. Common relapses include sensory symptoms, limb 
weakness, sphincter dysfunction and balance disturbance, with symptoms resulting 
from conduction delay along demyelinated axons. Relapse frequency is difficult to 
estimate as sometimes it can be difficult to distinguish relapses from fluctuations in 
existing disability.  For example, heat further slows conduction, exacerbating 
symptoms (Uthoff’s phenomenon). Also relapse frequency appears to decrease during 
the clinical course [65]. Hence studies report huge variability in relapse frequency 
from 0.1 to >1 per year [65] but about 0.5 relapses per year is felt to be a reasonable 
estimate in a standard RRMS population.  
 
Another phenomenon of demyelination is hyperexcitability with spontaneous 
discharge giving rise to brief, frequent, paroxysmal, stereotypical symptoms often 
triggered by movement such as Lhermitte’s phenomenon (electric shock sensation 
radiating down the spine or limbs on neck flexion), trigeminal neuralgia, tonic spasms 
and phosphenes (flashes of light visualized on eye movement). Throughout the 
clinical course, patients often complain of fatigue which compounds their physical 
disability. 
 
Approximately two thirds of RRMS patients develop a secondary progressive course 
within 25 years of symptom onset [66] and fifty percent of patients with RRMS are 
unable to walk unaided 15 years after disease onset [65]. During the progressive 
stage, exercise tolerance slowly declines, and increasing support is required from one 
to 2 sticks (EDSS 6), a wheelchair (EDSS 7), and assistance with transferring. The 
progressive phase may be exacerbated by relapses, leading to a sharp decline in 
function with partial recovery. The pyramidal pattern of weakness in secondary 
progression is usually accompanied by spasticity, spasms and clonus which can be 
painful and disturb sleep. Gait disturbance may be caused or exacerbated by 
cerebellar dysfunction. Upper limb weakness is much less common than paraparesis, 
  27but function may become limited by ataxia. Sphincter dysfunction often occurs in 
parallel with spastic paraparesis, and symptoms typically include urgency, frequency, 
incontinence, erectile dysfunction, and constipation. Incomplete voiding may lead to 
recurrent urinary tract infections which can exacerbate symptoms. Although frank 
dementia is rare in MS, patients often complain of poor memory and attention. 
Sensory symptoms are also common, ranging from numbness, tightness, paraesthesia, 
and can be very troublesome.  
 
On average the life expectancy of people with MS is lower than that of the general 
population, by about 10 years, as disability predisposes patients to bladder and chest 
infections [65]. 
 
Figure 1.5 Graphical description of the MS subtypes 
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Benign MS, relapses but complete recovery 
between attacks 
Relapsing remitting MS (RRMS), relapses but 
incomplete recovery between attacks 
Secondary progressive MS (SPMS), slow 
progression of disability develops after an initial 
RRMS course, +/- superimposed relapses. 
Primary progressive MS (PPMS), slow 
progression of disability from disease onset 
without relapses. 
 
1.3.3 MS variants 
Other variants of MS have been described.  Balo’s concentric sclerosis is a rare 
variant which is particularly prominent in the Philippines. The essential features are 
large plaques consisting of concentric rings of demyelination alternating with 
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can be seen on MRI (see Figure 1.3).  
 
 
Figure 1.6 showing the MRI appearance of Balo’s concentric 
sclerosis (sagittal FLAIR, PD and T2 weighted axials). 
 
 
Marburg variant is an aggressive form of MS, with rapid progression and widespread 
inflammatory lesions, typically of the same age, in the characteristic locations for 
demyelination; optic nerves, spinal cord, periventricular white matter and brainstem. 
Marburg variant usually leads to death within months or a very few years from onset 
due to the severe neurological debilitation. The lesions are generally destructive with 
tissue necrosis [68]. Inflammatory demyelination can also affect the peripheral nerves 
in this condition.   
 
Neuromyelitis optica (NMO), or Devic’s syndrome, is a variant with optic neuritis 
and/or myelitis, but no signs or lesions beyond the cord or optic nerves [69]. It is a 
relapsing disorder in the majority of patients [70], with early residual disability. MS 
limited to the optic nerves and spinal cord (optico-spinal MS) can be differentiated 
from NMO by disease severity, MRI appearances, and cerebrospinal fluid (CSF) 
findings. In NMO the ON is severe with poor visual recovery, and the MRI 
appearance of transverse myelitis show extensive, sometimes necrotic, spinal cord 
lesions extending across several vertebrae. CSF may have a pleocytosis (including 
polymorphonuclear cells not seen in MS) but oligoclonal bands are usually absent. 
Brain MRI at presentation is often normal or may show changes uncharacteristic of 
MS, such as hyperintense signal in periependymal regions including the 
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female, compared to 70% of MS patients. There is a strong association with 
autoimmune diseases such as thyroiditis, lupus and Sjörgrens syndrome; ANA is 
positive in 50% of NMO patients [69]. Recently an NMO IgG antibody has been 
discovered directed against aquaporin 4, but its pathogenicity and the mechanism of 
demyelination remain uncertain. Aquaporin 4 is not an oligodendrocyte protein, but is 
found on astrocytes, and is highly expressed in NMO sites.  Anti-aquaporin 4 is 
present in 9% of optico-spinal MS patients, and 73% of NMO patients. CIS patients 
presenting with idiopathic transverse myelitis and positive anti-aquaporin 4 antibody 
(present in 38%) are at high risk of recurrence of transverse myelitis or ON. Twenty 
percent of patients with recurrent ON are anti-aquaporin 4 positive, and their visual 
outcome is significantly worse than the patients negative for the antibody [69]. NMO 
diagnostic criteria require ON, acute myelitis and 2 out of the following 3 
characteristics: disease onset brain MRI that is not diagnostic for MS, contiguous 
spinal cord MRI lesion extending over 3 or more vertebral segments, and NMO-IgG 
seropositive status [71]. 
 
1.4 Prognostic markers in CIS/early MS 
1.4.1 Conversion to CDMS 
Therapeutic studies have given reliable indication of the rate of conversion to CDMS 
in the 2 years after CIS onset in patients considered high risk, i.e. with lesions on 
baseline MRI.  There have been two therapeutic studies; Early Treatment of Multiple 
Sclerosis Study (ETOMS)
 [72], and Controlled High Risk Avonex Multiple Sclerosis 
Prevention Study (CHAMPS) [73].  The MRI inclusion criteria differed between the 
two studies.  Whereas CHAMPS required two or more clinically silent lesions at least 
3mm (at least one lesion must be periventricular or ovoid), ETOMS required more 
active disease with at least four T2 lesions or three T2 lesions plus one gadolinium-
enhancing lesion.  By 2 years, 38% and 45% of the placebo arms converted to CDMS 
in CHAMPS, and ETOMS respectively.   
 
Natural history studies provide long-term data on rates of conversion and prognostic 
factors in patients with both normal and abnormal MRI at presentation.  The Optic 
Neuritis Treatment Trial [74] followed up patients 10 or more years from onset.  The 
risk of MS was similar in the 3 original treatment groups (intravenous or oral steroids 
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being 3 years.  The 15 year follow-up data has recently been published, and at this 
point 50% of patients had converted to CDMS [63]. The risk of converting to CDMS 
decreases with time, but never goes completely. Whereas between baseline and 5 
years, 29% of the CIS patients converted, 17% of the remaining CIS patients 
converted over the next 5 years, and 14% between 10 and 15 years [63]. An Italian 
study of 10 year follow-up of isolated optic neuritis patients reported a similar result 
to the 10 year ONTT data, with 42% risk of MS [75].   
 
Follow-up of a mixed CIS cohort (presenting with optic neuritis, brainstem or spinal 
cord syndromes), found a higher conversion rate compared to the ONTT, with 59% 
developing CDMS at 10 years and 63% at 20 years [61, 62].  
 
Whether different CIS presentations – ON, brainstem, spinal cord, multifocal – confer 
different risk of conversion to CDMS has not been established.   Eriksson and 
colleagues found that patients with efferent lesions had twice the risk of a later 
diagnosis of MS than patients with afferent lesions (optic neuritis or purely sensory 
symptoms) [76] which could explain the higher rate of conversion in the mixed CIS 
cohort than the optic neuritis cohorts.  Tintore et al found that patients presenting with 
optic neuritis carried a lower risk of conversion to MS, but if only patients with 
abnormal MRI were compared the risk was not significantly different between the 
CIS presentations [77].  However in Brex’s study, there was no significant difference 
in risk between the different CIS presentations, irrespective of MRI abnormalities 
[61].  The discrepancy may be due to the difference in proportion of ON patients 
presenting with abnormalities on MRI with 77% in England and 51% in Spain.   
 
Therefore there is some evidence to suggest that the type of CIS confers risk of 
further neurological events with optic neuritis having a lower risk of disease 
progression.   
 
1.4.2 Clinical factors related to disease course 
There is a high degree of variability in the final outcome between MS patients, and 
some patients do not appear to develop significant disability. The proportion of MS 
patients with a benign course varies between studies. The ONTT reported two thirds 
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years [63, 78] but the respective figure was 39% at 20 years in the mixed CIS cohort 
[62]. Thirteen year follow-up of early MS patients found only 5% were defined as 
benign MS [79]. Some patients develop progressive, irreversible decline in mobility, 
from limitation in ambulation (EDSS 4) to requirement of a unilateral aid for walking 
(EDSS 6), to becoming wheelchair bound (EDSS 7) over a period of 8, 20 and 30 
years respectively in one natural history study [64].  Thirty one to 50% of RRMS 
patients are unable to walk unaided 15 years from their first clinical event [61, 65, 
79].  
 
Development of a progressive course is the most important factor associated with 
long-term outcome [79, 80].  Approximately two thirds of RRMS patients develop a 
secondary progressive course within 25 years of symptom onset [66].  The median 
time from onset of CIS to secondary progression was 19 years and time from 
clinically definite/probable MS to secondary progression 12 years [76].   
 
At presentation, several studies report CIS topography and degree of recovery as 
independent risk factors for secondary progression and poor outcome.  By 25 years, 
patients presenting with an efferent lesion have twice the risk of secondary 
progression and nearly 3 times the risk of being wheelchair-bound than those 
presenting with purely sensory symptoms or optic neuritis [76].  Concurring with this, 
pyramidal, sphincter [79, 81], cerebellar [82, 83] and polysymptomatic presentations 
[66, 80] have been associated with poor outcome compared to ON or sensory 
presentations [65, 66, 81, 84, 85]. Complete recovery from the initial attack is also 
important prognostically [66, 76, 84]. Several studies support early age of onset to be 
associated with better prognosis [65, 81, 84, 85] and patients over 30 at CIS onset 
have a 1.7 fold increased risk of secondary progression 25 years from diagnosis than 
younger patients [76, 79].  Gender is consistently linked with prognosis, with females 
having better prognosis than males [65, 84, 85]. Family history of MS [82] has also 
been associated with unfavourable outcome.  
 
In early disease, high relapse frequency in the first 5 years [65, 76, 81] and short first 
remission [76, 81] have been shown to be predictive of secondary progression and 
disability.  By 25 years, patients having 5 or more attacks in the first 5 years have 
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wheelchair bound than patients with lower relapse frequency [76].  In agreement, a 
study compared patients with only 1 attack in the first 2 years with those who 
experienced 5 or more, and found the first group had significantly slower disease 
progression than the second, taking 20 years to require a walking aid compared to 7 
years [80].   Incomplete remission from early relapses nearly treble the risk of 
secondary progression and need for a wheelchair at 25 years [76].   
 
None of the early predictors for progression were able to predict the rate of 
subsequent progression [76]. Only late predictors, such as a shorter time from MS 
onset to secondary progression (1 to 10 years) and higher number of functional 
systems involved at onset of progression predicted a faster progression rate. Although 
time to EDSS 4 is variable among patients, the time course between EDSS 4 and 6 is 
similar [84], and rate of progression is similar in SPMS and PPMS if time from 
progression onset rather than disease onset is used as the baseline  [64, 80]. 
 
Table 1.1 summarising prognostic factors at various stages of disease 
Factors predicting 
conversion to CDMS 
Factors at CIS onset 
predicting secondary 
progression 
Factors in early years 
predicting secondary 
progression 
Factors predicting 
rate of progression 
Factors predicting 
disability other than 
secondary 
progression 
Purely afferent 
symptoms low risk 
Age > 30 [76, 79]  High relapse 
frequency [76, 80]  
Shorter interval 
between MS onset and 
progression [76] 
CIS due to efferent 
lesion [76, 79, 82] or 
polysymptomatic onset 
[80] 
Efferent symptoms 
high risk 
CIS due to efferent 
lesion 
Incomplete remission 
[76] 
Higher number of 
functional systems 
involved at onset of 
progression [76] 
Gender (males poorer 
prognosis) 
  Cognitive  symptoms 
in the 5
th disease year 
[76] 
  Shorter relapse free 
interval between first 2 
attacks [80] 
    Short  interval  from 
onset to secondary 
progression [79] [80] 
    H i g h e r   E D S S   a t  
inclusion [79]  
    Family  history  of  MS 
[82] 
 
 
  331.5 Cognitive impairment 
Cognition, including memory, attention and language, relies on distributed 
interconnected neural networks [86]. The multiple, subcortical connections and 
pathways of these networks are vulnerable to damage by multifocal lesions or diffuse 
axonal pathology.  Cortical involvement, which has recently become evident, is also 
likely to adversely affect cognitive function. Various cognitive deficits mainly 
affecting memory, attention and executive functions are seen in up to 43-60% [87, 88] 
of MS patients depending on the sample and sensitivity and specificity of 
neuropsychometric battery used.  Language and intellectual functions are generally 
preserved until late in the disease.  Subtle cognitive changes such as deficits in 
attention, generalised slowing in reaction times and information processing may be 
detectable at initial presentation in CIS patients [89-93]. 
 
In patients converting to CDMS, memory deficits can develop [87, 89, 94], and 
during the relapsing remitting phase can progress [95], but become more severe when 
the disease enters the progressive phase [89].   
 
Prediction of cognitive impairment from early clinical factors has not been 
consistently demonstrated.  Neither cross sectional nor longitudinal studies have 
shown a correlation between performance or decline in cognitive testing and 
demographic or clinical variables such as disease duration, disability level or relapse 
rate [93, 95, 96].   
 
1.6 Diagnosis 
A diagnosis of MS requires objective confirmation of 2 attacks (symptoms of 
neurological dysfunction characteristic of demyelination, demonstrated on 
examination, lasting more than 24 hours) separated by time (at least 1 month) and 
place. Paraclinical investigations show characteristic features of demyelination which 
can support the diagnosis, such as oligoclonal bands in cerebrospinal fluid, and 
delayed conduction on evoked potentials.  
 
1.6.1 Cerebrospinal fluid 
Two or more oligoclonal IgG bands (OCB) detected by separation of cerebrospinal 
fluid (CSF) proteins while not demonstrable in the corresponding serum, indicate a 
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methodology, OCB are demonstrated in 90-95% of CDMS patients and 46-61% of 
CIS patients, but may be present in other disorders [97, 98]. Once present, OCB 
persist in the MS patient irrespective of disease course or treatment. The antigenic 
target and the relationship to aetiology and pathogenesis remain to be established. 
OCB in the CSF are highly sensitive (up to 100%) for the development of CDMS 
with an equal negative predictive value, and are useful in supporting a diagnosis of 
MS [99]. However they are not specific (42% in one study) being present in other 
inflammatory CNS disorders. They have been incorporated into MRI diagnostic 
criteria, reducing the number of lesions required for dissemination in space. Studies 
evaluating the MRI criteria with and without OCB have produced conflicting results 
[100-102].  They may be useful with regards to prognosis in patients with normal 
MRI. Only 4% of patients with normal MRI and negative OCB convert to CDMS 
compared to 23% with positive OCB [102] and the hazard ratio of conversion to 
CDMS with positive OCB is 1.7, adjusting for brain lesions on MRI [103]. No 
association with disability was found in this study. 
 
1.6.2 Evoked potentials 
Brainstem auditory evoked potentials (BAEPs), short latency somatosensory evoked 
potentials (SSEPs) and pattern reversal visual evoked potentials (VEPs) can confirm 
the presence of lesions in patients with suspected clinical involvement and document 
the presence of clinically unsuspected lesions, providing evidence for dissemination 
in space. Although they provide limited information on the number, location or 
activity of lesions, they are sensitive to early subclinical damage, give functional 
information and prolonged latency is felt to be relatively specific for demyelination. 
BAEP or VEP detect subclinical lesions in about 50% of MS patients and when 
combined in 71%, whereas  SSEPs although frequently abnormal, show only a few 
silent lesions [104]. VEPs are very sensitive in patients with a history of optic neuritis, 
especially if there are compatible clinical signs. A review of evoked potentials in 
patients with CIS, possible or probable MS concluded that only VEPs were clinically 
useful, with sensitivities ranging from 25-83% and abnormality associated with a risk 
of CDMS 3 to 9 times that of patients with normal VEPs [105]. The association 
between CDMS and BAEPs or SSEPs was weak or inconclusive. Therefore, evoked 
potentials give valuable information in the majority of patients with uncertain 
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be performed.  
 
1.6.3 Diagnostic criteria 
Diagnostic criteria evolved incorporating these paraclinical investigations [106] and 
in 1983 the Poser criteria were published. Thus without clinical evidence of 2 attacks, 
a diagnosis could be made if there was paraclinical evidence of dissemination in space 
(DIS), see Table 1.2. 
 
Table 1.2 summarising the Poser criteria for diagnosis of MS [106]. ‘Attack’ defined as symptoms of 
neurological dysfunction characteristic of demyelination, demonstrated on examination, lasting more 
than 24 hours. * Paraclinical evidence of DIS includes neuroimaging (at this time mainly CT), evoked 
potentials and expert urological assessment. Laboratory support applies to cerebrospinal fluid 
examination for oligoclonal bands 
  No. of 
attacks 
Clinical 
evidence of : 
 Paraclinical   
evidence of 
Dissemination 
in space* 
Oligoclonal 
bands 
2 DIS        Clinically definite 
MS  2 only  1  lesion  AND  Yes   
2 only  1  lesion  OR  Yes  +ve 
1 DIS      +ve 
Laboratory 
supported definite 
MS  1 only  1  lesion  AND  Yes  +ve 
2 only  1  lesion       
1 DIS       
Clinically probable 
MS 
1 only  1  lesion  AND  Yes   
Lab supported 
probable MS 
2 only  1  lesion      +ve 
 
1.7 Differential diagnosis 
Other conditions can give rise to syndromes, such as optic neuropathy, myelitis and 
cerebellar ataxia, which may be relapsing-remitting in nature and have MRI and CSF 
findings similar to MS.  
 
1.7.1 Inflammatory causes 
Acute disseminated encephalomyelitis (ADEM) is usually a monofocal, post-
infectious illness in children. Headache, drowsiness, fever and seizures usually 
accompany focal neurology (motor, sensory, visual, ataxia, polysymptomatic) and 
some degree of encephalopathy is required for diagnosis (from irritability or 
behavioural change to coma). CSF transiently shows OCB, and grey and white matter 
lesions often resolve and new lesions at 3 months are rare.  
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syndrome can give rise to optic neuropathy and transverse myelitis. They are usually 
distinguishable from MS by systemic symptoms characteristic of the underlying 
condition and a raised ESR and autoantibodies can help with the diagnosis. Behçet’s 
disease, usually distinguishable from MS due to a history of orogenital ulceration, 
rarely resembles MS and can be a cause of spinal cord or brainstem syndrome.  
 
Primary CNS vasculitis can cause fluctuating symptoms which may involve the optic 
nerve, brainstem or spinal cord, but headache, reduced level of consciousness and 
seizures and stroke-like episodes are more characteristic. CSF and angiograms can 
sometimes aid diagnosis, but a diagnostic biopsy is required to enable aggressive 
treatment. 
 
1.7.2 Infiltrative causes 
Lymphoma can present with subacute and progressive hemiparesis, hemianopia, 
seizures, reduced level of consciousness and myelopathy. The response to steroids can 
lead to suspicion of MS, but symptoms recur and progress. A biopsy is required for 
definitive diagnosis. Sarcoidosis can cause a progressive myelopathy and steroid-
dependent optic neuritis. MRI may show meningeal enhancement, but a definitive 
diagnosis requires a Gallium scan and / or biopsy.  
 
 
 
1.7.3 Infective and other causes 
Infections (chronic borreliosis, syphilis, HIV, JC virus causing progressive multifocal 
leukoencephalopathy, chronic measles and Whipples), can cause evolving central 
neurological symptoms, and CSF and serum serology is required to exclude these as 
the cause. Other non-inflammatory causes include cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) where a 
family history of stroke is important, and mitochondrial disease. 
 
1.8 Current management strategies 
Currently no study has shown disease modification in progressive, non-inflammatory 
MS, therefore disease modifying therapy (DMT) is limited to those patients 
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MRI.  
 
Beta Interferons have many immunomodulatory actions, such as modulation of 
plasma cell IgG synthesis, inhibition of leukocyte proliferation, reduction in antigen 
presentation in microglia and reduction of T cell migration into the brain. Glatimer 
acetate (Copaxone) also modulates the immune system, by interfering with antigen 
presentation and inducing suppressor cells. Both classes reduce relapse rate by about 
30% and reduce MRI signs of disease activity in 30-80% and disability progression 
by 30% [107].  Three studies of early treatment of CIS patients (CHAMPS [73], 
ETOMS [72] and BENEFIT [108]) showed Interferon delays conversion to CDMS in 
CIS.  
 
Table 1.3 summarising results from Interferon (IFN) treatment trials 
Trial Treatment  F/U  duration  Treatment  arm 
conversion rate 
Placebo arm 
conversion rate 
HR 
CHAMPS 30μg IFN/wk  3 yrs  35%  50%  0.56 
ETOMS 22μg IFN/wk  2 yrs  34%  45%  0.69 
BENEFIT 250μg IFN alt days  2 yrs then  
open label 3yrs 
34% in 
immediate group 
48% in delayed 
Rx group 
0.5 
 
 
The long-term benefit of these therapies is not known, and the National Institute of 
Clinical Excellence (NICE) concluded that such DMTs were clinically effective but 
not cost effective and for this reason the Risk Sharing Scheme was agreed between 
pharmaceutical industry and the NHS, with cost of therapy adjusted on a sliding scale 
if patient outcomes differ from the agreed targets on annual monitoring. Currently, 
mobile patients who have 2 relapses in 2 years are eligible for DMT, but recent 
recommendations by the Association of British Neurologists stated that patients with 
a single disabling relapse in the last year or a diagnosis of McDonald MS within a 
year of CIS onset should also be eligible for DMT. 
 
Mitoxantrone is an anti-neoplastic agent that inhibits both DNA and RNA synthesis, 
suppressing B and T cell immunity. Results from clinical trials have demonstrated 
beneficial effect of treatment in RRMS or SPMS whilst in the inflammatory phase, 
reducing relapse rate, MRI activity and slowing down progression [109, 110]. 
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toxicity (limiting cumulative dose to less than 140mg/m
2), risk of acute leukaemia 
(about 1:400) and secondary amenorrhoea. It is restricted to patients with rapidly 
advancing disease (such as decline in EDSS by ≥2 point over a year) unresponsive to 
other therapies and with demonstrable persistent inflammatory activity with normal 
cardiac function.  
 
Several monoclonal antibodies strategically targeting the immune system have been 
developed and have either completed or are mid-trial. These include Natalizumab, 
Alemtuzumab and Rituximab. Natalizumab (Tysabri), a humanised monoclonal 
antibody that blocks the adhesion molecule a4β1 integrin and impedes 
transendothelial migration of lymphocytes, reducing lymphocyte entry into and 
surveillance of the CNS. Phase III studies showed reduction in relapse rate by two 
thirds and lesion accumulation by 83% [111, 112]. Two patients in the SENTINEL 
trial [112] (Natalizumab plus Interferon) developed progressive multifocal 
leucoencephalopathy, one of whom died. After exhaustive review of all patients 
exposed to Natalizumab, clinical trials were allowed to resume. It is currently 
recommended by NICE as monotherapy for rapidly evolving, severe RRMS (2 severe 
disabling relapses in a year with evidence of increasing lesion load/activity on MRI). 
However in August 2008 two further cases were reported in patients on Natalizumab 
monotherapy for more than a year, and the American Academy of Neurology 
recommends Natalizumab is reserved for patients who have failed other therapy 
(either with continued disease activity or medication intolerance) or who have 
particularly aggressive initial disease course. How this will affect NICE guidelines 
and its use in MS in the UK remains to be seen. As there is currently no screening 
method to identify patients at risk of PML, surveillance remains clinical vigilance. 
 
Alemtuzumab (Campath-H1), or anti-CD52 (present on T cells and monocytes) 
causes T cell depletion. In a phase II randomised controlled trial (CAMMS223), 
applied in up to 3 cycles in two years, Campath was shown to have superior efficacy 
in comparison to Interferon at 24 and 36 months. Cumulative number of relapses was 
reduced by 72-87% and the risk of sustained disability by 66-88% over a period of 24 
months. The 3 year follow-up data was presented at the American Academy of 
Neurology in 2008 and similar reductions in relapse rate and disability compared to 
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improvement in EDSS, with a reduction of 0.39 in EDSS from baseline, and a 
reduction of 0.77 in comparison to the Interferon group. Serious adverse events 
included idiopathic thrombocytopaenic purpura in 6 patients (1 patient died of 
intracranial haemorrhage), hyperthyroidism and listeria meningitis in a patient who 
ate unpasteurised cheese. 
 
Rituximab (anti-CD20) present on all B cells from pre-B cells to memory cells but not 
plasma cells, has been tested in a Phase II trial in RRMS patients. Results at 48 weeks 
following 2 infusions found, compared to placebo, 91% relative reduction in 
gadolinium enhancing lesions and 58% relative reduction in the proportion of patients 
experiencing relapses during follow-up. 
 
Oral agents are also in development, some of which are in the midst of large phase III 
trials. Potency of such agents varies, and many are being developed as supplemental 
therapy, whereas others are potentially as potent as monoclonal antibodies, targeting 
traffic of lymphocytes into the CNS. 
 
 
 
1.9 Measurements of disability 
Objective measures of disability are important for monitoring disease, particularly in 
clinical trials. The Disability Status Scale (DSS) was proposed by Kurtzke in 1955, 
which graded disability in steps from normal function to death as an ordinal scale, 
with 1-unit increments [113]. Later the DSS was expanded (EDSS) to include 
functional systems, to complement the DSS, which was weighted towards ambulation 
status [114]. The functional scores were supposed to pick up impairment in visual, 
cerebellar, brainstem, sensory, sphincter and mental functions. However EDSS above 
4 remain weighted to ambulation status, and impairment in other functional systems is 
only reflected in the lower EDSS range. Therefore the sensitivity of the EDSS for 
reflecting change in neurological impairment is greatly reduced above EDSS 4, which 
limits its capacity to detect treatment effects in clinical trials. The insensitivity of the 
EDSS to visual and cognitive function has also been criticised. The EDSS ratings also 
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the distances between scores are not equal. 
 
Other scales have been proposed to try to overcome the shortfalls of the EDSS. The 
MS functional composite (MSFC) is often used in conjunction with the EDSS as it 
measures manual dexterity (timed 9 hole peg test), attention and working memory (3 
second paced auditory serial addition test or PASAT) and mobility (timed 25 foot 
walk) [115].  Low Contrast Sloan Letter Charts may be added in clinical trials to 
better capture visual dysfunction. Z scores from the 3 or 4 components are acquired, 
and averaged for the overall score, yielding a continuous scale that is sensitive to 
small change in function. In an able population however it may be limited by ceiling 
effects. 
 
Table 1.4 summarising EDSS  
EDSS Mobility  Criteria 
1  minimal (min) signs in 1 functional system (FS) 
1.5  min signs in >1 FS 
2  min disability in 1FS 
2.5  min disability in >1FS OR mild disability in 1 FS 
3   moderate (mod) disability in 1FS OR mild disability in 3-4 FS 
3.5 
unimpaired 
mod disability in 1FS AND more than minimal disability in several others 
4  able to walk without rest or aid for >500m 
4.5  able to walk without rest or aid for 300m 
5  able to walk without rest or aid for 200m 
5.5 
restricted 
able to walk without rest or aid for 100m 
6  able to walk without rest with 1 cane 100m 
6.5 
aids required 
able to walk without rest with 2 canes 100m 
7  max 5m with 2 aids, transfers alone, wheels self 
7.5  few steps only, +/- help transferring/wheeling 
8 
wheelchair 
restricted to bed, effective use of arms 
9  confined to bed, can communicate / eat 
9.5 
bedbound 
unable to communicate/swallow 
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MRI physics 
2.1 MRI principles 
MRI is a non-invasive technique that can generate high resolution images exploiting 
the electromagnetic properties of spinning protons (positively charged particles).  A 
full description of MRI physics requires an understanding of quantum mechanics but 
for the purposes of this thesis a simple model is used. 
 
A moving electrical charge, such as a spinning proton, induces a magnetic field, in 
accordance with Faraday’s Law of electromagnetic induction. Atomic nuclei are made 
up of protons and neutrons (non-charged particles), each spinning about their own 
axes, either clockwise or anti-clockwise. Nuclei with equal numbers of protons and 
neutrons have no net spin as the spins cancel each other out. Only atoms with 
different numbers of the nuclear particles have net spin (see Figure 2.1).  
 
Figure 2.1 Net spin 
Molecule with even number of 
nuclear particles, and equal number 
of clockwise and anti-clockwise 
spins resulting in no net spin
Molecular nucleus with odd 
number of particles, resulting 
in net spin (red arrow)
 
 
As protons are positively charged, by spinning they induce magnetic fields around 
themselves and behave like magnetic dipoles. Magnetic fields have magnitude and 
direction, denoted by a magnetic moment and the total magnetic moment of the 
nucleus is the vector sum of the magnetic moments of all the nuclear protons (see 
Figure 2.2). 
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The total magnetic moment of the nucleus 
(red arrow) is the vector sum of the individual 
magnetic moments of all the protons in the 
nucleus (neutrons not shown). Due to 
differences in alignment, the total magnetic 
moment is small. 
The magnetic moment (red 
arrow) of a single proton, as in a 
Hydrogen atom, is relatively 
large. 
 
Due to the abundance of hydrogen atoms in the body (in the form of water, protein, 
fats etc), and because the hydrogen atom is a solitary proton giving a large magnetic 
moment, it is the proton that is imaged in MRI. However, for reasons discussed later, 
most imaging methods image only those protons in water. MRI works by generating a 
strong magnetic field which causes the protons to align in an equilibrium position. 
Energy is briefly put into the system, and absorbed by the protons (also known as 
spins) altering their energy state. On cessation of energy input, the spins return to the 
equilibrium position, releasing energy in the process. 
 
2.2 Equilibrium 
Exposing spinning protons to an external magnetic field causes the nuclear spins to 
align (either parallel or anti-parallel) with B0. Proportionally more protons align 
parallel to B0 than anti-parallel, as this is a lower energy state. At room temperature 
and 1.5 Tesla, the excess is only 11 in 1 million, but due to the numbers of hydrogen 
atoms in tissue, this difference is sufficient to produce a measurable net longitudinal 
magnetisation in the direction of B0 (see Figure 2.3). 
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In the presence of 
an external 
electromagnetic 
field, protons 
align either 
parallel or anti-
parallel to B0. As 
relatively more 
protons align 
parallel to B0
(lower energy 
state), there is a 
net longitudinal 
magnetisation in 
the direction of B0
(red arrow)
 
Figure 2.3 Equilibrium: net longitudinal magnetisation 
 
In the presence of an external magnetic field (B0) protons do not spin perfectly about 
their axis, but wobble, with gyration of the spinning axis about the axis of the external 
field B0 (precession). The precession frequency, also known as the Larmor frequency, 
is dependent on the gyromagnetic ratio (an intrinsic property of the spin of interest, 
~42.6MHz/T for protons in hydrogen atoms), and the strength of the external 
magnetic field B0. Precession generates a rotating transverse magnetic vector in 
individual spins (see Figure 2.4). 
 
Precession (Larmor) frequency =gyromagnetic ratio x strength of B0 (ν = γB/2π).   
                             
B0
 
Figure 2.4 Precession  
The spinning proton gyrates 
around the spinning axis (B0) and 
generates of a rotating transverse 
magnetic vector (blue arrow) 
 
The protons are aligned with the applied magnetic field, however there is no favoured 
phase for the precession around B0, which means that the protons are evenly spread 
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2.5). 
B0
 
Figure 2.5 Equilibrium: no net transverse magnetisation 
 
Therefore at equilibrium, before excitation pulses are applied, the net magnetisation 
vector is aligned with the external magnetic field B0 as there is only longitudinal 
magnetisation and no transverse component. 
 
2.3 Excitation  
By exposing protons to energy, in the form of a radiofrequency (RF) pulse, there is a 
tendency for them to switch to the anti-parallel state (higher energy state). Energy is 
most easily absorbed by protons spinning at the same frequency as the RF pulse 
(resonance) so the RF pulse applied has a frequency equal to the Larmor frequency. 
These changes result in reduction in net longitudinal magnetisation. The length and 
amplitude of the RF pulse will determine the extent of the change in the net 
magnetisation vector. If the proportion of spins anti-parallel to B0 exceeds that in the 
parallel state, the net longitudinal magnetisation becomes negative, that is in the 
opposite direction to B0.   
 
The RF pulse also causes phase coherence, and by bringing precessing spins into 
phase, generates net rotating transverse magnetisation (see Figure 2.6). 
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Figure 2.6 Excitation: A greater proportion of spins are in the higher energy state (anti-parallel to B0), 
and the net longitudinal magnetisation gets smaller and, in this example, becomes negative (red arrow). 
The spins precess in phase, generating net transverse magnetisation (blue arrow) 
 
At a quantum level the number of protons switching to the higher energy state, and 
thus the size and direction of the longitudinal magnetisation, depends on the strength 
and duration of the RF pulse.  Viewing the effects of the RF pulse on the net 
magnetisation vector, the reduction in longitudinal magnetisation and the rotating 
transverse component, the net magnetisation vector can be viewed as ‘flipped’ from 
parallel to B0 to some angle away from it, rotating around it (see Figure 2.7). The net 
magnetisation vector is used for explanation of MRI physics as it is simpler to work 
with than individual spins.  
 
2.4 Relaxation 
On cessation of the RF pulse, spinning protons return to equilibrium, with release of 
energy to their surroundings (spin-lattice interaction) as they tend to return to the 
lower energy state.  The net longitudinal magnetisation returns to the pre-RF pulse 
position, parallel to B0, due to a process known as T1 relaxation or recovery (see 
Figure 2.7).   
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RF pulse
z
y
x
Net magnetisation vector is 
flipped 90○and rotates 
around the z axis.
Excitation Relaxation Equilibrium
B0
Net magnetisation vector 
returns to the equilibrium 
position by spiralling up the z 
axis as longitudinal 
magnetisation recovers and 
transverse magnetisation
decays
Net magnetisation vector is 
in the direction of B0.
 
 
As the longitudinal magnetisation recovers, with release of energy, transverse 
magnetisation decays, as the spins dephase. This process, known as T2 decay, 
depends on the interaction of neighbouring spins (spin-spin interactions) and 
inhomogeneities in the external magnetic field. Unlike T1 relaxation, T2 decay does 
not involve net energy transfer and is unrelated to field strength.  
 
The recovery of the longitudinal magnetisation and the decay of the transverse 
magnetisation occur straight after the cessation of the RF pulse. They can be recorded 
on receiver coils near the sample. Changes in the net longitudinal magnetisation are 
lost in the overwhelming strength of the external magnetic field.  Receiver coils are 
only sensitive to variations in transverse magnetisation. Faraday’s Law of 
electromagnetic induction explains how the rotating transverse magnetism induces an 
electric current in the receiver coil, with a voltage oscillating at the Larmor frequency 
(see Figure 2.8).  
 
 
 
 
  47Figure 2.8 Induction of electric current in receiver coil 
Rotating transverse magnetisation induces an electric current in the 
receiver coil, with a voltage oscillating at the Larmor frequency.
 
The time taken for T1 recovery and T2 decay depend on the properties of the tissue in 
which the proton is spinning (see Figure 2.9). Water molecules are highly mobile with 
high inherent energy, whereas large molecules such as fat have a slow rate of 
molecular motion and low inherent energy. Energy transfer (during T1 recovery) is 
much more efficient, and thus T1 recovery time faster, in fat than water. Spin-spin 
interactions are greater in molecules with closely bound protons, such as fats, thus 
these dephase rapidly (short T2) whereas the protons in water molecules have less 
spin-spin interaction and dephase slowly (long T2) (See Figure 2.10). 
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Figure 2.9 Differences in rate of decay in transverse magnetisation and recovery of longitudinal 
magnetisation in fat and water 
 
 
 
 
  48Figure 2.10 Spin-spin interactions 
Protons in fat are closely bound with 
slow rate of molecular motion, 
facilitating spin-spin interactions.
Due to high rate of molecular motion 
and greater distance between molecules, 
spin-spin interactions are less in water 
than fat. 
 
 
Transverse magnetisation decays faster than it would with pure T2 effects due to 
inhomogeneities in the external magnetic field. This is known as T2* decay. To 
ensure the signal differences are only due to spin-spin interactions, rather than 
additional differences in the external electromagnetic field, the latter must be 
compensated for. This is achieved with gradients in the electromagnetic field or with 
180º pulses to reverse dephasing due to field inhomogeneities. 
 
 
2.5 Imaging 
The above principles can be used to produce 2D or 3D images of an object using the 
methods described below. One major difference between MRI and the principles 
described above is that the signal is not measured following the cessation of the RF 
pulse. This is because it is technically difficult to measure the decay so quickly after 
the RF pulse. A pulse sequence requires an excitatory RF pulse, and acquisition of the 
signal at echo time TE from the RF pulse after refocusing the signal by a further RF 
pulse and application of gradients (see below). The sequence can then be repeated at 
repetition time TR from the previous RF pulse (see Figure 2.11).  
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Excitatory 
RF pulse
Rephasing
mechanism
Echo Time (TE)
Repetition Time (TR)
Repetition of the sequence
Signal 
acquisition
Signal 
acquisition
 
 
2.6 Localisation 
Spatial localisation requires manipulation of the static magnetic field B0 to produce 
gradients in the magnetic field, with linear variation in magnetisation from the centre 
of the magnet.  Magnetic field gradients are applied at a specific time and in a specific 
plane.  Firstly a slice selection gradient is applied at the time of the RF excitation 
pulse.  This is applied perpendicular to the desired slice plane and reduces the 
precessional frequency of spins at the low end of the gradient and increases the 
frequency at the high end.  The desired slice precesses at the same frequency as the 
RF pulse (Larmor frequency) and thus only this slice will be excited by it. The 
bandwidth of the pulse and the strength of the gradient determine the slice thickness. 
 
To localise in the image plane, two further magnetic field gradients are applied which 
spatially encode the spins in the two in-plane directions (see Figure 2.12). The first is 
brief, and applied after the excitation pulse and is removed before signal acquisition. 
This is the phase encoding gradient which causes the spins in the direction of the 
gradient to get out of phase with each other.  The gradient causes the spins to precess 
at different rates during its application, thus they lose phase coherence, when the 
gradient is removed the neighbouring spins are out of phase but are precessing at the 
same frequency.  The change in phase is proportional to the distance from the centre 
of the gradient.  Multiple phase-encoding gradients are applied at incremental 
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phase-shifts between two points. This causes improved differentiation between two 
adjacent points and better spatial resolution.  Shallow phase encoding gradients cause 
small phase-shifts, and thus poor spatial resolution but they generate high amplitude 
signal.  
 
Lastly the frequency encoding gradient is applied at the time of signal acquisition, 
perpendicular to the phase-encoding gradient, and this affects the precessional 
frequency, speeding up where the gradient is higher and slowing down where it is 
lower.  
 
To create 3D images a much larger slab of tissue is excited with the ‘slice’ select 
gradient and a second phase encoding gradient applied in the same direction, thus 
encoding the spins in this direction as well. 
 
Figure 2.12 showing axes relative to the magnet and the field gradients on the image plane 
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The MR signal is a mixture of amplitudes and frequency- and phase-shifts.  The 
signal is digitised and raw data are written into a data matrix called K space. K space 
is a spatial frequency domain with 2 (or 3) axes; phase encoded data are stored on the 
vertical axis and frequency encoded data on the horizontal axis. Every combination of 
frequency and phase encoding represents a point in K space. Data with high spatial 
resolution, but low signal amplitude (from steep phase encoding gradients) fill the 
outer lines of K space and data with low spatial resolution and high signal amplitude 
fill the central portion of K space. To translate this digitised data into an image 
requires a 2D (or 3D) inverse Fourier Transform, a complex mathematical procedure 
which is beyond the scope of this thesis.  
  
2.8 Contrast 
High signal is seen when a tissue has a large transverse component of magnetisation 
at acquisition and vice versa. Contrast will be achieved when the different tissues in 
the image give off a range of MR signals, due to differences in their T1 and T2 
relaxation times. A third intrinsic contrast mechanism is proton density, which is 
proportional to the number of protons in each tissue. For example, gases inherently 
have a low density and will always give a low signal.  To produce images where the 
contrast is predictable, the images are ‘weighted’ towards one of the 3 contrast 
mechanisms, depending on the imaging objectives (e.g. anatomy, oedema, tissue-
characterisation). There are 3 parameters which are commonly altered to vary the 
signal contrast between tissues; the time between excitatory pulses (repetition time, 
TR), the time between excitatory pulse and echo acquisition (echo time, TE) and the 
initial flip angle induced by the excitatory pulse (gradient echo sequences only). 
 
2.8.1 T1 weighting 
The longer the TR, the greater the recovery of longitudinal magnetisation and any 
differences in signal due to T1 times of the different tissues are lost.  To exploit T1 
differences in tissues the TR must be short enough to ensure that the longitudinal 
magnetisation in fat and water have not relaxed back to B0. Differences in recovery of 
longitudinal magnetisation are converted to differences in transverse magnetisation by 
a 90º pulse, and the more the longitudinal magnetisation has recovered, the greater the 
transverse component of the net magnetisation vector when it is flipped by 90º (see 
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(such as fat) give off high signal and appear bright compared to tissues with longer 
relaxation times (such as water) which give low signal (see Figure 2.14).  A typical 
T1-weighted sequence has a TR of 300-600ms and a TE of 10-30ms. TE must also be 
short to diminish the T2 weighting described below. In gradient echo sequences the 
flip angle can also be used to vary the T1 weighting. A small flip angle will mean that 
the longitudinal magnetisation recovers very quickly, so minimising T1 weighting, 
hence a large flip angle should be used. 
 
Figure 2.12 T1 weighting 
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Longitudinal magnetisation recovers more quickly in fat 
than water and the difference in longitudinal magnetisation
is converted to transverse magnetisation when flipped by 
the 90◦pulse
As fat (red circle) then has 
a greater transverse 
component than water (blue 
circle), it gives off a 
stronger signal
 
 
2.8.2 T2 weighting 
Sequences with long TRs remove the effects of differences in tissues’ T1 properties 
by allowing full recovery of longitudinal magnetisation in all tissues between 
acquisitions.  Delaying signal acquisition creates contrast between tissues with 
different T2 decay times.  Tissues with slow T2 decay have greater transverse 
magnetisation at the time of signal acquisition than tissues with fast T2 decay, and 
thus produce a greater signal (see Figure 2.13). Small flip angles are used in T2 
weighted gradient echo sequences to minimise T1 weighting effects. In T2 weighted 
images fat appears dark and water bright (see Figure 2.14). A T2 weighted sequence 
has a TR of 2000ms or more and a TE of 70ms or more. 
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2.8.3 PD weighting 
PD weighted images minimise both T1 and T2 weighting effects by using a long TR 
and short TE (and small flip angle). Short TEs do not give enough time for signal 
decay in tissues with fast T2 times, reducing the tissue contrast due to T2 effects.  
Signal intensities vary in such sequences due to variation in proton density where 
tissues with tightly packed protons (such as fat) produce a stronger signal than those 
with less dense protons (such as water) (see Figure 2.14).   A PD weighted sequence 
has a TR of 2000ms or more and a TE of 10 to 30ms. 
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T1, T2 and PD weighted images showing differences in contrast. In T1 image water is dark, 
(vitreous humour and CSF in the temporal horns) and orbital fat is bright. Water is bright in T2 
weighted images (vitreous humour and temporal horn) but lower signal from orbital fat. Orbital 
fat and vitreous humour of more similar signal intensity on PD weighted images and right 
temporal horn not visible on PD weighted image due to lack of contrast with white matter.
T1 T2 PD
 
2.8.4 Contrast media 
Enhancement agents are used in MRI to increase the contrast between pathology and 
normal tissue. Gadolinium is a paramagnetic agent which produces local magnetic 
fields and accelerates T1 relaxation time of nearby water protons, resulting in high 
signal intensity on T1 weighted images. Gadolinium is a rare earth metal that cannot 
be excreted by the body and is therefore chelated to enable excretion. It can only enter 
the central nervous system where there is a breach in the blood brain barrier (BBB) 
and is therefore a marker of BBB breakdown (see Figure 2.15). 
 
 
Figure 2.15 Gadolinium enhancing lesion 
 
 
2.9 Pulse sequences 
In designing pulse sequences a balance between image quality and acquisition time 
has to be achieved. Image quality is determined by spatial resolution and signal to 
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achieved by reducing the slice thickness or field of view or increasing the matrix size. 
Noise is random variation in signal intensity affecting the transverse magnetisation 
signal and comes from sources such as the patient’s body and the MR machinery. 
Signal to noise ratio is increased at higher field strengths (as the excess in number of 
spins in the parallel state increases with field strength, thus the number of spins 
generating the MR signal is greater), with increased voxel size (as there are more 
spins per voxel), the number of excitations (or averages) per image and the receiver 
bandwidth (narrow bandwidth records less noise than wide bandwidths, but results in 
slow sampling and low intensity readout). Acquisition time depends on TR, number 
of excitations and number of phase encoding steps (increasing phase encoding 
gradients increases resolution). Sequences have been developed to reduce acquisition 
time, such as fast spin echo, and ultrafast gradient echo sequences. 
 
2.9.1 Spin Echo 
The spin echo sequence is a common imaging sequence.  This involves an excitatory 
90º RF pulse which causes i) loss of longitudinal magnetisation and ii) maximised 
transverse magnetisation with phase coherence.  Following the excitatory pulse, the 
longitudinal magnetisation recovers as energy is released to the lattice (T1 recovery) 
and the spins dephase (T2 decay).  To remove the T2* effects, a 180º pulse is given 
(at a time τ from the 90º pulse). After a 180º pulse, spins that are precessing faster 
than others (due to stronger electromagnetic field in that part of the magnet) ‘go to the 
back’, and slower precessing spins ‘get into the lead’. As they continue precessing at 
their pre-180º pulse rate, the faster spins will catch up with the slower spins and by 
time τ from the 180º pulse, the spins will be rephased. The oscillating signal of the 
precessing spins is maximal at this point and the echo is acquired (echo time TE). The 
180º pulse only reverses signal loss due to field inhomogeneities, and differences due 
to interactions of neighbouring spins (i.e. due to T2 tissue specific differences) 
remain.  Further rephasing 180º pulses can be given (and signal acquired) but due to 
T2 decay, the signal diminishes from subsequent echoes, thus requiring repetition of 
an excitatory 90º pulse.  The time between two 90º pulses is the repetition time (TR) 
(see Figure 2.16).  
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take a long time. 
 
Fig.2.16 diagrammatic representation of a spin echo sequence 
90○
180○
τ τ
TE
TR
90○
180○
echo echo
 
 
2.9.2 Dual echo  
Similar to the spin echo sequence, but dual spin echoes allow two images to be 
acquired with the same (long) TR per slice location. For every 90º pulse, two 180º 
pulses are given, thus one image is acquired with a short TE (generally proton density 
weighted) and the second acquired with a long TE (true T2 weighted), see Figure 
2.17. 
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2.9.3 Fast spin echo 
In fast spin echo for every excitatory 90º pulse, multiple 180º rephasing pulses are 
applied and spin echoes subsequently acquired, generating an echo train. A phase 
encoding step is applied with every 180º pulse and data is collected in K space. 
Several lines of K space are filled for every TR (instead of one line in conventional 
spin echo) filling K space quickly.  
 
Since every echo in the echo train has a different TE the contrast will be different.  
Those with longer TEs are T2 weighted and those with shorter TEs PD weighted. 
When the data is collected in K space, it is ordered so that the strongest signal 
(highest amplitude produced by the shallowest phase encoding gradient) are used on 
the echoes produced from the 180º pulses nearest the effective TE (the desired TE), 
therefore the bulk of the signal has the desired weighting. Steeper phase encoding 
gradients are performed with 180º pulses at other TEs, generating lower amplitude 
signal and these provide the spatial resolution.  
 
The advantage of fast spin echo is their speed, being able to acquire 256 phase 
encodings in as few as 16 TRs, using an echo train length of 16. Because the scan 
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disadvantage is the signal decays with echo train length, reducing signal to noise. 
Also with echo train length increase the difference in TEs can affect image quality. 
 
2.9.4 Gradient echo 
The sequences described above use 180º RF pulses to rephase spins. This can also be 
achieved by changes in the magnetic field gradient. After the excitatory RF pulse, the 
spins start to dephase. A negative gradient is first applied, further slowing down the 
slow spins and speeding up the faster spins, thus dephasing is accelerated. This is 
followed by a positive gradient which has the opposite effect, speeding up the slow 
and slowing down the fast spins, rephasing the signal. This method is less efficient 
than RF rephasing, as it does not reverse all the dephased spins. Also the rate of 
transverse decay will be faster as there will be T2* effects such as B0 inhomogeneities 
in the absence of the 180º pulse. The advantages of gradient echo are that it is faster 
and any flip angle can be used (unlike spin echo which requires an initial 90º pulse) 
allowing another parameter that can be altered to give the desired weighting. Using a 
large flip angle gives the images T1 weighting, as the majority of the net 
magnetisation vector is in the transverse plane. The larger the flip angle, the longer 
the longitudinal magnetisation recovery takes. Small flip angles reduce T1 weighting 
and can be quicker due to the reduced TR required for full longitudinal relaxation.  
 
2.10 Non-conventional MRI 
Changes observed in the grey matter and normal appearing white matter (NAWM) of 
biopsy and autopsy studies are not visible on conventional MRI. One reason for this is 
that conventional MRI visualises protons in association with water, and is unable to 
visualise protons in macromolecules, such as myelin and cell membranes, due to their 
very short relaxation times. It is not possible on conventional MRI to separate out the 
signal from different macromolecular structures and subtle changes in this signal 
cannot be detected. Magnetisation transfer imaging indirectly views the historically 
invisible macromolecules. 
 
  592.10.1 Magnetisation transfer imaging 
In conventional MRI the signal comes from freely mobile protons, such as in water, as 
these have long T2 relaxation times. The protons in macromolecules and phospholipid 
bilayers are semi-solid and their motion is restricted compared to water. Due to the 
close proximity of neighbouring protons, they have strong spin-spin interactions 
resulting in rapid T2 relaxation times. The signal from this so called ‘bound pool’ 
decays too quickly to be visible on conventional MRI however the protons from the 
bound pool can influence the signal coming from the mobile pool. Protons in the 
bound pool precess at a broad range of frequencies (tens of kHz), due to variation in 
macromolecular structures and spin-spin interactions within the individual molecular 
structures.  By contrast the protons in water precess at a narrow range of frequencies 
(a few Hz). The RF pulses in conventional MRI are at the Larmor frequency of 
protons in water.  In magnetisation transfer imaging, an additional off-resonance pulse 
is applied, affecting spins in macromolecules precessing at that frequency without 
exciting water protons. The off-resonance pulse is applied in such a way as to saturate 
a portion of the macromolecular protons, a dynamic process in which the spins are 
flipping between parallel and anti-parallel states at such a rate to have a net 
magnetisation of zero with no transverse component.  Magnetisation is then 
exchanged between the mobile proton pool and bound proton pool causing a reduction 
in the magnetic resonance visible signal from the water protons. This exchange of 
nuclear magnetisation occurs both through dipole-dipole interaction and through 
chemical exchange in which loosely bound protons are exchanged between the two 
pools.  The exchange results in reduction of the free-water transverse magnetisation 
and a reduction in signal intensity for any given voxel. The difference in signal from 
two acquisitions with and without the off-resonance pulse can be quantified as a 
magnetisation transfer ratio.  Breakdown of macromolecules, such as myelin and cell 
membranes, causes a reduction in MTR compared to normal tissue, thus providing a 
quantitative measure of structural integrity. MTR can be measured in percent units 
and is calculated using the following formula: 
 
{(M0-MS)/M0}x100 
 
where M0 and MS represent the signal intensities without and with the saturation pulse 
respectively. 
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The absolute MTR values will depend on the off-resonance pulse used and other 
scanner specific details, making comparisons between sites difficult. However results 
are consistent if the imaging is performed with the same sequence on the same 
imager, with one study finding MTR ranged between 37.6 and 40.6 pu. Age related 
differences are found however [116] .   
 
MTR can be averaged over a region of interest (ROI) to investigate focal disease, but 
to investigate diffuse changes it is desirable to analyse larger regions. The distribution 
of values from all pixels in the whole or segmented brain can be displayed in a 
histogram. Generation of histograms requires data acquisition, definition of the tissue 
area studied and selection of an interval (bin width) for display of the frequency 
distribution. As brain volumes differ between subjects, histograms are normalised by 
dividing all values by the total number of pixels and a frequency distribution is then 
obtained which represents a fraction of total brain volume in one interval.  Histograms 
can be described by parameters, namely mean MTR, peak height, peak location and 
percentiles and has allowed detection of subtle diffuse abnormalities which can be 
missed on ROI analysis [117, 118]. The mean MTR is most commonly referred to in 
MTR studies which have been shown to vary between patient subgroups. Other 
histogram parameters give an indication of the focality of the disease process. 
Reduction in peak location (without loss of peak height) results from a generalised 
reduction in MTR, suggesting a diffuse disease process with all voxels having 
reduced MTR values. Peak height reflects the amount of residual normal tissue. Focal 
changes in the normal appearing tissue are thought to reduce the peak height by 
increasing the number of voxels with low MTR values. Thus a proportion of voxels 
have low MTR, but the remainder of the brain tissue is unaffected and has normal 
MTR values (that is at a normal peak location). The more severe the disease process 
in these focal abnormalities, the greater the relative increase in the histogram at low 
MTR, and the histogram peak broadens at lower MTR values. Voxel based analysis 
compares large regions, and identifies focal MTR differences that are consistent 
between two groups. 
 
 
  612.10.2 Magnetic Resonance Spectroscopy 
As discussed above, in conventional MRI, protons in water molecules are targeted 
with excitatory RF pulses, which have a narrow range of precessing frequencies. The 
resulting signal is located using phase and frequency encoding gradients. In 
spectroscopy, signal location is sacrificed to quantify the protons in different 
molecules, and hence the molecules themselves. This is possible because protons in 
different molecules precess at different frequencies due to chemical properties 
(particularly the electron density associated with the molecule). MRS can look at 
31P, 
19F and 
1H atoms, (MR active nuclei), but since 
1H is at higher concentrations and 
existing 
1H imaging hardware can be used, 
1H spectra are most commonly acquired.   
 
A nucleus is surrounded by electrons which also have magnetic susceptibility and 
become slightly magnetized in the external magnetic field.  Their field minimally 
counteracts B0, thus the effective external magnetic field acting on the proton is lower 
than B0, reducing its precession frequency. Hence protons in different chemical 
environments precess at different frequencies, and the amount of signal at each 
frequency is detected on the spectrum. The position of the peak on the x axis is 
measured relative to a reference peak, and the distance between the peak of interest 
and reference peak is the chemical shift (as it is the shift in the proton’s precessional 
frequency due to the chemical environment). The height of the peak on the y axis is 
proportional to the number of 
1H nuclei in the molecule with the same chemical shift 
in the sensitive volume.  In this way molecules with known chemical shifts can be 
quantified. 
Chemical shift = nuclear shielding/applied magnetic field 
 
To obtain a spectrum from a region of interest (ROI), an image is first acquired and 
ROI marked as a cube (the sensitive volume). This is a large voxel compared to 
conventional MRI as the metabolites of interest are at low concentrations (volumes 
range typically from 1 to 8mls), see Figure 2.18.  
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Figure 2.18 showing positioning of a voxel 
(the sensitive volume) for single voxel 
spectroscopy 
 
 
 
Just as in conventional MRI, following an excitatory pulse, B0 inhomogeneities must 
be corrected over the sensitive volume before the resultant signal is acquired. As the 
voxel is larger than in conventional MRI and the compounds have frequency 
separations of a few parts per million, correcting the inhomogeniety in the voxel is 
even more important to prevent the frequencies associated with the same metabolite in 
different parts of the voxel resulting in multiple peaks. This is done with multiple 
shim coils generating small magnetic fields to correct B0 inhomogeneity.  Since the 
bulk of the signal from water and lipid totally dominates the signal from the 
metabolites, these are suppressed so as to quantify the metabolites at much smaller 
concentrations.  
 
 
Figure 2.19 Water suppression in 
spectroscopy. Demonstrating the 
dominant peaks from water and 
lipid, and the need to suppress 
these for investigation of 
metabolites at lower concentrations 
 
 
The time of the acquisition depends on the metabolites of interest. At longer echo 
times, N acetyl containing compounds, creatine and phosphocreatine, and choline 
containing compounds may be quantified (all of which have T2’s of about 250ms), 
  63while at shorter echo times additional metabolite peaks may be seen from myo-
inositol (Ins), glutamate and glutamine, and mobile lipids, however peak overlap can 
be a problem. The strength of the magnetic field also affects the spectra, with higher 
fields generating increased signal intensity and improved spectral separation.   
 
 
 
 
 
Figure 2.20 spectrum 
acquired at short echo 
time from a single voxel 
in normal appearing white 
matter in a CIS patient, 
and metabolite peaks 
observed.  
 
NAA 
Cho 
Cr 
Ins 
 
Deriving reliable data from spectroscopy is limited by several issues, such as variation 
in tissue composition of voxels, particularly partial-volume effects due to the presence 
of CSF within the voxel and the position of the voxel in relation to the inhomogenous 
radio-frequency of the coil.  The data must be standardised to enable comparison. A 
common internal standard is expressing the metabolite of interest relative to a 
metabolite that is not affected by the disease process. Cr has been used as an internal 
standard, but studies have shown this is not always stable, and is particularly affected 
in acute, gadolinium enhancing lesions [119, 120] and correlated with age in healthy 
adults [121]. Another internal standard used is tissue water or CSF but neither of these 
are reliable (MRI is very sensitive to changes in tissue water and this is therefore not a 
stable reference and measurement of CSF signal intensity is error-prone due to the 
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measurement of a phantom containing a known concentration of NAA (or other 
molecule of interest) to provide a calibration factor for quantification of absolute 
values of metabolites [122].   
 
  652.10.3 Measurements of brain atrophy 
Several methods have been developed to analyse brain volume or atrophy. Regarding 
brain volume, the simplest methods are linear measurements of brain or ventricular 
width, and have also been used to measure corpus callosal width. As well as being 
time-consuming, these techniques rely on careful positioning, the observer’s expertise 
and results in considerable inter-observer variability. Semi- and fully automated 
segmentation methods have been developed to reduce the inter-observer variability. 
These allow quantification of brain parenchymal and/or CSF volumes, driven by the 
difference in their signal intensities.  
 
MIDAS is a semiautomated technique to measure lateral ventricular volume. The first 
step involves segmentation of the brain from extracranial tissue (and setting the 
inferior cut-off as the lowest point of the cerebellum). Brain segmentation requires 
selection of a signal intensity threshold for the boundary between CSF and brain and 
is set at 60% of mean brain intensity. Thresholding weakens the links between brain 
and adjacent structures and the image is eroded to leave only brain tissue. The outer 
voxels of the brain eroded in the previous step are replaced with a dilation step. Mean 
whole brain signal intensity is re-calculated and the ventricular-brain boundary is 
again set at 60% of this value. The lateral ventricles (including the temporal horns but 
excluding the third and fourth ventricles) are outlined with a seed placing technique 
and the program automatically outlines the ventricles, recursive 2D growth beyond 
the ventricles being constrained by the intensity threshold range. High signal 
structures in the ventricles (such as the choroid plexus) are excluded. Volume is 
calculated by multiplying the outlined area by the slice thickness.  This technique has 
intra-observer coefficients of variation (CoV) ranging from 0.02% to 0.89%, with 
inter-observer CoV of 0.32% [123].  
 
Fully automated techniques such as SPM have been developed to reduce inter-
observer variance, and allow segmentation of grey and white matter whose signal 
intensities are variable within the brain and less dissimilar than brain/CSF intensities. 
After masking to remove extracranial tissue and correcting for intensity 
inhomogeneity, SPM assigns a probability of a voxel belonging to a tissue based on 
signal intensity and location. This is assisted by registration of the study image to 
prior belonging probability maps (generated from segmented images of 151 healthy 
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class are thus assigned and mutually exclusive masks are generated. The presence of 
MS lesions can result in misclassification as grey matter or CSF due to their different 
signal intensities from surrounding white matter. Masking of lesions prior to 
segmentation aims to prevent this. Further problems include partial volume effects 
blurring the boundaries between tissue types impeding their differentiation, and mis-
registration due to variability in anatomical landmarks. Intra- and inter-observer CoVs 
of 0.09% and 0.19% respectively have been reported [123].  
 
As there is a wide range of brain volumes in healthy populations, studies usually try to 
correct for head size, adjusting the raw inter-subject differences in regional or whole 
brain measurements. There are two techniques that correct for intracranial volume 
(ICV), an estimate of head size: proportion and residual methods. The proportion 
method corrects for head size by dividing the brain tissue volume by the total ICV 
generating brain fractions. This corrects for head size on an individual basis and is 
free of any requirement for group based corrections. However errors from numerator 
and denominator are combined and sources of error are masked in the final outcome 
ratio. The residual method requires group data and uses the correlation between (raw) 
absolute parenchymal volumes (APV) and ICV to calculate the regression line for 
predicted parenchymal volumes (PPV) taking into account ICV. A scatterplot of ICV 
against APV for each group is fitted with the (least-squares derived) regression line 
which determines the PPV for a given ICV. It is based on a least-squares solution 
which by definition minimises the error in derived predicted values. The latter method 
has been shown to be more robust to errors in brain volume analysis and therefore 
may provide advantages over the proportion method [124].  
 
The techniques described generate area or volumetric measures, and atrophy can be 
calculated from serial measurements. However small changes in volume may be 
missed by these methods due to dependence on reproducibility. Registration based 
methods have been recently developed to enable direct quantification of brain volume 
change by spatially registering serial images and subtracting the volume and these 
techniques are more sensitive to change [125]. 
 
  673 The use of MRI in the study of multiple sclerosis 
 
3.1 Conventional MRI  
3.1.1 Lesion appearance  
MRI is very sensitive for detecting inflammatory activity in the white matter of the 
central nervous system in MS.  Typical findings are multiple hyperintense lesions in 
the white matter on T2 and PD weighted imaging. Over time individual T2 
hyperintensities may remain static or increase in size, and occasionally recede or 
disappear. They tend to accumulate with disease duration, increasing at a rate of 5-
10% per year. They can represent pathologically diverse processes, including active 
demyelination, remyelination and glial scarring [126]. T1 weighted imaging, 
particularly with contrast can provide some additional information regarding plaque 
age and degree of axonal and myelin loss. 
 
Figure 3.1 Typical MRI 
findings on T2 weighted 
images in CIS and early 
MS, demonstrating 
multiple, focal 
hyperintensities in a 
periventricular 
distribution. 
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gadolinium, a finding which has been shown to correlate with active demyelination on 
histology [127].  Enhancement may precede new T2 lesions by hours or days, and 
persist for 2 to 8 weeks so providing a marker of recent disease activity. On 
corresponding T2-weighted scans, acute lesions may appear target-like, with 
surrounding oedema which later resolves (see Figure 3.2).  Being a marker of acute 
inflammation, gadolinium enhancing lesions are more frequently seen in relapses than 
remissions [128], and in relapsing-remitting more than secondary progressive patients 
[129, 130]. Scanned monthly for 10 months, 90% of untreated RRMS patients would 
have enhancing lesion(s) [131]. The number of enhancing lesions is low, with a 
median of 0 to 1 [132, 133], and declines with disease duration [134]. Like T2 lesions, 
the majority are asymptomatic. 
 
Baseline                         1 year
 
Figure 3.2 Acute lesion on PD- and T1 
weighted images at baseline, demonstrating 
surrounding oedema on PD weighted MRI, 
with resolution of oedema and accrual of 
new lesions at 1 year. The corresponding T1 
weighted image shows acute Gd 
enhancement and subsequent development 
of a black hole. 
 
 
Most gadolinium-enhancing lesions appear hypointense on T1-weighted scans (see 
Figure 3.3), but only 40% remain hypointense 6 months later, the remainder 
recovering to some degree back to isointense with the normal appearing white matter 
[135]. Histopathology studies have shown that the degree of hypointensity correlates 
with axonal loss [136], thus persistent T1 hypointensities represent irreversible 
structural damage and axonal loss.   
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Figure 3.3 T1 
hypointensities, 
demonstrating some 
PD-weighted 
lesions appear 
hypointense on 
corresponding T1 
image  
 
Figure 3.4 Change in lesion appearance during follow-up. Demonstrating a new lesion at 3 months with 
surrounding oedema, corresponding to Gd enhancing lesion on T1 post contrast. At subsequent 1 year 
scan, oedema has resolved but lesion appears hypointense on corresponding T1 MRI. MRI at 5 years 
shows accumulation of lesions, with further T1 hypointensity development. Ventricular enlargement 
and sulcal widening indicate atrophy. 
 
 
Baseline    3 months         1 year          5 years 
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3.1.2 Location of lesions 
CNS locations considered characteristic of demyelination are periventricular, corpus 
callosum, juxtacortical (this direct subcortical zone is typically spared in 
hypoxic/ischaemic disease), infratentorial (other diseases tend to be confined to the 
supratentorial compartment) and spinal cord (see Figure 3.5). Lesions are 
characteristically ovoid, representing breakdown in the blood brain barrier of venules 
with inflammation extending into adjacent white matter.  
 
 
 
Figure 3.5 Characteristic locations for demyelination, showing (from left) spinal cord, callosal, 
infratentorial, juxtacortical and periventricular lesions  v) 
 
At first presentation with a clinically isolated syndrome (CIS), asymptomatic brain 
lesions are seen on T2 weighted MRI in 50-74% of patients [99, 137-140], and in 
95% of patients with CDMS.  Asymptomatic spinal cord lesions are seen in 27-42% 
of CIS patients [140-142], and are usually accompanied by brain lesions. Spinal cord 
lesions in patients with CDMS are most frequent in the cervical cord, tend to be focal, 
rarely cause cord expansion (3%) or appear hypointense on T1 weighted images 
(<0.1%) [143].  
 
MRI activity tends to be greater than clinical activity in RRMS and for every clinical 
relapse there may be 5 to 10 new T2 lesions. Similarly, with monthly gadolinium 
enhanced T1 weighted imaging, about 10 gadolinium enhancing lesions will be 
observed for every clinical relapse [131, 144].   
 
3.1.3 Conventional MRI features associated with prognosis 
MRI is the most sensitive paraclinical test in MS diagnosis and a normal MRI at 
presentation carries a negative predictive value of early conversion of 97% [99, 145].  
The presence of one or more MRI lesions at CIS presentation increases the risk of 
CDMS, with 82% of patients with abnormal baseline MRI converting to CDMS by 20 
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years compared to 21% of patients with normal imaging [61, 62]. Other studies have 
reported similar results (see Table 3.1).   
 
Table 3.1 comparing conversion rates in CIS cohorts with normal and abnormal baseline MRI 
(*symptomatic lesion excluded) 
% developing CDMS  CIS cohorts 
with normal MRI   with abnormal 
MRI  
Duration of follow-
up 
22% 56%  10  years  ON only  
[63, 74]   25% 72%  15  years 
6% 72%  5  years 
11% 83%  10  years 
19% 88%  14  years 
Mixed CIS cohort  
[61, 62, 145, 146] 
21% 82%  20  years 
ON only [75]  0% 52%  6.3  years 
Mixed CIS cohort [147]  8% 60%  7  years 
 
Short follow-up studies suggested that the number or grade of MRI abnormalities 
influences the risk of developing CDMS.  Morrissey et al showed at 5 years the risk 
of progression to MS in a mixed CIS cohort was 54% in patients with 1-3 lesions and 
85% in patients with 4 or more [145].  Similar findings were reported from the two 
year follow-up of the North American optic neuritis treatment trial (ONTT), in which 
17% of patients with grade 2 MRI abnormalities (one periventricular or ovoid lesion 
>3mm in size) developed CDMS compared to 36% of patients with grade 3 or 4 MRI 
abnormalities (2 or more periventricular or ovoid lesion >3mm in size) [148]. 
Recently Tintore et al demonstrated risk of conversion in a mixed CIS cohort by 7 
years was clearly stratified by baseline lesion number [147]. However longer follow-
up of both the ONTT and early mixed CIS cohort found the risk of CDMS at 14-15 
years was not significantly different in patients with 1 or more lesions (ranging from 
81-85% in the mixed CIS cohort [61, 62] and 60-78% in the ONTT depending on 
lesion number (see Table 3.2)) [63, 74]. Together these results suggest that baseline 
lesion number may predict early conversion. It should be noted however that the early 
follow-up studies are based on MRIs acquired 15 to 20 years ago, and were of lower 
resolution than those acquired more recently. It is likely that the number of lesions 
was underestimated by today’s standards. Longer follow-up of more recent cohorts 
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are required to determine the risk of baseline lesion number visible at higher 
resolution. 
 
Table 3.2 showing percentages of patients converting to CDMS with 7-20 year follow-up depending 
on number of brain lesions at baseline. Note that the MRIs in the studies marked with an * were 
acquired in the 1980’s. 
Percentage of patients converting to CDMS by number of lesions   
0  1  2  3  4 5 6 7 8 9 ≥10 
F/U 
Mixed CIS 
cohort [147] 
8% 30%  50%  73%  7y 
17% 67%  6% 
54% 
92% 80%  5y 
33% 87%  11%
79% 
87% 85%  10y 
19% 89% 87%  88%  14y 
Mixed CIS 
cohort* [61, 
62, 145, 146] 
 
21% 82% 85%  81%  20y 
21% 51% 50%  70%  57%  10y 
60% 68%
ON only*  
[63, 78]  25%
65% 
78%  15y 
 
Evidence of MRI dissemination in time is strongly predictive of conversion to 
CDMS. A new lesion at 1 year was identified in 68% of CIS patients with abnormal 
baseline MRI, of whom 81% developed CDMS after 5 years compared to 22% of 
patients not acquiring new lesions [145]. In patients with normal baseline imaging, 
only 31% acquired new lesion(s), of whom 20% developed CDMS by 5 years 
compared to no patients with persistently normal imaging. Both the appearance of 
new T2 lesions and new gadolinium lesions at 3 months follow-up were highly 
predictive of CDMS at 12 to 19 months [140] (specificity 81% and 89%, sensitivity 
92% and 54% respectively). Using only the baseline scan, the presence of a 
gadolinium enhancing lesion was found to be the most useful imaging correlate for 
predicting CDMS by 1 year (specificity 80%, sensitivity 61%) [149]. Therefore the 
identification of T2 and gadolinium lesions at baseline and new lesions at follow-up 
are helpful in predicting the risk of conversion to CDMS.  
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The prediction of long-term disability is more uncertain and perhaps more important.  
The ONTT found no correlation between baseline MRI findings and disability at 10 
and 15 years [63, 74], whereas a consistent association between baseline lesion 
number and EDSS at 10, 14 and 20 years was found in the mixed CIS cohort 
(correlation coefficients of 0.45 - 0.48) [61, 62, 146]. None of the patients in this 
mixed CIS cohort with normal baseline MRI had developed clinically significant 
disability at 14 years, whereas over a third of patients with abnormal baseline MRI 
were unable to walk unaided [61].  By 20 years 6% of patients with normal baseline 
MRI were unable to walk unaided compared to 25% of patients with abnormal 
imaging [62]. In a recent study 10 or more lesions increased the hazard of significant 
disability at 7 years more than three fold [147], concurring with findings from the 
earlier CIS cohort followed up at 10 years in which three quarters of patients with less 
than 10 lesions at baseline had little or no disability (EDSS≤3) and three quarters of 
patients with more than 10 lesions having significant disability (EDSS>3) [146].  
 
The chronological relationship of EDSS and lesion load has been investigated, and 
early change in lesion volume found to correlate more strongly with later rather than 
concurrent disability [61, 112, 150]. These findings led to an ‘MRI-clinical 
disconnect theory’, that the CNS is able to compensate for MS-related pathology up 
until a certain threshold, beyond which functional deterioration and clinical 
progression become manifest. This is supported by the finding in over a thousand MS 
patients that T2 lesion load correlated with disability until EDSS 4.5, following which 
the relationship plateaued [151]. These data suggest that pathogenic processes 
additional to T2-visible lesions might become more important over time.   
 
The relationship with disability and lesion activity has also been investigated in 
CDMS patients.  Gadolinium enhancement is a marker of disease activity, and 
predicts the occurrence of relapses [152-154] but their significance regarding 
disability is not clear. Whereas a cross sectional study found a correlation between 
EDSS and number of enhancing lesions [155], longitudinal studies have failed to 
show their ability to predict later disability [150, 152, 153, 156]. Location of lesions 
for prognosis has been proposed and one study found the presence of two or more 
infratentorial lesions to be a strong predictor of disability [156].   
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As well as physical disability, cognitive impairment is an important aspect of MS. 
Although correlations between total lesion load and cognitive impairment in 
established disease are recognised [157, 158], the relationship between 
neuropsychology scores and lesion load in patients with early disease has been weak 
[159] or absent [93, 95, 96].   
 
The correlations of early conventional MRI markers and later disability have been 
moderate at best. Therefore it seems that in the early years, relapse rate and lesion 
load has an influence on time to develop moderate disability, (EDSS 4) but not the 
subsequent evolution to more severe disability. The histological observation of 
cortical lesions and changes in the normal appearing white matter (NAWM) 
‘invisible’ on conventional MRI may add important prognostic information and 
explain the missing variation in disability.   
 
3.1.4 MRI in diagnosis 
With the recognition of the sensitivity of MRI to MS pathology and its ability to 
predict CDMS in CIS patients, came its integration into diagnostic criteria as 
paraclinical evidence of dissemination in space (DIS).  Such criteria were designed to 
be used only in CIS cases considered absolutely characteristic of demyelination, such 
as unilateral optic neuritis, bilateral intranuclear ophthalmoplegia and partial 
transverse myelitis. Early criteria involved number of lesions on a single scan [160, 
161] but when tested on cohorts of CIS patients were found to have low specificity.  
The relative importance of individual MRI parameters at presentation was 
subsequently evaluated to predict conversion to CDMS using logistic regression 
[162].  The presence of a gadolinium enhancing lesion and a juxtacortical lesion were 
the most relevant, followed by an infratentorial lesion and three periventricular 
lesions.  The presence of three out of four of the above was more specific (78% 
compared to 54%) and accurate than the earlier criteria (80% compared with 69%).  
These were later modified and 9 or more T2 lesions were allowed in place of a 
gadolinium enhancing lesion (since accuracy was found to be optimal at a minimum 
of 9 lesions) [163].  
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Table 3.3 summarising early MRI diagnostic criteria 
  Required MRI findings 
Paty’s criteria [160]  4 lesions or 3 lesions one of which is periventricular 
Fazekas’ criteria 
[161] 
3 lesions, including 2 of the following characteristics: infratentorial location, 
periventricular location, lesion >6mm 
Barkhof’s 
criteria[162] 
3 of the following: ≥9 T2 lesions or ≥1 Gd enhancing lesion 
                               ≥3 periventricular lesions 
                               ≥1 juxtacortical lesion 
                               ≥1 infratentorial lesion 
 
The early MRI criteria appeared to support evidence of DIS but failed to address the 
need for dissemination in time (DIT), fundamental to a diagnosis of MS.  Brex et al 
following up a CIS cohort at 1 year found that the presence of new T2 lesions at 
follow-up and enhancing lesions at baseline provided the best combination of 
sensitivity and specificity for CDMS [140]. In 2001 the McDonald criteria were 
published which included MRI evidence for DIT to improve the specificity of MRI 
criteria.  The modified Barkhof criteria were retained as evidence of DIS and a 
gadolinium lesion more than 3 months from symptom onset confirmed DIT (DIT 
could also be fulfilled with a new T2 lesion with reference to a baseline scan more 
than 3 month from symptom onset). DIS is also fulfilled with 2 T2 lesions and 
oligoclonal bands in the CSF. The criteria are highly specific for the development of 
CDMS at 3 years, (greater than 90%), but they have limited sensitivity (59%) [164].  
Sensitivity increases to 76-83% if the 1 year scan is used for evidence of DIS and DIT 
(when a new T2 lesion subsequent to a scan at least 3 months after the attack could 
count for DIT), but specificity drops to 83-86% [164, 165]. In response to 
demonstration that a new T2 lesion on 3 month follow-up scan as evidence of DIT 
could be used to increase sensitivity from 58% to 84% without compromising 
specificity, [166] the McDonald criteria were recently modified, with a new T2 lesion 
(with reference to a baseline scan more than a month from CIS onset) acting as 
evidence of DIT [167].  The use of the McDonald criteria improves the rate of 
diagnosis, with the McDonald 2001 criteria more than doubling diagnosis of MS 
within a year of presentation with a clinically isolated syndrome [164]. This is 
potentially important as clinical trials have shown delay to CDMS with early 
Interferon treatment and the Association of British Neurologists (ABN) guidelines 
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have recently recommended disease modifying therapy for patients with McDonald 
MS. 
 
3.2 Non-conventional MRI 
An autopsy study suggested that T2 weighted MRI may detect only about 65% of 
plaques in the white matter identified grossly on pathological inspection [168]. 
Therefore conventional MRI fails to detect a substantial proportion of MS lesions, 
particularly in the grey matter where lesions are rarely seen on MRI but frequently 
evident at post mortem. Conventional MRI also lacks pathological specificity. 
Following the acute active demyelinating stage, signal intensity and borders of lesions 
appear the same on T2 weighted images, irrespective of the wide variability seen on 
histopathology. T2 weighted imaging does not allow distinction between 
remyelinated and fully demyelinated, gliotic lesions or assessment of the degree of 
axonal loss, differentiation of which could have prognostic implications.  Also, MRI 
reveals no abnormality in non lesion white matter, although it can appear highly 
abnormal in autopsy studies [38].  Non-conventional MRI techniques, such as 
magnetisation transfer imaging, spectroscopy and diffusion, offer a new perspective 
on MRI imaging, quantifying abnormalities in what appears normal appearing brain 
tissue on conventional imaging.  
 
3.2.1 Double Inversion Recovery 
Cortical lesions are poorly visualised on T2 weighted MRI [40] due to poor contrast 
resolution between grey matter and lesions in cortex compared to lesions in the white 
matter. Grey matter lesions tend to be less inflammatory, and therefore have shorter 
relaxation times than white matter lesions. FLAIR acquisition identifies a few more 
cortical lesions than PD or T2 weighted images, but a newer technique, double 
inversion recovery (DIR) identifies considerably more, with 538% gain compared 
with conventional spin echo, and 152% gain compared to FLAIR. It still detects much 
lower numbers of intracortical lesions compared with histopathology studies [168]. 
 
In a large study of CIS, relapsing-remitting and secondary progressive MS patients, 
DIR identified cortical lesions in 58% of patients, including 36% of CIS patients. The 
mean number of cortical lesions was significantly higher in secondary progressive 
MS patients compared to CIS patients. Thus cortical lesions seem to increase with 
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disease activity and their presence at CIS onset may have important prognostic 
implications, but their ability to predict disability or CDMS has not been evaluated. 
Three types of intracortical lesions were identified by DIR: 60% small round/ovoid 
lesions, 31% worm shaped lesions which followed the profile of gyri with extension 
into the grey matter, and the rest were wedge shaped with subpial base and apex 
towards the white matter [169].  
 
 
3.2.2 Magnetisation Transfer Imaging 
Magnetisation transfer imaging (MTI) and ratio (MTR) offer improved pathological 
specificity, correlating with axonal density and myelin in lesions in autopsy studies 
[136].  However animal models of experimental allergic encephalitis have shown that 
MTR is also reduced in inflammation, in the absence of demyelination and axonal 
loss [170, 171] and may indicate changes in myelin content or structural changes in 
response to inflammation, not necessarily a loss of myelin.  Therefore MTR changes 
are not specific for changes in myelin content but represent changes in myelin 
pathology including oedema, axonal loss and more general tissue injury.  
 
There is wide variation in lesion MTR which may reflect different stages of plaque 
development and tissue loss.  Post mortem studies have shown that compared with 
mildly hypointense T1-weighted lesions, severely hypointense lesions have the lowest 
MTR and myelin content [126], whereas remyelinated lesions have higher MTR than 
demyelinated lesions [172]. Voxel-based analysis of a gadolinium-enhancing lesion 
observed over 6 months in vivo and subsequently biopsied, showed MTR was low 
and stable in the lesion core. On subsequent histopathology this corresponded to the 
demyelinated centre, with diffuse presence of macrophages and marked loss of 
oligodendrocytes. Over follow-up, increase in MTR was noted in lesion voxels 
bordering the normal appearing white matter (NAWM), which corresponded on 
histopathology to the partially remyelinated lesion border [173]. MTR has also been 
found to correlate with myelin and axonal density in NAWM [136].   
 
MTR reduction in lesions relative to NAWM has been demonstrated in vivo and 
studies have shown that mean lesion MTR significantly declines with plaque age 
[174], with detectable change over a year [175].  Progressive reduction in MTR in 
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pre-lesion white matter has been demonstrated up to 2 years prior to lesion detection 
on conventional MRI [174, 176]. These findings suggest myelin pathology precedes 
lesion visualisation and progresses following its appearance on conventional MRI.  
 
Autopsy studies have shown the disease process in MS is not restricted to lesions, and 
MTR can detect abnormalities in NAWM in vivo [177]. Compared to controls, 
reduction in MTR in NAWM has been reported in patients with minimal disability 
and disease burden [178, 179] and therefore pathology in normal appearing brain 
tissue (NABT) is not restricted to the progressive phase of the disease. Some studies 
have shown reduction in NAWM MTR of CIS patients compared to controls [180-
182], although this was not found in smaller studies [183, 184], and may be greater in 
patients with abnormal imaging. In the same way that lesions accrue, changes in 
NAWM progress. Significant decline in NAWM MTR over a year, not found in 
controls, has been observed in CIS, RRMS and SPMS patients [185] resulting in 
SPMS patients having the lowest values of MTR [186]. This possible evidence for 
myelin pathology is potentially irreversible, as CIS patients who have not had a 
further event 14 years later still had detectable MTR reduction in NAWM when 
compared to controls [181]. 
 
MTR reduction has also been detected in grey matter, in patients at all stages of the 
disease [178, 179] including CIS patients [182]. Again, change in MTR over a year in 
grey matter is detectable in CIS [187], RRMS [187, 188] and SPMS patients [187], 
with MTR decreasing at a greater rate in grey matter than NAWM [188]. Back 
extrapolation of the data in this latter study suggested that changes in the NAWM 
began prior to symptom onset, and in the grey matter soon after the first clinical 
event. MTR reduction in grey matter may reflect cortical lesions not visible on 
conventional MRI.  However voxel based analysis of the occipital cortex in CIS optic 
neuritis patients showed selective reduction in MTR in the visual cortex compared to 
controls [189]. The selective location of MTR reduction argues against this being due 
to cortical lesions, as the reduction would be more global, and suggests a more 
specific link with the symptomatic inflammatory demyelinating optic nerve lesion, 
via a trans-synaptic pathogenic mechanism. 
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Studies have shown an association between MTR, particularly in the grey matter, and 
disability.  Cross sectional studies in CDMS patients have shown moderate 
correlation of MSFC [190] or EDSS and grey matter MTR parameters; mean [179], 
peak height [190, 191] and peak location [190]. Whereas a PPMS study found a 
correlation with regional NAWM MTR and EDSS [192], other studies have not found 
an association between histogram NAWM parameters and disability [179, 191]. An 
association between MTR and cognitive impairment has also been reported in a 
mixed MS cohort [193], and in both early [159] and later disease [193]. 
 
Medium and longer follow-up of a mixed cohort of CIS, RRMS and SPMS have 
shown that certain MTR parameters may predict worsening of disability. Worsening 
of EDSS at 4.5 years was predicted by baseline T2 lesion volume and percentage 
change in whole brain MTR over 1 year [175] but grey matter peak height and 
average lesion MTR percentage change over 1 year predicted longer term disability 
[187]. The prognostic power of MTR has not been fully explored in CIS patients, but 
studies suggest that early MTR changes do not predict CDMS independently of T2 
lesions [182, 184, 189, 194] although one study has shown baseline NABT MTR 
independently predicts CDMS [180]. 
 
3.2.3 Magnetic Resonance Spectroscopy 
Magnetic resonance spectroscopy (MRS) offers further insight into MS pathology by 
quantifying certain metabolites which have been shown to correlate with cell types or 
disease processes.  Water-suppressed proton MR spectra detect protons associated 
with N-acetyl aspartate (NAA), choline (Cho), creatine (Cr) and phosphocreatine, 
myo-inositol (Ins), glutamate and glutamine (Glx) and free lipids.  NAA has been 
shown in vitro cell culture analysis to be a neuronal marker [195], and correlates with 
axonal loss in lesion biopsies [196], although it is also present in oligodendrocyte 
precursor cells. Ins is most raised in chronic lesions with predominant astrocytosis 
and is therefore a marker of gliosis [195], but is also raised in acute lesions and is a 
marker of active myelin breakdown [196]. Cho is thought to represent inflammation 
[197] and membrane turnover [196]. Cr is found at high concentration in glial cells 
(highest in oligodendrocytes and astrocytes [195]), and is a putative marker of gliosis. 
As creatine phosphate serves as a phosphate reserve and buffer in ADP/ATP 
metabolism in neurons, reduction in Cr has been described as indicating metabolic 
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dysfunction [198]. It was thought to be a stable metabolite [199], changing little 
throughout the brain in MS, and therefore used in ratios to express relative 
concentrations of other metabolites. However studies have suggested it may not be as 
stable as first thought. Cr is raised in acute, gadolinium enhancing lesions [119, 120], 
and found to correlate with age in healthy adults [121]. Glutamate is a 
neurotransmitter which is metabolised and released by neurons. It is cleared from the 
synaptic cleft by astrocytes and converted to glutamine which is re-taken up by 
neurons and regenerated into glutamate. An excess of glutamate has been implicated 
in the neuroexcitotoxicity cascade, and may be involved in neuronal loss. 
 
Deriving reliable data from spectroscopy is limited by several issues, such as 
variation in tissue composition of voxels, particularly partial-volume effects due to 
the presence of cerebrospinal fluid within the voxel and the position of the voxel in 
relation to the inhomogeneous radio-frequency of the coil.  The data must be 
standardised to enable comparison. A common internal standard is expressing the 
metabolite of interest relative to a metabolite that is not affected by the disease 
process. Cr has been used as an internal standard, but studies have shown this is not 
always stable, as described above. Another internal standard used is tissue water or 
cerebrospinal fluid but neither of these are reliable (MRI is very sensitive to changes 
in tissue water and this is therefore not a stable reference and measurement of 
cerebrospinal fluid signal intensity is error-prone due to the pulsatile nature of 
cerebrospinal fluid flow). An external standard is often used, with regular 
measurement of a phantom containing a known concentration of NAA (or other 
molecule of interest) to provide a calibration factor for quantification of absolute 
values of metabolites [122].   
 
In acute lesions, transient changes in metabolites have been demonstrated. Reduction 
in NAA [140, 199-203] and raised Cho [119, 140, 201, 204-207], Cr [119], free lipid 
peaks [199, 205, 206] and glutamate [120] have been detected, which partially 
recover over follow-up [119, 199, 203, 205]. Permanent changes in metabolites are 
observed in chronic lesions, particularly those that appear hypointense on T1 images. 
These include reduced NAA [120, 205, 206, 208] and raised Ins [120, 207, 208]. 
These findings suggest inflammation, membrane turnover and transient axonal 
dysfunction in acute lesions, with more permanent damage in chronic lesions. 
  81    
Changes including raised Cho [204, 205] and free lipid peaks [205] have been 
detected in pre-lesion normal appearing white matter (NAWM). These findings are 
consistent with MTR changes in NAWM prior to lesion development and suggest 
inflammation and/or membrane turnover is occurring for some time prior to lesion 
visualisation on conventional MRI. 
 
Cross sectional studies have shown reduction in NAA in NAWM of patients at all 
stages of CDMS [192, 202, 209, 210] including early relapsing-remitting MS [178, 
210] but reduction is greatest in secondary progressive MS patients [200]. Although 
NAA was significantly lower in secondary progressive MS than relapsing-remitting 
MS patients, further decline in NAA over follow-up was only detected in the 
relapsing-remitting MS patients [200, 211, 212], suggesting progressive axonal loss 
in the relapsing remitting but not progressive phase. The changes in NAWM NAA 
ratios over time appeared to be independent of lesion volumes or clinical activity, 
suggesting that axonal damage is partly dissociated from MRI detectable or clinical 
disease activity [213]. Other metabolite changes in the NAWM of MS patients 
include elevated Ins [210, 214], Cho [120, 201, 215] , Cr [201, 215], and Glutamate 
[120] compatible with the autopsy finding of increased inflammation and glial cells in 
NAWM. 
 
Reduction in NAA has also been reported in the grey matter of CDMS patients [207, 
216] including early RRMS patients [210].  Cho [210] and Glx [210, 214] were also 
reduced in the grey matter.   
 
CIS cohorts have been studies to investigate how early in the disease course changes 
in the NAWM can be detected. Studies of whole brain or white matter have found 
reduction in NAA [217, 218] and increased Cho [218, 219] in CIS patients compared 
to controls; however these have included lesions which consistently show metabolite 
derangement. One longitudinal study of a patient with a single lesion adjacent to the 
corpus callosum showed transient reduction in NAA in the homologous site in the 
contralateral hemisphere (with highest density of axonal projections to or from the 
lesion) that was not detected elsewhere in the NAWM [203]. Recently a high field 
single voxel study demonstrated reduction in NAA in CIS patients [220] not detected 
at lower field strength [221, 222]. The same group found NAA was only significantly 
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lower in the subgroup of patients who converted to definite MS suggesting a 
prognostic role [223]. Fernando et al demonstrated raised Ins compared to controls at 
lower field strength, which was not significant in the smaller high field study [221].  
Together these findings suggest that there is evidence of increased inflammation and 
axonal injury at the onset of the disease. 
 
Some cross sectional and longitudinal studies have shown correlation of various 
metabolite measures with EDSS, MSFC and/or cognitive function in CDMS patients.  
Correlation of white matter (i.e. including lesions) NAA:Cr with EDSS has been 
demonstrated in patients with early or mild disease, [224] with decrease over 30 
months correlating with increase in EDSS in RRMS but not SPMS patients [211]. 
This may reflect changes in lesion NAA as studies of NAA in NAWM (i.e. excluding 
lesions) have not correlated with outcome [207, 209, 210, 214]. Studies have shown a 
correlation with NAWM Ins and EDSS [207, 214] and MSFC [210, 214] suggesting a 
role for gliosis rather than axonal loss in disability progression.  Cortical grey matter 
Glx [210] and NAA [214] have been shown to correlate with EDSS and MSFC in 
some but not all [225] studies. 
 
3.2.4 Atrophy 
Brain lesion volume measurement is sensitive for monitoring disease evolution but is 
only modestly correlated with clinical disability. Measurements of brain atrophy are 
thought to reflect the neurodegenerative components of the condition, namely axonal 
loss and demyelination, and therefore better reflect the irreversible pathology 
occurring in MS, and may be better surrogate markers of disability or predictors of 
outcome than T2 lesion volume. Other variables affect brain volume measurement 
such as hydration status and oedema.  
 
MS patients have reduced brain volume compared to healthy age- and gender-
matched controls [226-228], with one study showing 3.5% brain parenchymal 
fraction reduction [226]. With annual atrophy of 0.5 to 0.7% [229, 230], volume 
change can be detected over as little as 3 months [229, 231].  
 
Brain segmentation, and more recently programs that measure mean and regional 
cortical thickness have shown that atrophy occurs in both grey [232, 233] and white 
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matter [226] in MS patients. Most cortical areas appear to be involved [233], with 
frontal regions being particularly affected [233-235] and pre-central gyri (primary 
motor cortex) involvement in patients with severe disability.  
 
Atrophy rate appears to be similar across all MS subtypes [227, 230, 232, 236] and 
occurs early in the disease [226, 237]. Atrophy is even detectable in CIS patients 
within a year of symptom onset [233, 238, 239], however this is mainly significant in 
those CIS patients who have a high risk of conversion to CDMS [233, 238-241]. 
Volume loss in CIS patients appears to be mainly due to grey matter rather than white 
matter atrophy [233, 241] which may be due to increasing lesion load and oedema 
during the early stage masking white matter atrophy. 
 
Cross sectional atrophy measures brain parenchymal fraction [227, 229], ventricular 
fraction [227] and cortical measures (thickness [235, 242] and volume [232]) have 
been found to correlate with disability. In regression analysis of one study, every 
0.08mm loss of cortex caused a unit rise in EDSS [242]. Another study found atrophy 
in areas corresponding to clinical presentation and correlation with individual 
functional system scores of the EDSS [233]. Longitudinal atrophy studies have found 
concurrent correlation with disability [229, 237, 243] and importantly the ability to 
predict disability status at 8 year follow-up [229].  
 
Cognitive impairment has been associated with volume loss in MS, and cognitive 
function shown to correlate with cortical atrophy, brain parenchymal volume loss and 
increased ventricular width [95, 234, 244]. 
 
Cross sectional measures of brain atrophy have been related to MRI measures of 
axonal damage [232] and lesion burden [226, 232, 239, 245], but this relationship 
does not fully explain the extent of acquired brain atrophy with only 33 to 50% of 
atrophy measures explained by variation in T2 lesion volume [226, 242, 245]. Some 
studies have shown a delayed relationship with lesions [246, 247], but the results 
suggest that atrophy is due to more diffuse processes occurring in normal appearing 
tissue. 
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In summary histopathology studies have revealed changes beyond white matter 
demyelination, including axonal transection and loss, cortical demyelination, and 
inflammation in normal appearing tissue. Compatible changes have been detected in 
vivo using newer quantitative MRI    
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3.3 Aims 
The aims of the studies in this thesis are to investigate diagnosis and prognosis in CIS 
patients using MRI parameters obtained at baseline (within 3 months of CIS onset) 
and early follow-up (3 months from baseline). Previous imaging studies of CIS 
cohorts have provided great insight into the prognostic power of MRI in MS; 
however images from these studies were acquired in the 1980’s at low resolution. 
Since this time, MRI techniques have improved and quantitative techniques 
developed. Between 1996 and 2004, patients within 3 months of CIS onset were 
recruited into an MRI and clinical follow-up study at the NMR research unit at the 
Institute of Neurology. This allows investigation of conventional and non-
conventional MRI measures acquired at higher resolution and their association with, 
and prediction of, clinical outcome.  
 
3.3.1. Investigation of the global frequency of MRI abnormalities in isolated 
optic neuritis 
The geographical distribution of MS is well known although poorly understood. It is 
also clear that the presence of lesions on MRI in CIS patients increases the risk of 
CDMS. The frequency of such abnormalities varies between cohorts reported from 
different regions of the world. The first aim of this thesis is to investigate whether this 
geographical difference in frequency of MRI abnormalities and development of 
CDMS are related. This is potentially important for interpretation of results from MRI 
studies and evaluation of diagnostic criteria as they may not apply to patients from 
other prevalence regions.  
 
3.3.2. Modification of MRI criteria for the diagnosis of MS in CIS patients 
Improving diagnosis of MS is important for follow-up in specialist clinics and 
potentially for the initiation of disease modifying treatment. The recognition of the 
sensitivity of MRI to MS pathology has led to its incorporation into diagnostic 
criteria. The McDonald criteria were published in 2001 and allow MS to be diagnosed 
in a CIS patient where there is MRI evidence of dissemination in space and time (DIS 
and DIT). These criteria are highly specific for the development of CDMS but have 
limited sensitivity. They were modified in 2005, with a major modification being the 
allowance of an early new T2 lesion to count as DIT. The 2005 McDonald criteria 
have not yet been evaluated but are potentially more sensitive than the 2001 criteria. 
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However they remain complex and require administration of gadolinium. The second 
aim of this thesis is to simplify the MRI diagnostic criteria for MS to improve 
sensitivity and accuracy, without compromising specificity and remove the need for a 
contrast agent. These simplified criteria along with the McDonald criteria are 
evaluated with the Poser criteria as the ‘gold standard’ in my cohort. 
 
Within the Magnims European multicentre collaborative research network which 
studies MRI in MS, a collaborative study was initiated with groups from Barcelona, 
Milan and Amsterdam who are investigating similar CIS cohorts. This allows 
evaluation in a larger cohort with a greater number of patients presenting with non-
ON CIS. Also as the McDonald criteria are currently accepted globally, European 
evaluation is important due to the differences in MS prevalence and frequency of 
MRI abnormalities. 
 
3.3.3 Early MRI in optic neuritis: risk for CDMS and disability 
The final aim is to identify prognostic markers from baseline and early follow-up 
scans which would be potentially useful for patient counselling and improved 
targeting of disease modifying therapy. It is not clear from earlier MRI studies of CIS 
patients whether number of lesions at baseline increases the risk of CDMS or 
disability, and whether location or activity of lesions contributes independently. Also 
quantitative measures from normal appearing brain tissue have been shown to be 
abnormal in CIS patients compared to controls, and whether such measures are 
stronger markers of clinical outcome has not been determined and is investigated in 
this thesis.  The risk of a second clinical event is investigated in all patients followed 
up at least once, but the risk of disability is limited to the subgroup followed up at 5 
years to allow a spectrum of disability to develop. As 80% of my cohort presented 
with ON and location of lesions is investigated, this part of the thesis is limited to the 
ON presentations, to remove the potential difficulty in differentiating symptomatic 
from asymptomatic lesions in brainstem and spinal cord syndromes. 
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Chapter 4 Methods 
4.1 Patients 
Patients aged 16 to 50 within 3 months of CIS onset were recruited from the wards 
and clinics of the National Hospital for Neurology and Neurosurgery and from the 
Neuroophthalmology clinic at Moorfields Eye Hospital from 1995 to 2004 following 
approval from the medical ethics committees of both hospitals. Written, informed 
consent was obtained from all patients prior to study entry and participation was 
voluntary at all stages. Follow-up visits were planned for 3 months, 1, 3 and 5 years 
from baseline and involved clinical assessment and MRI. Follow-up of this CIS 
cohort is on-going, and several other research fellows preceded me in the patients’ 
recruitment and follow-up. All patients bar one had been recruited prior to my starting 
this project. I assessed 5 patients at 3 months, 14 at 1 year, 29 at 3 years and 128 at 5 
years. Some of the data from the early assessments had been analysed by my 
predecessors and I completed the data set. Although not used in this thesis, I also 
analysed the 5 year data from the same MRI acquisitions as described in this thesis. 
 
CIS was defined as an acute isolated event affecting one region of the CNS, presumed 
to be demyelinating in aetiology, with no previous history of possible demyelinating 
events, and with maximal symptoms and signs by 14 days of onset. Appropriate 
investigations were conducted to exclude alternative diagnoses. Study inclusion was 
based on clinical characteristics and was not influenced by MRI findings. 
 
Patients reported any further neurological events and were classified as CDMS where 
there was symptomatic and examination evidence of a second neurological episode 
attributable to demyelination and occurring in a CNS location separate from the initial 
episode, of more than 24 hours duration and more than 4 weeks from the initial 
attack. When no symptoms were reported, patients were reviewed clinically to 
confirm clinical status. Disability was recorded at each visit with the Kurtzke 
expanded disability scale.  
 
The NHS Strategic Tracing System was used in those cases where the contact details 
were found to be incorrect, following approval for access from the Security 
Confidential Advisory Group of the NHS Information Authority and local Research 
Ethics Committee. Patients who had emigrated and left no forwarding address were 
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not contactable. When patients were unable or unwilling to attend for a follow-up 
visit, clinical status was assessed by telephone [248].  
 
Different subgroups of patients were used for the analyses in the results chapters. 
Figure 4.1 shows the number of CIS patients recruited and followed-up at the end of 
my study, and Figure 4.2 shows the same data for the ON subgroup.  
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Figure 4.1 showing 
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The number of patients analysed in the results chapters depended on how many had 
been followed up at the time of the analyses, and the type of analysis performed. This 
is explained below. 
Chapter 5: included all optic neuritis patients (ON) initially recruited (n=143) (see 
Figure 4.2).  
Chapter 6: included the 81 CIS patients who had been followed up for 3 or more 
years at the time of the analysis (2005), along with 9 other CIS patients who had 
developed CDMS prior to the 3 year scheduled follow up.  
Chapter 7: the London cohort of this multicentre study was composed of the 111 CIS 
patients who had been followed up at 3 years at the time of the analysis (2007).  
Chapter 8: included all 142 ON patients who had been followed up at least once (one 
patient dropped out after the baseline scan) (see Figure 4.2)  
Chapter 9: included only the ON patients who had been followed up at 5 years 
(n=100).  
 
4.2 MRI acquisition protocols 
MRI studies were acquired on a 1.5 Tesla GE Signa Echospeed scanner (General 
Electric Medical Systems, Milwaukee, WI, USA).  
 
4.2.1. Conventional brain MRI 
The following brain images were acquired at each visit 5 minutes after administration 
of 0.1mmol/kg of gadolinium-diethylenetriamine pentaacetic acid (DTPA).  For each 
sequence 46x3mm contiguous slices were acquired in the axial oblique plane (parallel 
to the anterior/posterior commissural line), with field of view 24cm, matrix 256x256, 
and 1 excitation: 
Proton density and T2-weighted images: dual echo fast spin echo sequence, 
TR 3200ms and TE 15/90.  
T1 weighted images: spin echo sequence TR 600ms TE 14ms 
 
4.2.2. Spinal cord MRI 
Spinal cord sequences were performed at baseline, 1, 3 and 5 years after gadolinium 
administration. For each sequence 9x3mm contiguous sagittal slices were obtained 
through the whole spinal cord, employing phased array coils, 48cm field of view and 
512x512 matrix. 
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  PD and T2 weighted FSE: TR 2500ms TE 56/98 
  T1 weighted: TR 500ms TE 19ms  
 
4.2.3. Magnetisation transfer imaging  
Obtained at 3 month and 5 year visits (from October 1998). A dual echo spin echo 
sequence (28x5mm contiguous axial oblique slices parallel to the anterior/posterior 
commissural line) covering the whole brain was performed prior to gadolinium 
administration using an interleaved sequence; TR 1720ms TE 30/80ms, number of 
excitations 0.75, matrix 256x128, field of view 24x24cm. Magnetisation and non-
magnetisation transfer images were acquired for both TEs; the interleaved nature of 
the sequence removes the need for coregistration of the images. The sequence was 
magnetisation weighted by the application of a presaturation pulse (Hamming 
apodized 3 lobe sinc pulse, duration 64ms, flip angle of 1430 degrees and a peak 
amplitude of 14.6 μT giving a normal bandwidth of 62.5 Hz, applied 2Hz from the 
water resonance). MTR maps were calculated on a pixel by pixel basis using the short 
echo data because of higher signal to noise compared to the longer echo data. 
 
4.2.4. Spectroscopy  
1H-MRS was acquired prior to gadolinium administration at 3 months, 1, 3 and 5 
years from baseline (from August 1997). A fast spin echo axial localising scan (TR 
3000ms, TE 14/84ms, matrix 256x192, slice thickness 5mm, interslice gap 1.5mm) 
was acquired first. Single voxel 
1H-MRS was then acquired from the NAWM in the 
posterior parietal or centrum semi-ovale regions. The voxel was manually placed so 
as to maximise the area of NAWM sampled whilst excluding lesions, grey matter and 
CSF. Either hemisphere could be chosen as studies have shown no evidence for 
hemispheric differences in NAWM metabolite concentrations [249]. The 
1H-MRS 
acquisition used a point-resolved spectroscopy (PRESS) sequence with TR 3000ms, 
TE 30ms and 192 averages. Shimming and water suppression were optimised using a 
standard automated prescan (GE Medical Systems, Milwaukee, WI, USA), and an 
ongoing quality assurance programme confirmed that water suppression remained 
stable throughout the study period.  
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4.3 Image analysis 
4.3.1 Lesions  
Hard copies were reviewed by an experienced neuroradiologist (Dr Katherine 
Miszkiel) blinded to the patients’ clinical status. Number and location of T2, 
gadolinium-enhancing and T1 hypointense lesions were marked on baseline images 
as were new lesions identified at follow-up through close comparison with previous 
films. All further image analysis was performed on Sun workstations (Sun 
Microsystems Inc. Palo Alto CA). Dispimage image display software (D.L Plummer 
University College London Hospitals, London UK), a semi-automated thresholding 
technique, was used to contour lesions (identified above) on the computer images for 
calculation of lesion volumes and for lesion masking in subsequent analyses. T2 
hyperintense lesions were contoured on the PD-weighted images, using the T2-
weighted image for reference. T1 hypointense brain lesions were contoured on the 
spin echo images. Number of cord lesions identified by the neuroradiologist was also 
noted. Lesion volumes were calculated by 2 observers (myself n=78 and Kryshani 
Fernando n=100), and 22 lesion volumes were repeated by both observers to assess 
agreement. Regression coefficient was 0.99 (95% CI 0.91-1.07 p<0.001, constant -
30.42 95% CI -278.79 to 217.95 p=0.801), and 0.98 without the constant (95% CI 
0.93-1.04 p<0.001). The mean difference between the raters’ lesion volumes was 
0.23mls (95% CI 0.01 to 0.64). To test reproducibility, 10 lesion volumes were 
repeated by the same observer several days apart. Intra-rater regression coefficient 
was 1.03 (95% CI 1.00-1.06 p<0.001, constant 40.56 95% CI -180.87 to 99.75 
p=0.524) and remained 1.03 without the constant (95% CI 1.00-1.05 p<0.001). The 
mean difference between the 10 lesion volumes was 0.14mls (95% CI 0 to 0.43mls).  
 
4.3.2 Magnetisation transfer imaging 
The MTR data was processed by Kryshani Fernando. Lesions were contoured on the 
non-magnetisation transfer images to create lesion masks which were used to remove 
the lesions from the images before subsequent analyses. A whole brain mask 
(excluding CSF and other non-brain parenchyma) was generated in SPM99 
(Wellcome Department of cognitive Neurology, Institute of Neurology, Queen 
Square London UK) and then applied to the (inherently registered) calculated MTR 
map. The MTR map was then segmented into grey matter and white matter, using a 
maximum likelihood algorithm with a probability threshold of 75% certainty to allow 
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separate NAWM and NAGM analyses. Partial volume effects were minimized using 
a 10 percent units thresholding and outer voxel erosions. NAWM and NAGM 
histograms, normalized for brain volume, were generated with a bin width of 0.1 
percent units and a smoothing window of 0.3 percent units, and the following 
parameters measured: peak height, peak location, mean MTR. MTR values at the 
25
th, 50
th and 75
th percentiles were also obtained.   
 
4.3.3 Spectroscopy  
The spectroscopy data was analysed by Kryshani Fernando. Metabolite 
concentrations (N-acetyl aspartate (NAA), creatine (Cr), choline (Cho), glutamate and 
glutamine (Glx) and myo-inositol (Ins)) were estimated using the linear combination 
model (LCModel), a fully automated program requiring input of a calibration factor. 
The spectra were assessed for quality of acquisition and processing by an experienced 
observer blinded to the clinical data (Kryshani Fernando) and quality control was 
achieved by weekly scanning of a phantom solution of 50mM NAA. The calibration 
factor was adjusted appropriately to compensate for any temporal variations noted in 
the metabolite phantom measures.  
 
 
4.3.4 Brain tissue segmentation  
2D T2 weighted images were segmented using SPM99, a fully-automated technique, 
following semi-automated lesion contouring (described above) and masking to 
prevent misclassification. Images were registered and segmented automatically 
(correcting for image inhomogeneity) into images representing the probability of any 
given voxel containing grey matter (GM), white matter (WM), CSF and other tissues 
based on localisation and signal intensity.  A voxel was partitioned to one mask only 
(the lesion mask overrode all SPM99 tissue classifications). Segmentations were 
inspected to qualitatively confirm adequate segmentation. GM, WM (segmented WM 
plus lesions) and brain parenchymal (BP) volumes (GM +WM + lesion volumes) 
were normalized by dividing by total intracranial volume, generating GM-, WM- and 
BP fractions (GMF, WMF, BPF). Segmentation was performed by myself (n=66) and 
Catherine Dalton (n= 58). In 19 cases segmentation could not be performed as the 
images were not available.  
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4.3.5 Ventricular volume 
A second volumetric measure was obtained from 2D scans using MIDAS interactive 
algorithm in T1-weighted post-gadolinium brain images. Whole brain was initially 
segmented using a semi-automated interactive morphologic technique and mean 
signal intensity over these brain regions was calculated. Ventricular regions were 
outlined using a semi-automated seed placing thresholding technique with the 
ventricular-brain boundary set at 60% of whole brain signal intensity. The ventricular 
region consisted of the lateral ventricles including the temporal horns but excluding 
the 3
rd and 4
th ventricles. High signal structures within the ventricles on enhanced 
images (e.g. blood vessels) were excluded.  Ventricular volumes were automatically 
calculated from the outlined regions by multiplying the total area outlined by the slice 
thickness. Ventricular volumes were quantified by two separate observers (myself 
n=66 and Catherine Dalton n=58). In 19 cases electronic images could not be located 
in the archives. Ten ventricular volumes were measured by both observers to assess 
agreement and the regression coefficient was 0.97, (95% CI 0.95-0.99 p<0.001, 
constant -1.88, 95% CI -220.54 to 216.79 p=0.985) and 0.97 on removal of the 
constant (95% CI 0.96-0.98 p<0.001). The mean difference in observers’ ventricular 
volumes was 0.22mls (95% reference range 0.02 to 0.80). To assess reproducibility, 
10 ventricular volumes were repeated by the same observer. Intra-rater regression 
coefficient was 0.99 (95% CI 0.97 to 1.01 p<0.001, constant 50.89 95% CI -143.25 to 
245.04 p=0.562) and 1.00 without the constant (95% CI 0.99 to 1.01 p<0.001). Mean 
difference in the 10 ventricular volumes by the same rater was 0.07mls (95% 
reference range 0.03 to 0.37). 
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Chapter 5 
Is the frequency of MRI abnormalities in isolated optic neuritis related to the 
prevalence of multiple sclerosis? A global comparison 
 
5.1 Introduction 
The presence of brain lesions on MRI at presentation with clinically isolated optic 
neuritis (ON) has been shown to increase the risk of developing clinically definite 
multiple sclerosis (CDMS) [61, 74, 147] but the proportion of ON patients with MRI 
abnormalities varies widely between cohorts reported from different regions of the 
world [77, 148, 250-252].  A question arising is whether the frequency of MRI 
abnormalities and development of MS in ON patients are related to the prevalence of 
MS  per se [253] as this would have potential implications in the use of MRI in 
diagnosis and prognosis of MS. This was explored by examining the frequency of 
MRI abnormalities in my London ON cohort and other published studies and the 
prevalence of MS reported from similar geographical locations.  
 
5.2 Methods 
London optic neuritis cohort 
143 patients with acute ON were recruited between 1995 and 2004 from Moorfields 
Eye Hospital in London and underwent brain MRI. All patients were referred by 
ophthalmologists and reviewed by a single, experienced neuroophthalmologist. 
Patients with a history of previous neurological events or signs of abnormality outside 
the optic nerves were excluded.  Brain MRI was performed on a 1.5 Tesla scanner 
within 3 months of symptom onset.  The scans were reviewed by an experienced 
neuroradiologist and the numbers of high signal lesions on both PD- and T2-weighted 
scans were noted.  Scans were reported normal if there were no lesions compatible 
with demyelination.   
 
Other optic neuritis cohorts 
Prospective brain MRI studies of 5 other large ON cohorts from around the world 
were identified and the frequency of MRI abnormalities noted [77, 148, 250-252].  
Other features of the studies also noted included geographical location and year of 
study, number of subjects, method of referral, recruitment criteria including age range 
and history of previous or bilateral ON or clinical features such as disc pallor, 
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duration of symptoms at time of MRI and definition of abnormality on MRI and slice 
thickness.   
 
Regional MS prevalence estimates 
Regional MS prevalence data was acquired from a recent review by Rosati [253] and 
compared in the countries in which the identified ON studies had been performed: 
>80/100,000 was defined as high prevalence, 30-80/100,000 medium and 
<30/100,000 low.  As there may be variation in regional MS prevalence within a 
single country, data from a region close to that of the ON study was used where 
possible.  An exception was the United States, where estimated average prevalence 
for the country as a whole was used because ON MRI data came from the Optic 
Neuritis Treatment Trial (ONTT), which was a multicentre trial involving patients 
from across the country.  Using the annually conducted National Health Interview 
Survey of the United States from 1989 to 1994, the national prevalence of MS was 
estimated at 85/100,000 [254]. 
 
5.3 Results  
London cohort 
The patients were aged 16-49 years (median 31.9 years), 97 (68%) were female and 
46 (32%) male.  Two had bilateral sequential ON (2 to 3 weeks interval between 
episodes) and 141 had acute unilateral ON. Brain MRI performed in all cases within 3 
months of symptom onset (median 5 weeks, range 1 to 12).  One or more 
asymptomatic brain lesions compatible with demyelination were present in 112 (78%) 
patients (median 5 lesions, range 0 to 142). 
 
Other optic neuritis cohorts 
Data from other ON cohort studies is summarised in Table 5.1.  The frequency of 
MRI abnormalities ranged from 14% [252] (Japan) to 65% [250] (Sweden).  
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Table 5.1 comparing methodology and percentage of isolated ON patients with baseline MRI 
abnormalities and nearest regional MS prevalence estimate. *In the Danish study, abnormal MRI was 
defined as the percentage of patients with at least 2 lesions and data for one or more lesions was not 
given, therefore this data was excluded from Figure 5.1. **Data represents the 90% ONTT patients in 
whom MRI findings are reported. 
 Years  of 
recruitment 
MRI slice 
thickness 
Age 
range 
(years) 
Maximum time 
from symptom 
onset to MRI 
% with 
abnormal 
MRI  
MS 
prevalence 
(/100,000) 
[253] 
England, London  
n=143 
1995-2004 3mm  16-49 3  months  78%  104 
Sweden, Stockholm  
n=116
[250] 
 
1990-1995  5mm  12-57  24 weeks  65%   96 
Denmark, Copenhagen,  
n=120
[251] 
1987-1993 4mm  12-59 4  weeks  53%*  112 
North America,  
n=389
[148] 
1988-1991  5mm  18-46  8 days  54% **  85
[254] 
Spain, Barcelona, 
n=123
[77] 
1995-2001 5mm  14-50 3  months  51%  57
  
Japan  
n=70
[252] 
1991-1996 Not 
specified 
15-55 14  days  14%  1-4
  
 
 
Brain MRI in ON and regional prevalence of MS 
Where available, the frequency of MRI abnormalities in ON and a corresponding 
reported regional prevalence for MS is provided in Figure 5.1. 
Figure 5.1 showing the variation in percentage of isolated ON patients with baseline MRI 
abnormalities and the prevalence of MS in that country 
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5.4 Discussion 
In comparison with rates previously reported in other geographical regions (14-65%) 
[77, 148, 250-252], a higher proportion (78%) of my cohort of ON patients from 
southern England exhibited brain MRI abnormalities suggestive of demyelination at 
presentation.  A high prevalence of MS is well documented in southern England 
[253].  Inspection of the frequency of MRI abnormalities in ON cohorts and 
corresponding regional MS prevalence suggest that the two are broadly related 
(Figure 5.1), although the apparent link is not entirely consistent and should be 
interpreted with caution because of the observational nature of the analysis and 
multiple methodological differences between reported studies. Such global 
differences in MRI abnormalities may affect accuracy of diagnostic criteria based on 
MRI parameters, depending on the strength of the association with MS prevalence. 
For example in regions with low MS prevalence, diagnostic criteria may be less 
specific, over-diagnosing patients with abnormalities on MRI at presentation and vice 
versa, unless the frequency of such abnormalities is closely associated to regional 
prevalence. Multicentre studies are therefore important in the assessment of MRI 
criteria. Similarly the prognostic role of MRI may also vary geographically. 
 
It is likely that the Japanese cohort was phenotypically different in some visual 
features from other cohorts e.g. there was a high frequency of poor visual acuity in 
the Japanese cohort during the acute phase: 61% had visual acuity worse than 6/60 
compared with 36% of the ONTT cohort.  MS is much less common in Japan than in 
Europe or North America.  Furthermore, 15-40% of cases of MS in Japan are of the 
optico-spinal type and 58-63% of this group have been shown to be positive for anti-
aquaporin 4 antibody, or NMO-IgG [255, 256], a marker of neuromyelitis optica 
(NMO) [256]. NMO was previously reported to have fewer lesions on brain MRI than 
seen in conventional MS [255-257]. However NMO-IgG has brought about change in 
NMO diagnostic criteria, and up to 60% of patients fulfilling these criteria were found 
to have brain lesions on MRI, although these were atypical for MS [258].  The overall 
evidence suggests that ON in Japan is more often associated with NMO or an isolated 
syndrome with normal MRI and less often due to classical MS. 
 
The ONTT [148] recruited patients from all over the United States limiting 
comparison of geographical prevalence in studies from smaller, well-defined 
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catchment areas such as the Scandinavian studies [250, 251].  However the ONTT 
provided a wealth of clinical and MRI data and, like the London cohort, included a 
multiethnic and immigrant rich population.  By contrast in the Swedish study all 
patients were Caucasian and only 4% were of non-Swedish origin [250].  Variation in 
migration patterns and ethnicity may influence MS risk and prevalence and add 
complexity when comparing studies from different geographical regions.   
 
Considering studies from the last 20 years, the incidence of ON in Japan (1992-1993) 
of 1.6 to 2/100,000 [259]
 appears to be similar to incidences reported in Sweden
 
(1990-1995)
 1.46/100,000 [260]; Croatia (1985-2001) 1.6/100,000[261], and the UK 
(1995-1996) 1/100,000 [262].  A higher incidence was reported from Minnesota with 
age and sex adjusted incidence of 5.1/100,000 [263] (1985 to 1991) although 
epidemiological ascertainment is likely to be particularly high in this well-defined 
local region that is served by the Mayo Clinic. Earlier studies report incidences less 
than 1 per 100,000 and there may have been improvement in case ascertainment or an 
increase in incidence with time.  A study in Hawaii compared the incidence of ON in 
the Oriental and Caucasian populations and found no significant difference between 
the two races (0.7 and 1.1/100,000 respectively) [264].  Taken together, these data 
suggest that the incidence of ON is relatively similar across regions where the 
prevalence of MS varies markedly:  it is therefore plausible that the frequency with 
which ON is due to MS will also vary.  Since the studies reported did not include 
other known causes (e.g., sarcoidosis, vasculitis, syphilis) it seems likely that in low 
MS prevalence regions – especially when MRI is normal – ON is often a monophasic 
inflammatory syndrome. In regions such as Asia with relatively high optico-spinal 
MS prevalence, neuromyelitis optica may potentially be the underlying cause. 
 
A clinically isolated syndrome study from Barcelona [77] reported that subjects with 
a brainstem or spinal cord syndrome had a higher frequency of MRI abnormalities at 
presentation (76%) and a higher conversion rate to clinically definite MS than did 
those with ON (of whom 51% had abnormal MRI at presentation).  The Barcelona 
study also showed that when only those with abnormalities on MRI were compared, 
no significant difference in risk for conversion to MS was found between the 
clinically isolated syndrome subtypes. A medium (~50%) prevalence of MRI 
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abnormalities in ON patients is concordant with the medium prevalence of MS 
reported in the same region of Spain [253].  
 
The hypothesis that there is a link between proportions of ON patients with MRI 
abnormalities and corresponding regional prevalence of MS is not proven by the 
present work, which is observational in nature.  Potential biases exist that limit 
interpretation of the various ON cohort datasets:  these include possible referral 
biases; different inclusion and exclusion criteria (e.g. age range, unilateral and/or 
bilateral ON); variations in time from onset of visual symptoms to having MRI; the 
stringency with which ON patients with other neurological features were excluded; 
differential proportions of long-term resident versus more frequent migrant 
populations; use of different MRI scanners, field strengths, acquisition sequences and 
slice thicknesses; and variable definitions of abnormality on MRI.  Furthermore, the 
cited MS prevalence studies were performed at different time periods and may have 
had their own biases related to case identification and diagnosis.  While the 
observations support a link between frequency of MRI abnormalities in isolated ON 
and regional MS prevalence, a prospective epidemiological study design that uses a 
standardised approach to case identification and diagnosis would be required for 
definitive clarification.   
 
These caveats aside, this study suggests a link between frequency of MRI 
abnormalities in ON and MS prevalence. This may have global implications in 
performance of MRI criteria and prognostic markers for MS.  
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Chapter 6 
Modification of MRI criteria for multiple sclerosis in patients presenting with 
clinically isolated syndromes. 
 
6.1 Introduction 
In 85% of patients with MS the onset is with a clinically isolated syndrome (CIS) 
defined as an acute clinical event of presumed demyelinating aetiology, such as optic 
neuritis, bilateral internuclear ophthalmoplegia or partial transverse myelitis, in a 
patient with no history of neurological symptoms suggestive of demyelination. An 
essential requirement in making the diagnosis of MS is that there should be objective 
evidence for central nervous system (CNS) white matter lesions disseminated in 
space (DIS) and time (DIT).  Past criteria relied mainly on clinical evidence for DIS 
and DIT [106].  Brain MRI criteria for DIS have been developed to improve 
prediction of clinically definite MS (CDMS) [162, 163, 265]. These criteria have 
focused on the number, activity (presence of gadolinium enhancement) and location 
of lesions, and include lesions in three regions that are considered characteristic for 
demyelination: juxtacortical, infratentorial and periventricular.  The McDonald 2001 
MRI criteria also require evidence of DIT [266]. While the McDonald criteria have 
high specificity for subsequent development of CDMS when applied in prospectively 
followed cohorts with CIS [164, 165], they have several limitations [267, 268].   
Notably, the complex MRI DIS criteria [162, 163] (developed for brain MRI by 
Barkhof et al and Tintore et al, in addition allowing a spinal cord lesion to substitute 
for a brain lesion [162, 165]) (see Table 6.1) have been considered too stringent. The 
DIS criteria also include gadolinium enhancement, which – strictly speaking - is a 
feature of lesion activity rather than location. In addition the requirement for a 
gadolinium-enhancing lesion for DIT on a 3-month follow-up scan resulted in low 
sensitivity at this time point (i.e. many cases who develop CDMS do not fulfil the 
criteria after 3 months [164]). When a new T2 lesion on follow-up scanning was 
allowed as evidence for DIT if the reference scan was obtained within 3 months of 
CIS onset, the criteria became more sensitive and remained highly specific [166].   
 
An early and accurate diagnosis of MS is increasingly important for counselling 
individual patients and potentially for making decisions on use of disease modifying 
treatments.  This preliminary study explores whether the MRI criteria for DIS and 
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DIT could be modified to improve the accuracy of early diagnosis. The combination 
of a less stringent definition for DIS and allowing a new T2 lesion per se after 3 
months as evidence for DIT are evaluated in my London CIS cohort who have been 
followed up for 3 years or until the development of CDMS. 
 
6.2 Methods 
Rationale for modified criteria 
The MRI criteria for DIS were modified with the intention of: (i) retaining the 4 
anatomical regions that were included in the McDonald 2001 criteria as they are 
considered characteristic for demyelination i.e. periventricular, juxtacortical, 
infratentorial or spinal cord; (ii) reducing to a minimum the number of lesions and 
regions needed for radiological DIS i.e. there had to be ≥1 lesions(s) in ≥2 of the 4 
regions; (iii) removing the option to include gadolinium enhancement as a feature of 
DIS (i.e. only T2 lesions and their location are considered). The DIS criteria were 
evaluated on the 3 month brain scans with and without the inclusion of baseline cord 
MRI findings. In cases of brainstem and spinal cord syndromes, all lesions within the 
symptomatic region were excluded.  
 
The rationale for modifying the DIT criteria was that in an earlier study of a subgroup 
of 56 patients from the currently reported cohort, a new T2 lesion at 3 months follow-
up was more sensitive but almost as specific as a gadolinium enhancing lesion 
(required by the McDonald 2001 criteria) for the development of CDMS [166]. Thus, 
the modified DIT criteria required ≥1 new T2 lesion(s) at 3 months follow-up (a new 
lesion on the 3 month scan could also contribute to DIS if situated in the regions 
specified by the criteria).   
 
Patients 
This exploratory study was undertaken in 90 prospectively recruited CIS patients (38 
males, 52 females, median age 32 years, range 17-50): 67 with optic neuritis (ON; 
unilateral in 66, bilateral sequential in 1), 15 with a brainstem syndrome, seven with a 
spinal cord syndrome, and one with an optic tract lesion.  Written informed consent 
was obtained from all patients.  Patients were followed clinically until they developed 
CDMS or for a mean of greater than 3 years if they did not.  The study was approved 
by the Joint Medical Ethics Committee of the Institute of Neurology and National 
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Hospital for Neurology and Neurosurgery.   
 
MRI 
The first MRI was performed within three months of clinical onset (median 5.5 
weeks, range 1-12), and consisted of a T2-weighted and gadolinium enhanced T1-
weighted brain and spinal cord scan (see Chapter 4 for protocol details [164]).  The 
second MRI was performed approximately 3 months after the first (median 12 weeks, 
range 9-49) and consisted of a T2-weighted and gadolinium enhanced T1-weighted 
brain scan.  
 
Statistical analysis 
The McDonald 2001 and modified criteria were assessed by comparison with the gold 
standard for the disease that was defined as CDMS by the Poser criteria [106]. The 
number of true positives (TP=criteria positive and developing CDMS by 3 years), 
true negatives (TN=criteria negative and not developing CDMS by 3 years), false 
positives (FP=criteria positive but not developing CDMS by 3 years) and false 
negatives (FN=criteria negative and developing CDMS by 3 years) were calculated 
and used to determine the following: 
Sensitivity: the probability of the test finding the disease among those who have the 
disease (TP/TP+FN). 
Specificity: the probability of the test finding no disease among those who do not 
have the disease (TN/TN+FP) 
Accuracy: the proximity to the true value (TP+TN/TP+TN+FP+FN) 
 
6.3 Results 
Thirty nine of the 90 patients (43%) developed CDMS as defined by the Poser criteria 
[106] during follow-up after a median of eight months from clinical onset (mean 14, 
range 2-48). The 51 (57%) patients who did not develop CDMS were followed up for 
a median of 39 months (mean 41, range 33-64). Both the McDonald 2001 and 
modified criteria had a high specificity for development of CDMS but the modified 
criteria were more sensitive and accurate (Table 6.1).  
 
Both DIT criteria per se had high specificity for CDMS but a new T2 lesion was 
considerably more sensitive than a new enhancing lesion. The DIS criteria per se 
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were less specific than the DIT criteria. The modified criteria for MS had a higher 
specificity in the ON than non-ON subgroup (95% versus 83%; Table 6.2).   
 
The modified criteria had a high specificity for CDMS in the subgroups of patients 
whose first scan was performed less than or more than 6 weeks from symptom onset 
(specificities 93% and 91% respectively; Table 6.3). 
 
Table 6.1 Sensitivity, specificity and accuracy of the McDonald 2001 and modified criteria for CDMS 
TP  = true positive (criteria positive & CDMS), FP  = false positive (criteria positive & not MS), TN = 
true negative (criteria negative & not MS) FN = false negative (criteria negative & CDMS) 
Sensitivity = TP / (TP+FN), Specificity = TN / (TN+FP), Accuracy = (TP+TN)/(TP+TN+FP+FN) 
 
  TP FP TN FN Sensitivity Specificity Accuracy 
McDonald criteria for MS:  
brain MRI only  
 
18 
 
3 
 
48 
 
21 
 
46%  
 
94%  
 
73% 
McDonald criteria for MS:  
brain & cord MRI  
 
18 
 
3 
 
48 
 
21 
 
46%  
 
94%  
 
73% 
Modified criteria for MS:  
brain MRI only 
 
29 
 
4 
 
47 
 
10 
 
74% 
 
92%  
 
84%  
Modified criteria for MS:  
brain & cord MRI 
 
30 
 
4 
 
47 
 
9 
 
77%  
 
92%  
 
86%  
McDonald criteria for DIS:  
brain MRI only 
 
30 
 
11 
 
40 
 
9 
 
77%  
 
78%  
 
78% 
McDonald criteria for DIS:  
brain & cord MRI 
 
31 
 
11 
 
40 
 
8 
 
79%  
 
78%  
 
79% 
Modified criteria for DIS: 
brain MRI only 
 
35 
 
13 
 
38 
 
4 
 
90% 
 
75%  
 
81%  
Modified criteria for DIS: 
brain & cord MRI 
 
37 
 
15 
 
36 
 
2 
 
95%  
 
71%  
 
81%  
 
McDonald criteria for DIT 
 
19 
 
5 
 
46 
 
20 
 
49% 
 
90%  
 
72% 
 
Modified criteria for DIT 
 
30 
 
6 
 
45 
 
9 
 
77%  
 
88%  
 
83% 
 
McDonald criteria for DIS on baseline scans:   Modified criteria for DIS on baseline scans: 
3 out of: ≥ 9 T2 brain lesion or ≥1 Gd lesion  ≥ 1 T2 lesion(s) in ≥2 of the following regions 
  ≥ 1 infratentorial lesion      periventricular 
  ≥ 3 periventricular lesions     juxtacortical 
  ≥ 1 juxtacortical lesion      infratentorial
# 
  (1 spinal cord lesion can substitute    spinal cord* 
for 1 brain lesion) 
# and * excluded in cases of brainstem and spinal 
cord syndromes respectively 
 
 
McDonald criteria for DIT on 3month scans:   Modified criteria for DIT on 3month scans: 
≥ 1 new gadolinium enhancing lesion  ≥ 1 new T2 lesion 
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Table 6.2 Performance of the McDonald 2001 and modified criteria* in optic neuritis and non-optic 
neuritis subgroups 
TP  = true positive (criteria positive & CDMS), FP  = false positive (criteria positive & not MS), TN = 
true negative (criteria negative & not MS) FN = false negative (criteria negative & CDMS) 
Sensitivity = TP / (TP+FN), Specificity = TN / (TN+FP), Accuracy = (TP+TN)/(TP+TN+FP+FN) 
  TP FP TN FN Sensitivity    Specificity 
McDonald criteria for MS 
 
12 2  37 16 43%  95%  Optic neuritis 
patients 
Modified criteria for MS 
 
20 2  37 8  71%  95% 
McDonald criteria for MS 
 
6 1 11  5 55%  92%  Non-optic 
neuritis patients 
Modified criteria for MS 
 
10 2  10 1  91%  83% 
 
 
 
Table 6.3 Sensitivity and specificity of the McDonald 2001 and modified criteria* for clinically 
definite MS in subgroups first scanned less than and more than 6 weeks after CIS onset. 
TP  = true positive (criteria positive & CDMS), FP  = false positive (criteria positive & not MS), TN = 
true negative (criteria negative & not MS) FN = false negative (criteria negative & CDMS) 
Sensitivity = TP / (TP+FN), Specificity = TN / (TN+FP), Accuracy = (TP+TN)/(TP+TN+FP+FN) 
 
  TP FP TN FN Sensitivity    Specificity 
McDonald criteria for MS
 
8 2 26  9 47%  93%  Patients   < 6/52 
from CIS onset 
(n=45)  Modified criteria for MS 
 
13 2  26 4  76%  93% 
McDonald criteria for MS
 
10 1  22 12 45%  96%  Patients   > 6/52  
from CIS onset 
(n=45)  Modified criteria for MS 
 
17 2  21 5  77%  91% 
 
 
*Brain and spinal cord MRI findings are included, except that in patients with a brainstem or spinal 
cord syndrome, lesions in the symptomatic region (i.e. infratentorial and spinal cord respectively) were 
excluded. 
 
6.4 Discussion 
The modified MRI criteria for MS proposed in this study were more accurate than the 
McDonald 2001 criteria in my London cohort.  This was because of an increased 
sensitivity of both the DIS and DIT components whilst maintaining a high overall 
specificity.  As well as improving the overall accuracy of diagnosing MS in patients 
with typical CIS, the modified criteria are also less complex than the existing criteria 
and should be easier to use. In not requiring gadolinium-enhanced MRI, there are 
potential savings in time and cost.  
 
High specificity is especially important in order to avoid diagnosing a disease when it 
is not present.  It is notable that in both the McDonald 2001 and modified criteria the 
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DIT component was required to maintain specificity greater than 90%.  Both DIS 
components alone were less specific especially for the modified criteria; this should 
discourage making a diagnosis of MS in CIS patients based solely on the findings of a 
single scan.  
 
Although the present study was confined only to patients with a typical CIS, the 
lower specificity of MRI DIS criteria per se – especially the modified criteria - 
suggest that if MRI is used to establish a diagnosis of MS, the MRI DIT criteria 
should also be required in patients who have equivocal clinical evidence for DIT e.g. 
a typical CIS plus another vaguely defined neurological episode.  
 
High diagnostic specificity was obtained from brain MRI findings alone, and 
inclusion of spinal cord MRI findings only slightly increased the overall diagnostic 
accuracy of the modified criteria.  Whilst cord MRI is a primary investigation for 
spinal cord CIS, its role in patients with ON or brainstem syndromes appears more 
limited; it may be helpful, especially if brain MRI is abnormal but the DIS criteria are 
not fulfilled. The similar outcomes for the subgroups first scanned more or less than 6 
weeks from symptom onset suggests that the exact timing of the first scan (within 3 
months of symptom onset) is not crucial to the performance of the diagnostic criteria.   
 
In order for MRI criteria to be applied reliably, several conditions should be met.  
First, the CIS should be unambiguously typical of those seen in MS e.g. unilateral 
ON, bilateral internuclear ophthalmoplegia, partial myelopathy. Neither the 
McDonald 2001 nor these modified criteria have been tested in cohorts with clinically 
atypical or equivocal syndromes, nor have they been rigorously compared in 
established MS versus other white matter diseases. Furthermore, the non-ON cohort 
in this study was small and other studies of larger non-ON CIS cohorts are warranted. 
In some populations, the frequency of MRI abnormalities may differ between ON and 
non-ON CIS [77], and this may influence the performance of diagnostic criteria.  
 
Secondly, CIS diagnosis should be made by an experienced clinician, normally a 
neurologist or (in ON) a neuroophthalmologist.  Thirdly, the criteria should only be 
applied in younger adults (ages 16-50 years): in children, monophasic acute 
disseminated encephalomyelitis is more commonly seen, and in older adults non-
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specific MRI white matter lesions are frequently encountered.  Fourthly, the MRI 
scans should be of high quality, with careful attention to re-positioning and 
consistency of image acquisition, and they should be interpreted by an experienced 
neuroradiologist.  Finally, cerebrospinal fluid examination for oligoclonal bands may 
still be a useful investigation especially where clinical features are atypical; their 
value in combination with MRI criteria warrants further investigation in prospectively 
followed CIS cohorts.   
 
This preliminary study suggests that modification of the McDonald 2001 criteria can 
improve their sensitivity whilst maintaining specificity, within the limits described 
above. While the modifications used in the present study indicate potential areas for 
revision of the existing criteria in patients with CIS, it would be prudent that their 
performance is further evaluated in other CIS cohorts, especially non-ON cases. Also 
as the frequency of MRI abnormalities appears to vary geographically, it would be 
beneficial to assess the criteria in cohorts from regions of different MS prevalence.    
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Chapter 7 
MRI criteria for multiple sclerosis in patients presenting with clinically isolated 
syndromes: a multicentre study 
 
7.1 Introduction 
By requiring MRI evidence of dissemination in time (DIT) and space (DIS) the 
McDonald 2001 criteria [266] are highly specific for the development of clinically 
definite (CD)MS in patients presenting with a clinically isolated syndrome (CIS), 
however their sensitivity is limited by stringent DIS criteria and gadolinium 
enhancement for DIT [164, 165]. In 2005, the McDonald criteria were revised [167]. 
Changes in imaging criteria included: (i) a greater role for spinal cord lesions as 
evidence for DIS whilst retaining essentially the same Barkhof-Tintore DIS findings 
for brain abnormalities, and (ii) allowing a new T2 lesion occurring any time after 30 
days from CIS onset as evidence of DIT [167]. The performance of these criteria in 
predicting CDMS has not been reported.  
 
The results from the preliminary study in chapter 6 suggested that the MRI DIS 
criteria could be simplified (≥1 T2 lesion(s) in ≥2 of 4 locations considered 
characteristic for MS in the McDonald criteria: juxtacortical, periventricular, 
infratentorial and spinal cord), without compromising specificity if evidence of DIT 
was sought (a new T2 lesion on a follow-up scan regardless of the timing of a 
baseline scan). As well as being simpler than the McDonald 2001 criteria, they were 
more sensitive with similar (high) specificity in my London CIS cohort. Also these 
new criteria are based on the findings of T2-weighted images alone and do not require 
gadolinium enhancement. It was important to evaluate the new criteria in a larger CIS 
cohort, ideally with more non-optic neuritis presentations, as the previous study had 
suggested the criteria performed less well in such cases. My observational study of 
optic neuritis CIS patients in Chapter 5 suggested variation in frequency of MRI 
abnormalities in different geographical regions. Therefore it was decided to evaluate 
the criteria in a multicentre European cohort to test how robust the MRI criteria were 
in regions of different MS prevalence and frequency of MRI abnormalities.  
  
Within a European multicentre collaborative research network that studies MRI in 
MS (called Magnims), data was collected on 282 CIS patients from 4 centres - 
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Barcelona, Amsterdam, Milan and London - who had two MRI scans within 12 
months of CIS onset and were followed up clinically. Some of the patients from one 
centre are included in previous reports evaluating diagnostic criteria [164, 269]. The 
performance of the two McDonald (2001 & 2005) and new MRI diagnostic criteria 
with respect to development of CDMS was investigated.  
 
7.2 Patients and Methods 
Patient selection 
Each centre was asked to identify CIS patients recruited into prospective MRI and 
clinical follow-up studies who had the following: (i) baseline scan obtained within 3 
months of CIS onset; (ii) follow-up scan obtained between 3 and 12 months of CIS 
onset (timing dependent on individual centre study protocols and some inevitable 
variation in scheduling appointments); (iii) clinical follow-up for 3 years or until 
development of CDMS if this was within 3 years; (iv) not on disease modifying 
treatment before having a second confirmed clinical episode (i.e. developing CDMS). 
Each of the centres was a secondary or tertiary referral centre, and consecutive 
patients were included at each centre.   
 
A total of 282 patients were identified who had two MRI scans within one year of 
CIS onset and for whom clinical status (CDMS or not) at latest follow-up was known. 
Of these, 63 who had not developed CDMS had been followed up for less than 3 
years, 13 had started disease modifying treatment prior to development of CDMS (4 
of these had also been followed up for less than 3 years without developing CDMS) 
and 2 had a baseline scan much longer than 3 months following CIS onset (29 and 34 
weeks). That left a core group of 208 patients who fulfilled all 4 of the above features 
(including 2 whose first scan was a few days more than 3 months).  In this core 
group, the performance of each of the diagnostic criteria (specificity, sensitivity, 
accuracy, positive predictive value and likelihood ratio) was investigated, with 
CDMS within 3 years as the outcome measure.   
 
Clinical details 
The following clinical information was provided by each centre: age of CIS-onset, 
gender, topography of CIS (and second event if applicable), disability using the 
Kurtzke expanded disability status scale (EDSS) [114]; and the dates of symptom 
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onset, disease-modifying therapy (DMT), MRI scans and last follow-up visit.   
Patients were classified as CDMS according to the Poser criteria i.e. where there was 
symptomatic and examination evidence of a second neurological episode attributable 
to demyelination of more than 24 hours duration, more than 4 weeks from the initial 
attack [106]. Alternative diagnoses were ruled out by appropriate tests according to 
local standards.  Diagnosis of CDMS was confirmed by an experienced neurologist at 
each centre based on clinical information only and regardless of MRI findings. 
 
MRI acquisition and analysis 
MRI scans were performed on 1.5 Tesla (94%) or 1.0 Tesla (6%) scanners and in 278 
cases consisted of axial Proton density (PD) and T2-weighted fast spin echo (FSE) 
and post contrast T1-weighted spin echo brain MRI (in 4 cases, fast-fluid-attenuated-
inversion-recovery (FLAIR) brain images were provided in place of the PD images).  
T2-weighted sagittal MR images through the spinal cord were also available, on the 
baseline scan only, in 130 patients; slice thickness varied from 3 to 5mm. For follow-
up brain scans, internal landmarks were used for slice positioning identical to 
baseline. 
 
Areas of increased signal intensity present on both T2 and PD (or FLAIR) images 
(referred to as T2 lesions) were marked independently by two readers blinded to 
clinical status. Both readers were trained by experienced neuroradiologists to identify 
and classify lesions.  Only areas of increased signal intensity marked by both readers 
were counted.  Brain lesions were classified as periventricular, juxtacortical, 
infratentorial or discrete (supratentorial lesions that were neither juxtacortical nor 
periventricular).  Gadolinium enhancing lesions identified on the T1-weighted scans 
were confirmed on the PD- and T2-weighted scans.  Follow-up brain scans were 
closely compared with the baseline images for new T2 and gadolinium enhancing 
lesions.  The brain and cord images were reported as normal if they had no lesions 
compatible with demyelination.  
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Classification of scans using MRI criteria 
Table 7.1 Three MRI criteria for Dissemination in Space and Time for MS 
 McDonald  2001
[266] McDonald  2005
[167] New  criteria
[269] 
Dissemination in 
space (on either 
baseline  or follow-up 
MRI)* 
3 or more of: 
 
9 T2 lesions or 1 Gd-
enhancing lesion 
3 or more PV lesions 
1 or more JC lesions 
1 or more PF lesions 
 
1 cord lesion can 
replace 1 brain lesion 
3 or more of: 
 
9 T2 lesions or 1 Gd 
lesion 
3 or more PV lesions 
1 or more JC lesions 
1 or more PF lesions or 
spinal cord lesion 
 
Any number of cord 
lesions can be included 
in total lesion count 
≥1 lesion in each of ≥2 
characteristic locations: 
 
PV  
JC 
PF 
Cord  
 
All lesions in 
symptomatic region 
excluded in brainstem  
and spinal cord 
syndromes 
Dissemination in time  (i) a Gd-enhancing 
lesion at least 3 months 
after CIS onset 
 
(ii) A new T2 lesion 
with reference to a 
prior scan at least 3 
months after CIS onset. 
(i) A Gd-enhancing 
lesion at least 3 months 
after CIS onset 
 
(ii) A new T2 lesion 
with reference to a 
baseline scan obtained 
at least 30 days after 
CIS onset. 
A new T2 lesion on 
follow-up MRI 
irrespective of timing 
of baseline scan 
 
JC:
Juxtacortical
lesion
PV:
Periventricular 
lesion
PF: 
Posterior fossa
lesion
Cord: 
Spinal cord 
lesion
Gd:
Gadolinium 
enhancing lesion 
 
* The McDonald 2001 and 2005 DIS criteria also include the presence of two or more T2 lesions plus 
cerebrospinal fluid (CSF) oligoclonal bands. Because CSF was not examined systematically in the 
Magnims cohort, only the MRI criteria for DIS are considered in this study 
 
Each scan was classified according to the McDonald 2001 and 2005 and new criteria 
(Table 7.1), plus their separate components of DIS and DIT. For the new criteria, all 
lesions within the symptomatic region were excluded in patients presenting with 
brainstem or spinal cord syndromes (not required for the McDonald criteria). 
 
Statistical analysis 
Core cohort 
The performance of the MRI criteria was evaluated using the clinical status of the 
core cohort patients at 3 years as the outcome: CDMS or CIS.  The number of true 
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positives (TP; fulfilling the MRI criteria and developing CDMS), false positives (FP; 
fulfilling the criteria but not developing CDMS), true negatives (TN; not fulfilling the 
criteria and not developing CDMS) and false negatives (FN; not fulfilling the criteria 
but developing CDMS) was determined. From this, the sensitivity, specificity, 
accuracy, positive predictive value, and both positive and negative likelihood ratios - 
all with 95% confidence intervals - were calculated:  
Sensitivity: the probability of the test finding CDMS among those who have CDMS 
(TP/TP+FN) 
Specificity: the probability of the test finding no disease among those who do not 
have CDMS (TN/TN+FP) 
Accuracy: the proximity to the true value (TP+TN/TP+TN+FP+FN) 
Positive predictive value: the proportion of patients with positive test results who are 
correctly diagnosed (TP/TP+FP) 
Positive likelihood ratios: how many times more likely patients with CDMS are to 
have a positive test result than patients without CDMS (sensitivity/1-specificity) 
Negative likelihood ratio: how many times less likely patients without CDMS are to 
have a positive test result than patients with CDMS (1-sensitivity/specificity) 
 
Survival cohort 
The time to CDMS from CIS onset was analysed using Cox proportional hazards 
regression; patients who did not develop CDMS were censored at the time of last 
follow-up.  The following covariates were entered into all the Cox regressions, in 
order to adjust the effects of the diagnostic criteria: gender (binary), disease 
modifying treatment (binary), centre (categorical: Barcelona, Amsterdam, Milan, 
reference category London) and type of patient (categorical: brainstem, spinal cord, 
‘other’, reference category optic neuritis).  Estimates can also be considered age-
adjusted, since although age was not included in final models, its inclusion (non-
significant) did not materially alter estimates. 
 
In order to assess the effect of the diagnostic predictors, two types of model were 
used to generate the curves in Figures 7.1 and 7.2 respectively:   
 
i) Figure 7.1 shows predicted survival curves for the four groups ‘neither DIS nor 
DIT’, ‘DIS only (not DIT)’, ‘DIT only (not DIS)’ and ‘both DIS and DIT’.  The aim 
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of the first type of model, used for Figure 7.1, was to estimate the independent effects 
(as measured by hazard ratios) of DIS and DIT: in these models DIS and DIT were 
adjusted for each other, so that any estimated effect of, say, DIS, was due to just the 
patients’ DIS status and not also to their DIT status.  These models were also used to 
assess (using an extra DIS+DIT indicator) whether there was any additional effect of 
being both DIS and DIT over and above the accumulation of the independent DIS and 
DIT effects.  There was no evidence for such an additional effect, and so the 
combined DIS+DIT term was omitted from these models: this implies that on average 
the increase in hazard due to a patient being DIS is the same whether that patient is 
DIT positive or not; and that the most efficient and potentially least biased estimate of 
the hazard ratios ‘DIS only’ vs. ‘neither’, and ‘both’ vs. ‘DIT only’, are given by a 
single weighted average of the two comparisons (and correspondingly for DIT).  It 
should be noted therefore that although, for example, the hazard ratio reported with 
the ‘DIS only’ curves in Figure 7.1 are ‘DIS only’ vs. ‘neither’, the same quantity 
also estimates ‘both’ vs. ‘DIT only’ (and correspondingly for ‘DIT only’).  The ‘both 
DIS and DIT’ vs. ‘neither’ hazards ratio was estimated by accumulating the separate 
DIS and DIT effects.     
 
ii) Figure 7.2 shows predicted survival curves for the four groups ‘neither DIS nor 
DIT’, ‘DIS only or both DIS and DIT’ (i.e. all DIS), ‘DIT only or both DIT and DIS’ 
(i.e. all DIT), and ‘both DIS and DIT’.  The aim of the second type of model, used for 
Figures 7.2a, b and c, was to estimate the effects of DIS or DIT per se, unadjusted for 
each other, that is, including, in the DIS estimate, any effect due to DIS positive 
patients tending also to be DIT positive; and vice versa.  The hazard ratios associated 
with the two middle curves in Figure 7.2 are thus ‘DIS or both’ vs. ‘neither’ and ‘DIT 
or both’ vs. ‘neither’.     
 
In the type ii) models, the ‘both DIS and DIT’ vs. ‘neither’ effect was estimated 
explicitly using a DIS+DIT term, rather than, as in models in i), by accumulating 
separate DIS and DIT estimates.  As a result the estimated hazards ratio of ‘both’ vs. 
‘neither’ is very slightly different in i) than in ii), but their great similarity confirms 
the evidence from the data that the ‘both’ effect can be considered as the 
accumulation of the two independent effects.  In calculating the plots in Figures 7.1 
and 7.2, covariate values were set at the sample mean, thus predicting the survival 
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curves for varying DIS and DIT status of patients with otherwise ‘average’ covariate 
values.   
 
To compare statistically the relative performance of the three diagnostic criteria, 
terms from the three criteria were entered together (along with the covariates) in a 
Cox regression model.  This was repeated for the DIS terms, the DIT terms, and 
finally the DIS+DIT terms; the latter model is reported in full in Table 7.6.   
 
The natural origin for a survival time scale is CIS onset and all 282 patients were 
included in a survival analysis from CIS onset, which estimated the proportion who 
were conversion free (i.e. had not developed CDMS) at last follow-up. However, 29 
patients developed CDMS before their second MRI scan.  Most of these were both 
DIS and DIT positive at the follow-up scan (20, 23 or 25 by the McDonald 2001, 
2005 or new criteria respectively), but their status prior to conversion cannot be 
known precisely, in contrast with the remaining 253 patients; as a precaution, a 
secondary survival analysis was carried out using the second scan as origin for the 
time scale, thus excluding the 29 early converters and an additional six patients whose 
conversion time was the same as their second scan.  This secondary analysis thus 
comprised 247 patients. There was no evidence that the proportional hazards 
assumption of the Cox models was violated.  Analyses were carried out in Stata 9.2 
(Stata Corporation, College Station, Texas, USA).  Statistical significance is taken at 
the 5% level. 
   
7.3 Results 
Clinical and MRI features of the three year “core” cohort (Table 7.2) 
The demographic data of the cohort (n=208) followed up for 3 years or until 
development of CDMS is summarised in Table 7.2.  Median age of the cohort was 31 
years.  One hundred and twenty three (59%) patients presented with optic neuritis, 42 
(20%) with a brain stem and 27 (13%) a spinal cord syndrome; most of the remaining 
cases had an isolated cerebral hemisphere syndrome.  Median EDSS at baseline was 2 
(range 0-8). Baseline MRI scans were performed a median of 6.2 weeks from CIS 
onset (range 0-13.6); 72 were performed less than 30 days from CIS onset. Follow-up 
scans were all performed a median of 4.7 months from CIS onset (range 3.0 to 11.9).  
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The median interval between baseline and follow-up scans was 3.2 months (range 1.5 
to 10.0 months). 
 
Table 7.2 Demographic, clinical and MRI findings in the CIS cohorts followed up for 3 years 
Characteristic  3-year core cohort (n=208)  All cases (n=282) 
Age of onset (yr)  31.0 yrs  
(range 14-52) 
31.0 
(range 14-52) 
Gender (M/F)  72:136  
(35 % ♂ 65% ♀) 
102:180 
(36 % ♂ 64% ♀) 
London  109 (52.4%)  111 (39.4%) 
Barcelona  60 (28.9%)  118 (41.8%) 
Amsterdam  13 (6.2%)  23 (8.2%) 
Center 
location 
Milan  26 (12.5%)  30 (10.6%) 
Optic neuritis  123 (59.0%)  155 (55.0%) 
Brainstem 
syndrome 
42 (20.2%)  57 (20.2%) 
Spinal cord 
syndrome 
27 (13.0%)  45 (16.0%) 
Presenting 
clinical 
syndrome 
Other  16 (7.7%) (9 hemispheric, 1 
polyregional, 6 unknown) 
25 (8.8%) (12 hemispheric, 1 
polyregional, 12 unknown) 
Median EDSS baseline   2 (range 0-8)  2 (range 0-8) 
Median time between event onset 
and baseline MRI 
6.2 weeks 
(range 0-13.6 weeks) 
5.1 weeks 
(range 0-34 weeks) 
Median time between baseline and 
follow-up MRI 
3.2 months  
(range 1.5-10.0 months) 
3.2 months 
(range 1.5-10.0 months) 
Median time between event onset 
and follow-up MRI  
4.7 months 
(range 3.0-11.9 months) 
4.6 months 
(range 2.5-11.9 months) 
Median duration of follow-up in 
non-converters 
45.0 months  
(range 36-119 months)  
39.1 months 
(range 3.8-119 months) 
No. with abnormal baseline brain 
MRI (%) 
163 (78.4%)  213 (75.5%) 
No. with abnormal follow-up brain 
MRI (%) 
167 (80.3%) 
 
218 (77.3%) 
No. with abnormal baseline cord 
MRI (%) 
45/130 (34.6%)  52/147 (35.4%) 
No. fulfilling 2005 McDonald 
criteria for DIS at baseline (%) 
 95 (46%)  123 (44%) 
No. fulfilling 2005 McDonald 
criteria for DIS at follow-up (%) 
 102 (49%) 
 
130 (46%) 
Median no. of T2 lesions at 
baseline 
6 (range 0-120)  6 (range 0-120) 
Median no. of T2 lesions at follow-
up 
7 (range 0-122)  7 (range 0-122) 
No. with new T2 lesion (%)  88 (42.3%)  115 (40.8%) 
No. with Gd lesion on follow-up 
(%) 
55 (26.4%)  72 (25.5%) 
No. developing CDMS (%)  85 (40.9%)   101 (35.8%) 
Median time to CDMS (range)  7.9 months (1-35 months)  12 months (1 to 68 months) 
 
Baseline MRI 
Brain MRI was abnormal in 163 (78%) at baseline. Abnormal baseline cord imaging 
was seen in 45/130 (35%) of patients where cord imaging was available; 5/45 with 
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abnormal cord imaging had normal brain imaging. The 2001 and 2005 McDonald and 
new DIS criteria were fulfilled in 95 (46%), 95 (46%) and 117 (56%) respectively 
 
Follow-up MRI 
Brain MRI was abnormal in 167 (80%) at follow-up. The McDonald 2001 and 2005 
and new DIS criteria were fulfilled in 104 (50%), 102 (49%) & and 123 (59%) 
respectively. New T2 lesions were seen in 88 (42%) and gadolinium enhancing 
lesions in 55 (26%) of follow-up scans.     
 
Clinical follow-up 
After 2 years 69/208 (33%) and after 3 years 85/208 (41%) had developed CDMS.  
 
Performance of the MRI diagnostic criteria (Table 7.3) 
With CDMS after 3 years as the outcome, the performance of the 2001 and 2005 
McDonald and new criteria, along with their DIS and DIT components alone, are all 
presented in Table 7.3. The main findings are: (i) all 3 criteria have high specificity 
(87-91%) and positive predictive value (77-79%) for CDMS; (ii) the new criteria 
(72%) are more sensitive than the 2005 McDonald criteria (60%), which in turn are 
more sensitive than the 2001 McDonald criteria (47%); (iii) for all 3 criteria, having 
both DIS and DIT gives higher specificities and positive likelihood ratios than either 
the DIS or DIT components alone; (iv) the DIT component of all 3 criteria is more 
specific than DIS alone with higher positive likelihood ratios.  
 
A new T2 lesion per se had a specificity of 80% when all cases were considered and 
81% in those whose baseline scan was performed more than 30 days from CIS onset 
(n=136); a gadolinium enhancing lesion per se on follow-up (all cases) had a 
specificity of 89%. When the new criteria were applied in the subgroup whose 
baseline scan was performed more than 30 days from CIS onset (n=136), specificity 
was 87% and sensitivity 69%.   
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Table 7.3 Performance of MRI criteria for development of clinically definite MS 
OVERALL CRITERIA 
 
DIS DIT 
  
No. test 
positive 
Sensitivity
(95% C.I) 
Specificity
(95% C.I) 
Accuracy 
(95% C.I) 
PPV 
(95% C.I) 
+ve L.R. 
(95% C.I) 
-ve L.R 
(95% C.I) 
McDonald 
2001  
McDonald 
2001  
51 
 
47.1% 
(36-58%) 
91.1% 
(85-95%) 
73.1% 
(67-79%) 
78.4% 
(65-89%) 
5.3 
 (3-10) 
0.6 
 (0.5-0.7) 
McDonald 
2005  
McDonald 
2005  
66 60.0% 
(49-70%) 
87.8% 
(81-93%) 
76.4% 
(70-82%) 
77.3% 
(65-87%) 
4.9 
 (3-8) 
0.5 
 (0.3-0.6) 
New criteria  
 
New criteria 
 
77 71.8% 
(61-81%) 
87.0% 
(80-92%) 
80.8% 
(75-86%) 
79.2% 
(68-88%) 
5.5 
 (3-9) 
0.3 
 (0.2-0.5) 
DISSEMINATION IN SPACE CRITERIA 
 
DIS DIT 
 
No. test 
positive 
Sensitivity
(95% C.I) 
Specificity
(95% C.I) 
Accuracy 
(95% C.I) 
PPV 
(95% C.I) 
+ve L.R. 
(95% C.I) 
-ve L.R 
(95% C.I) 
McDonald 
2001  
-----  104 76.5% 
(66-85%) 
68.3% 
(59-76%) 
71.6% 
(65-78%) 
62.5% 
(52-72%) 
2.4 
 (2-3) 
0.4 
 (0.2-0.5) 
McDonald 
2005 
-----  102 75.3% 
(65-84%) 
69.1% 
(60-77%) 
71.6% 
(65-78%) 
62.8% 
(53-72%) 
2.4 
 (2-3) 
0.4 
 (0.2-0.5) 
New criteria   -----  123 85.9% 
(77-92%) 
59.4% 
(50-68%) 
70.2% 
(63-76%) 
59.4% 
(50-68%) 
2.1 
 (2-3) 
0.2 
 (0.1-0.4) 
DISSEMINATION IN TIME CRITERIA 
 
DIS DIT 
  
No. test 
positive 
Sensitivity
(95% C.I) 
Specificity
(95% C.I) 
Accuracy 
(95% C.I) 
PPV 
(95% C.I) 
+ve L.R. 
(95% C.I) 
-ve L.R 
(95% C.I) 
------ McDonald 
2001  
55 51.8% 
(41-63%) 
88.6% 
(82-94%) 
73.6% 
(67-79%) 
75.9% 
(63-86%) 
4.6 
 (3-8) 
0.5 
 (0.4-0.7) 
------ McDonald 
2005  
80 68.2% 
(57-78%) 
82.1% 
(74-88%) 
76.4% 
(70-82%) 
72.5% 
(61-82%) 
3.8 
 (3-6) 
0.4 
 (0.3-0.5) 
------ New  criteria 
 
88 74.1% 
(63-83%) 
79.7% 
(71-86%) 
77.4% 
(71-83%) 
71.6% 
(61-81%) 
3.7 
 (3-5) 
0.3 
 (0.2-0.5) 
INDIVIDUAL DISSEMINATION IN TIME FEATURES 
 
DIT on follow-up scan 
 
No. test 
positive 
Sensitivity
(95% C.I) 
Specificity
(95% C.I) 
Accuracy 
(95% C.I) 
PPV 
(95% C.I) 
+ve L.R. 
(95% C.I) 
-ve L.R 
(95% C.I) 
New gadolinium enhancing 
lesion  
55 49.4% 
(38-60%) 
89.4% 
(83-94%) 
73.1% 
(67-79%) 
76.4% 
(63-87%) 
4.7 
 (3-8) 
0.6 
 (0.5-0.7) 
New T2 lesion All cases 
 
88 74.1% 
(63-83%) 
79.7% 
(71-86%) 
77.4% 
(71-83%) 
71.6% 
(61-81%) 
3.7 
 (3-5) 
0.3 
 (0.2-0.5) 
New T2 lesion  
& baseline scan at least 30 
days after CIS onset (n=136) 
56 68.9% 
(56-80%) 
81.3% 
(71-89%) 
75.7% 
(68-83%) 
75.0% 
(62-86%) 
3.7 
 (2-6) 
0.4 
 (0.3-0.6) 
 
 
Table 7.3 footnotes 
 
DIS = dissemination in space    DIT = dissemination in time 
+ve L.R. = positive likelihood ratio   -ve L.R.= negative likelihood ratio 
PPV = positive predictive value    95% CI = 95% confidence interval 
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When the baseline spinal cord MRI findings were excluded, there was slight decrease 
in specificity (New: 86% vs. 87%, McDonald 2001: 90% vs. 91%, McDonald 2005: 
87% vs. 88%) and sensitivity (New: 69% vs. 72%; 2001 McDonald 2001: 46% vs. 
47%; 2005 McDonald: 58% vs. 60%) of all 3 criteria. 
 
If the lesions in the symptomatic region were included in brainstem and spinal cord 
syndromes, the new criteria were slightly more sensitive and less specific (73% and 
85% respectively.) 
 
Clinical and MRI features of the survival analysis cohort (Table 7.2) 
The clinical characteristics of this group are very similar to the core cohort. There 
were 180 females (64%) and 102 males; median age at CIS-onset was 31 years (range 
14-52), median EDSS was 2 (range 0-8); 155 (55%) presented with optic neuritis, 57 
(20%) with a brainstem syndrome, 45 (16%) with a spinal cord syndrome and 25 
(9%) with other syndromes. All patients converting to CDMS before the end of their 
follow-up period were included as CDMS in this analysis (i.e. including those 
converting after 36 months). Duration of follow-up ranged from 3.3 to 119 months, 
median 40 months. One hundred and one patients (35.8%) converted to CDMS a 
median 12 months from CIS onset (range 1 to 68 months).  Of the 282 patients 
included in the survival analysis, 55 had received disease modifying treatment, which 
was initiated before a second neurological event in 13 patients and after a diagnosis of 
CDMS in 42 patients. Patients who only received disease modifying treatment after 
CDMS conversion were included in the ‘not receiving treatment’ group. 
     
Conversion free survival analyses (Figures 7.1 & 7.2 and Tables 7.4 & 7.5) 
 
Table 7.4: Cox regression survival analysis from time of CIS onset: all hazards ratios are compared 
with having neither DIS nor DIT (n=282) 
Criteria  Hazard ratio  95% C.I.  P 
DIS only  3.30  2.0 to 5.6  <0.001 
DIT only  2.52  1.6 to 4.1  <0.001 
All DIS  6.34  3.7 to 10.8  <0.001 
All DIT  8.43  4.8 to 14.9  <0.001 
McDonald 2001 
DIS&DIT  9.17  5.2 to 16.3  <0.001 
DIS only  2.64  1.6 to 2.1  <0.001 
DIT only  3.44  2.1 to 5.6  <0.001 
All DIS  6.72  3.8 to 11.8  <0.001 
All DIT  8.24  4.7 to 14.5  <0.001 
McDonald 2005 
DIS&DIT  9.71  5.4 to 17.3  <0.001 
DIS only  3.75  2.0 to 6.9  <0.001 
DIT only  3.45  2.1 to 5.7  <0.001 
All DIS  7.76  4.1 to 14.7  <0.001 
All DIT  10.33  5.4 to 19.9  <0.001 
New 
DIS&DIT  12.33  6.4 to 23.9  <0.001 
 
 
The following covariates had significant (or borderline significant) associations with 
conversion free survival probability and were therefore retained in the model for all 
survival analyses: (i) gender (less conversion in males); (ii) study centre (less 
conversion in Barcelona versus London patients); (iii) CIS location (higher 
conversion in non optic neuritis than optic neuritis patients); (iv) disease modifying 
treatment (slightly lower conversion in those receiving treatment).  Age was not 
significant, and made no material difference to estimates when included, and so was 
omitted from all models. 
 
 
Table 7.5: Cox regression survival analysis from time of CIS onset: 
Hazards ratios when all 3 ‘both DIS and DIT’ criteria are entered with covariates (n=282) 
  Hazard ratio  95% C.I  p 
New criterion  4.46
a 2.4-8.4  <0.001* 
2001 McDonald criterion  1.29
a 0.7-2.5  0.47 
2005 McDonald criterion  1.41
a 0.6-3.2  0.41 
Male vs. female  0.56 0.3-0.9  0.018* 
Barcelona  0.49 0.3-0.9  0.016* 
Amsterdam  0.64 0.3-  1.5  0.30 
Site: vs. London 
Milan  0.65 0.3-1.3  0.24 
Brainstem  1.58 0.9-2.8  0.11 
Spinal cord  1.96 1.0-3.9  0.058 
CIS type: 
Vs. Optic 
neuritis  Other  1.86 0.8-4.1  0.13 
Treatment  0.27 0.08-0.9  0.04* 
aHazard ratio for ‘both DIS and DIT’ vs. ‘neither or one only’. 
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In Table 7.4 the ‘DIS only’ and ‘DIT only’ hazard ratios estimate the independent 
increased conversion risks due to a patient having DIS or DIT, controlling for each 
other.  These hazard ratios were used to construct the corresponding survival curves 
in Figure 7.1.  The ‘DIS&DIT’ survival curve in Figure 7.1 was constructed by 
accumulating the hazards ratios of these independent DIS and DIT risks, making the 
assumption that the combined risk to a patient with both is simply the product of the 
two independent effects; this is the ‘DIS+DIT’ hazard ratio is shown in Figure 7.1.   
 
The ‘All DIS’ and ‘All DIT’ hazard ratios in Table 7.4 reflect the increased hazard 
ratios without controlling for each other, thus including any effect due to DIS positive 
patients tending also to be DIT positive and vice versa.  These hazard ratios were 
used to construct the corresponding survival curves in Figure 7.2.  The ‘DIS&DIT’ 
hazard ratio in Table 7.4 is estimated directly from an explicit comparison of the 
‘both DIS & DIT’ group with patients who are neither DIS nor DIT, without 
assuming independent effects, and this hazard ratio is used to construct the 
corresponding survival curves in Figure 7.2.  The ‘DIS&DIT’ hazard ratios with and 
without the independence assumption are quite similar, tending to confirm the 
validity of the independence assumption. 
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Figure 7.1: Survival probabilities for 
(i) neither DIS nor DIT 
(ii) DIS only (adjusted for DIT) 
(iii) DIT only (adjusted for DIS) 
(iv) both DIS and DIT.  
Figure 7.1a: 2001 McDonald criteria 
Figure 7.1b: 2005 McDonald criteria 
Figure 7.1c: New criteria 
All graphs adjusted for other 
covariates. 
 
 
0
.
1
.
2
.
3
.
4
.
5
.
6
.
7
.
8
.
9
1
s
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
0 1 2 3 4 5 6 7 8 9 10
Years from CIS onset
neither DIS only DIT only both
Conversion free survival predicted by New criteria
HR=12.93
HR=3.75
HR=3.45
0
.
1
.
2
.
3
.
4
.
5
.
6
.
7
.
8
.
9
1
s
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
0 1 2 3 4 5 6 7 8 9 10
Years from CIS onset
neither DIS only DIT only both
Conversion free survival predicted by 2005 McDonald criteria 
HR=9.08
HR=3.44
HR=2.64
0
.
1
.
2
.
3
.
4
.
5
.
6
.
7
.
8
.
9
1
s
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
0 1 2 3 4 5 6 7 8 9 10
Years from CIS onset
neither DIS only DIT only both
Conversion free survival predicted by 2001 McDonald criteria 
HR=2.52
HR=3.30
HR=8.33
a) 
b) 
c) 
  121    
 
Figure 7.2: Survival probabilities for  
(i) neither DIS nor DIT 
(ii) all DIS (i.e. not adjusted for DIT) 
(iii) all DIT (i.e. not adjusted for DIS) 
(iv) both DIS and DIT. 
Figure 7.2a: 2001 McDonald criteria 
Figure 7.2b: 2005 McDonald criteria 
Figure 7.2c: New criteria  
All graphs adjusted for other 
covariates. 
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For all three sets of criteria, Table 7.4 shows estimated hazard ratios are higher for 
patients with both DIS and DIT than for those positive on just one criterion alone, and 
this is reflected in the Fig 7.1 survival curves.  For the new and the 2001 McDonald 
criteria, ‘DIS only’ has a higher hazard ratio than ‘DIT only’, but this is reversed for 
the 2005 McDonald criteria, as reflected in the Fig 7.1 curves.  The ‘only’ hazard 
ratios are highest for the new criteria. 
 
As would be expected, Table 7.4 shows the ‘All DIS’ and ‘All DIT’ hazard ratios are 
closer to the ‘DIS+DIT’ hazard ratios, since they include the effect of patients with 
both; and this is reflected in the proximity of the survival curves for these groups in 
Figure 7.2.  For all three sets of criteria, the ‘All DIT’ hazards ratios are higher than 
for ‘All DIS’, again shown in Figure 7.2.  Table 7.4 shows the ‘All DIS’ and ‘All 
DIT’ hazards ratios are highest for the new criteria; this is reflected in Figure 7.2c, by 
the wider gap between the ‘neither’ curve and the other groups: the ‘neither’ New 
group has higher conversion free survival than for the other criteria, with rather 
similar curves for the other groups.   
 
When the three indicator terms for being DIS positive (by the three criteria) were 
entered together into a model (along with the covariates), the hazards ratios for the 
two McDonald criteria were substantially reduced and lost statistical significance, 
suggesting no evidence of further predictive contribution once the new criteria was in 
the model.  When the corresponding new criteria term was entered into the model, 
similar reductions in hazard ratios and loss of significance for the two McDonald 
criteria occurred for the DIT  positive criterion, and for the ‘both DIS and DIT’ 
criterion.  The details of the latter model are given in Table 7.5. This shows that the 
hazard ratio for being both new DIS and DIT positive, vs. neither or one only, is 4.46, 
and still highly significant, whereas the corresponding hazard ratios for the McDonald 
2001 and 2005 criteria are respectively 1.29 and 1.41, and no longer significant (when 
entered singly into the model the new and the 2001 and 2005 McDonald criteria gave 
highly significant hazard ratios of respectively 6.54, 4.21 and 5.12).   
 
The secondary analysis using time from second MRI scan, and excluding patients 
who converted before the second scan, gave very similar comparative results between 
the three sets of criteria, but with hazard ratios reduced throughout by around 15%.         
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7.4 Discussion 
Because all 3 criteria have a high specificity for CDMS, they provide a reliable 
diagnosis of MS within the first year after CIS onset. The similar positive predictive 
values (77-79%) indicate that most patients who fulfil any of the 3 criteria will 
develop CDMS within 3 years and further support their reliability as diagnostic tools. 
 
The 2001 McDonald criteria are less sensitive in detecting cases of MS in the first 
year of CIS follow-up. This relates to the requirement for a gadolinium enhancing 
lesion as evidence for DIT on follow-up when the baseline scan is performed less 
than 3 months from CIS onset (as usually occurs in practice). The McDonald 2005 
criteria allows a new T2 lesion after 30 days from CIS onset and this is the main 
reason for increased diagnostic sensitivity compared with the 2001 criteria (60% vs. 
47%). The new criteria allow a new T2 lesion seen at any time on a follow-up scan, 
which further increases sensitivity compared to the 2005 McDonald criteria (72% vs. 
60%), although the more liberal new DIS criteria also contributes. 
 
For all 3 diagnostic criteria, the DIS component per se was less specific for CDMS 
than the DIT criteria per se. Consistent with this observation; the survival curves 
show a higher HR for all DIT cases versus all DIS cases (Figure 7.2). The greater 
conversion to CDMS when there is DIT is consistent with studies in established MS, 
which show that relapses are more likely to occur in patients who develop new MRI 
lesions [153]. The lower specificity and positive predictive value of all the DIS 
criteria per se caution against making a diagnosis of MS in CIS patients until there is 
also evidence of DIT. The new DIS criteria were least specific (59%), and suggest 
that two lesions in two MS-characteristic locations are not sufficient to diagnose MS 
in CIS patients.   
 
A recent study from the same Magnims collaboration assessed the Barkhof-Tintore 
(i.e. 2001 McDonald) brain DIS criteria alone in a cohort of 349 patients followed up 
for at least 2 years, and found a higher specificity (79% vs. 68%) and lower 
sensitivity (49% vs. 75%) than the same criteria applied in my study cohort followed 
for 2 years [265]. A contributory cause for this difference is that there was a second 
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follow-up scan in the present study that identified additional cases of DIS. Another 
potential reason is that in the previous study, lesions were defined as areas of 
increased signal intensity greater than 3mm, whereas no such rule was applied in the 
present study and small white matter abnormalities that were considered to be definite 
were called lesions. While requiring a minimum lesion size may increase the 
specificity of DIS criteria, they will also become less sensitive, i.e. more cases of MS 
do not fulfil the criteria. In the North American Optic Neuritis Treatment Trial, 
lesions had to be >3mm in size for a scan at baseline to be considered abnormal and 
this may have contributed to the unusually low frequency of patients in whom any 
MRI abnormality was reported (46%) [74]. Deciding lesion size during reporting is 
problematic since actual measurement is impractical. It is also noteworthy that the 
specificity of both DIT and the overall diagnostic criteria were high in my study 
without requiring a minimum lesion size. It is doubtful whether a minimum lesion 
size is necessary, especially in the brain and when imaging is of high quality and has 
the slice thickness of this study (3-5mm). 
 
The high overall specificity of the new criteria (DIS + DIT both present) suggests that 
as long as DIT is present, the simpler new DIS criteria may be sufficient for 
diagnosis. The new criteria had the highest positive likelihood ratio and lowest 
negative likelihood ratio of the criteria tested, and were therefore the strongest at 
ruling in and out the disease respectively. Whereas sensitivity and specificity evaluate 
how the outcome predicts a particular test result, likelihood ratios do the reverse, i.e. 
evaluate how a particular test result predicts the risk of the outcome [270]. The 
simplified new criteria were also the only criteria that remained significant in the 
survival curve analysis when all 3 criteria were added to the model. Compared to the 
McDonald DIS criteria, the new criteria should be easier to remember and apply in 
practice; furthermore, they do not require gadolinium enhanced imaging, which 
provides time and cost savings that could be helpful in some health delivery settings 
and avoid rare adverse effects. Not including gadolinium enhancement in DIS criteria 
may seem logical since it is a feature of lesion state or activity, not location per se.  
The advantage of not administering gadolinium (time, costs & safety) most likely will 
counter-balance the slight loss of differential diagnostic information (e.g. 
leptomeningeal enhancement in sarcoidosis). A limitation of the new criteria is that 
they require two scans in order to show both DIS and DIT, and it is noted that when 
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the first scan is obtained at least 3 months after CIS onset, it is possible – using the 
McDonald criteria - for both DIS and DIT to be fulfilled on the single scan that 
includes gadolinium enhanced images.  
 
Spinal cord MRI was available in over a half of the patients at baseline, although 
inclusion of cord lesions as allowed by each of the three diagnostic criteria only 
slightly improved their specificity and sensitivity (increases ranging from 1-3%). 
Similar experience has been reported in previous analyses of a subgroup of CIS 
patients from one of the centres, where most patients had isolated optic neuritis [141, 
166], but not in a study of patients recently diagnosed with MS, which found a larger 
increase of sensitivity for the McDonald 2001 criteria [143]. Cord images were not 
available at follow-up to determine their impact on DIT. However, in established 
relapsing remitting MS, serial MRI shows considerably more new lesions occurring 
in the brain than in the cord [271] and it seems improbable that the situation is 
different in CIS patients. Spinal cord imaging will be required when there is a spinal 
cord CIS, especially if there is clinical concern that it is not due to inflammatory 
demyelination; it is unlikely to alter diagnostic classification in most patients with a 
non-spinal cord CIS, although detection of characteristic cord lesions may increase 
confidence that the syndrome is due to demyelination [272].  
 
In the 2005 McDonald DIT criteria, a new T2 lesion on follow-up scanning must be 
identified with reference to a scan obtained at least 30 days from CIS onset - this is 
intended to ensure that new T2 lesions are not attributable to the presenting event 
(monophasic disease) [167]. However, in the new criteria, a new T2 lesion on follow-
up scan is counted as DIT irrespective of timing of the baseline scan. Since many 
patients have their first scan within 30 days of CIS onset, it is advantageous to allow 
this scan as the baseline for determining subsequent DIT. The new criteria were 
equally specific (87%), whether applied to all cases or to the subgroup of patients 
with baseline scans after >30 days.  
 
In addition to the MRI criteria, several covariates had a significant effect on risk of 
conversion to CDMS. Females had a higher risk than males and this finding is 
consistent with some previous reports of cohorts with optic neuritis [273, 274]. 
Baseline brain MRI was more often abnormal in females than males (78% vs. 72%) 
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and this may have contributed to their higher risk of conversion. Compared with the 
London cohort, conversion to CDMS was less common in Barcelona patients. 
Baseline brain MRI abnormalities were less common in the Barcelona cohort (65% 
vs., 76%) and the prevalence of MS is probably lower in Spain than in the United 
Kingdom, as discussed in chapter 5 [77, 275]. These factors may have influenced the 
risk for developing CDMS. In chapter 6 concern was raised that the modified criteria 
were less specific in the non optic neuritis cohorts than the optic neuritis cohort. In 
this multicentre study with greater numbers of non optic neuritis patients, there was a 
trend for higher conversion rates in the non optic neuritis versus optic neuritis 
cohorts. This may also be related to the higher frequency of brain MRI abnormalities 
seen at presentation in the former groups (84% of non optic neuritis and 68% of optic 
neuritis) [77]. The lower rate of conversion to CDMS in the small group of 13 
patients who received disease modifying treatment before having a second clinical 
episode is consistent with the known effect of such treatment in delaying the time to 
convert from CIS to CDMS [72, 276, 277]. Importantly, the influence of all these 
covariates was taken into account in the survival model and the clear effect of the 
MRI diagnostic criteria on risk for CDMS was retained. 
  
There are several limitations to the present study. First, scanning was limited to the 
first year of follow-up; it does not evaluate the imaging criteria at longer intervals 
following CIS, although since CDMS will develop in more patients over time, their 
main use is to make an early and accurate diagnosis. Secondly, clinical follow-up in 
the core cohort was limited to 3 years. However, many who develop MS will do so 
within 3 years of a CIS, and the survival analysis captured additional subjects with 
later conversion to CDMS. There is also some evidence that a short interval to the 
first relapse has a poorer long-term prognosis [80, 81, 84], which gives added 
relevance to criteria that predict early conversion. Furthermore, a recently reported 
Kaplan Meier analysis of a CIS cohort followed up for a median of 7 years showed 
that the presence on baseline MRI of DIS using the Barkhof-Tintore criteria was a 
risk factor for both conversion to CDMS and disability [147]. Further investigation is 
warranted to evaluate the criteria after 5 or more years when more patients would 
have converted to CDMS. It may be that with longer follow-up, the DIS criteria alone 
prove to be more reliable in predicting long-term risk of MS as is suggested by the 
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survival curves. Longer follow-up would also clarify the long-term outcome 
following an early diagnosis of MS based on both MRI DIS and DIT. 
 
Thirdly, in all patients, scanning was performed on 1.5 Tesla or lower field strength 
scanners; 3 Tesla scanners are now entering practice and seem to impact at least the 
McDonald criteria [278]. Fourthly, all but 4 patients in this study had dual echo T2-
weighted (fast) spin echo rather than FLAIR imaging; the latter is more sensitive to 
juxtacortical and less sensitive to infratentorial lesions. While FLAIR imaging is 
useful as an adjunct to conventional T2-weighted scanning, the diagnostic criteria 
should be evaluated on the latter scans. Fifthly, disease modifying treatment was 
given before a second clinical event to 13 patients in the survival analysis cohort.  Of 
these patients the majority did not go on to have a second event thus explaining the 
significance of disease modifying treatment in the survival analysis. However, these 
patients were excluded from the analysis of the diagnostic criteria in the core cohort. 
Sixthly, because many patients did not have a lumbar puncture, cerebrospinal fluid 
findings were not included in the evaluation; however, cerebrospinal fluid oligoclonal 
bands are included in the McDonald DIS criteria.   Seventhly, the cohort remained 
weighted to ON presentation, (55% of the overall cohort), and spinal cord and 
brainstem presentations were under-represented. As non-ON presentations were 
significantly associated with increased conversion to CDMS in the Cox regression 
analysis, it would be helpful to have a more representative spread of CIS topographies 
for evaluation of the criteria in the different subgroups.  
 
Finally, the criteria were applied retrospectively to cohorts that were recruited in 
centres with an interest in MS and neuroimaging, and only cases considered to have a 
clinical syndrome characteristic for demyelination were included. The performance of 
the criteria in CIS patients with clinical features considered atypical for MS and in 
patients with other multifocal diseases of CNS white matter has not been addressed, 
nor have the criteria been assessed in a new, prospectively recruited cohort. 
Nevertheless, the patients in this study reflect the spectrum of CIS encountered at 
presentation in patients who go on to develop MS and, unlike the placebo arm of 
cohorts studied in trials of beta Interferon in CIS who were selected for the presence 
of MRI abnormalities, the present study includes patients with normal baseline MRI; 
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inclusion of such cases is necessary to properly evaluate diagnostic criteria. Overall, 
this study supports the use of MRI diagnostic criteria for MS in CIS patients. 
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Chapter 8 
Early MRI in optic neuritis. I: the risk for clinically definite MS  
 
8.1 Introduction 
As discussed in the previous chapters, white matter lesions characteristic of 
demyelination are seen on MRI in 50-74% of CIS patients at presentation [99, 137, 
138, 222, 279], and their shape, size, activity and location aid diagnosis. Whether 
such MRI characteristics have an additional prognostic role is of equal interest, and 
their ability to predict outcome is investigated in the following two chapters.   
 
Thirty eight to 78% of patients presenting with a CIS converted to clinically definite 
(CD)MS in studies of up to 20 years follow-up [61, 74, 147, 156, 280-282]. MRI 
studies have shown that patients with no lesions at presentation have a 15-22% risk of 
CDMS compared to 56-88% of patients with 1 or more lesions [61, 74, 147].  While 
the simple presence of lesions on MRI increases the likelihood of developing CDMS, 
the predictive effect of more detailed early MRI measures – including lesion number 
and volume, location and activity – has been less studied.  
 
Whereas long-term follow-up of an ON cohort and another mixed CIS cohort 
recruited in the 1980s showed no obvious effect of lesion number on the risk for 
CDMS [61, 74, 280], follow-up of a later CIS cohort (recruited in the 1990s) showed 
that risk of CDMS was stratified by baseline lesion number [147].  MRI contrast 
agents were not used in the early studies, and gadolinium-enhancing lesions (which 
are typically present for 2 to 8 weeks during the initial evolution of a new lesion and 
correspond  to active inflammation on histology [127]) have since been associated 
with conversion to CDMS [149, 162, 283, 284]. New T2 lesions on follow-up scans 
have also been reported to predict a subsequent clinical episode [140, 145, 149]. 
Certain locations of white matter lesions, namely periventricular, corpus callosum, 
juxtacortical, infratentorial and spinal cord are considered characteristic of 
demyelination and their relative contribution in predicting CDMS has been 
investigated at 0.5 or 0.6T [162].  Higher field strengths are now routinely acquired 
and may preferentially influence detection of lesions in certain locations. The spinal 
cord was not imaged in the early CIS cohort studies and asymptomatic cord lesions 
are found in 27%-42% of CIS patients at presentation [140-142]. These may add 
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independent prognostic information in patients with brain lesions [143, 285]. Lastly, 
changes in normal appearing brain tissue detected by non-conventional, quantitative 
MR techniques may help differentiate CIS patients at greatest risk of conversion to 
CDMS [180, 241, 286]. 
 
It is potentially important to identify patients who are at high risk of early conversion 
to CDMS, as such patients may be at greater risk of developing significant disability 
[81]. 
 
I therefore have now investigated in the ON subgroup of a CIS cohort who have been 
followed in the NMR Research Unit over the last decade [140-142, 164, 166, 241, 
287] whether brain lesion number at presentation demonstrated at 1.5T increased the 
hazard of a second clinical episode after an average follow-up of ~5 years. I also 
investigated whether location of lesions in the brain and spinal cord, or new brain 
lesion activity on an early follow-up scan or non-conventional MRI parameters adds 
prognostic information independent of total lesion number and volume.    
 
I have limited this follow-up report to the 80% of my CIS cohort who presented with 
ON due to limited statistical power of the small non-ON groups and to ensure all 
brain and cord lesions were asymptomatic.  
 
8.2 Methods 
Patients 
Patients aged between 16 and 50 within 3 months of ON onset with no previous 
neurological history suggestive of demyelination or evidence of CNS abnormality 
outside the optic nerves, were consecutively recruited from a Neuroophthalmology 
clinic at Moorfields Eye Hospital between 1995 and 2004 as part of a prospective 
follow-up study.  All patients were reviewed by a single neuroophthalmologist and 
blood tests were performed as required to exclude other causes.  Local ethics 
committee approval was obtained prior to starting the study, and informed consent 
was obtained from patients at each visit.  Follow-up assessments were planned at 3 
months, 1, 3 and 5 years from baseline and included MRI, history of further events, 
clinical examination and documentation of EDSS.  Patients were classified as CDMS 
where there was symptomatic and examination evidence of a second neurological 
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episode attributable to demyelination and occurring in a CNS location separate from 
the initial episode, of more than 24 hours duration and more than 4 weeks from the 
initial attack. Duration of follow-up was calculated as the time from ON onset to the 
last follow-up visit.  When patients were unwilling or unable to attend for follow-up, 
but were happy to be contacted, history was obtained over the telephone. As it was 
not possible remotely to confirm a second clinical episode, only patients who had 
been given a diagnosis of CDMS by a neurologist locally were classified as such for 
the purposes of this study. 
 
MRI acquisition protocols 
All images were acquired on a 1.5 Tesla GE scanner and have been described in 
detail in chapter 4 and summarised in Table 8.1. In this report, MRI findings at 
baseline and 3 month follow-up only are considered as the focus is on early imaging 
predictors. 
Table 8.1 summarising MRI acquisition protocols and image analysis, FOV: field of view, MTI: 
magnetisation transfer imaging, MRS: magnetic resonance spectroscopy GMF: grey matter fraction, 
WMF: white matter fraction, BPF: brain parenchymal fraction, TIV: total intracranial volume, NAWM 
normal appearing white matter, GM: grey matter 
 Slice 
thickness 
Orientation Matrix  FOV    TR/TE 
(comments) 
Image analysis 
Brain  
post 
contrast, 
baseline and 
3 months  
46x3mm contiguous 
axial slices 
256x256 24cm 3200/15ms   
3200/90ms  
600/14ms 
Number and location of T2, Gd-enhancing, T1-
hypointense  lesions identified by neuroradiologist 
and contoured using semi-automated thresholding 
technique to calculate volume [288].  
Ventricular volume measured on T1 weighted 
scans at baseline using MIDAS [239, 289].  
GMF, WMF and BPF calculated from SPM99 
segmented T2-weighted images following lesion 
masking [241]: GMF=GM/TIV, 
WMF=WM+lesion volume/TIV, 
BPF=GM+WM+lesion volume/TIV 
Cord  
post 
contrast, 
baseline  
9x3mm contiguous 
sagittal slices 
512x512 48cm 2500/56ms   
2500/98ms  
500/19ms  
Number of T2, Gd-enhancing lesions identified by 
neuroradiologist  
MTI 
[182, 290]  
pre contrast, 
3 months 
28x5mm contiguous 
axial oblique 
slices 
256x128 24cm 1720/30ms 
1720/80ms  
(MT weighted 
with application 
of presaturation 
pulse.) 
Lesion masks created on non-MT images, whole 
brain mask generated and segmented into NAWM 
and GM in SPM99 and applied to calculated MTR 
map determining NAWM and GM pixels. 
Normalised NAWM and GM histograms 
generated.  
1H-MRS 
[221] pre 
contrast, 3 
months 
 single  voxel 
manually 
placed in 
NAWM  
   3000/30ms 
(PRESS 
sequence with 
192 averages 
with optimised 
shimming and 
water 
suppression) 
Metabolite concentrations estimated using 
LCModel and spectra assessed for quality of 
acquisition and processing by observer blinded to 
the clinical data  
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Statistical analysis 
Cox proportional hazard regression was used to assess the association between early 
MRI parameters and time to CDMS in all patients followed up at least once from 
baseline scan (n=142).  In patients not converting to CDMS, duration of follow-up 
was used as the censoring time.     
 
Cox proportional hazard regression analysis was performed in 4 stages.  
 
Stage 1: the strongest independent predictors of CDMS on the baseline scan were 
determined from multivariate analysis from within each of 4 baseline scan variable 
types: (i) lesion load (T2 lesion number, T1-hypointense and T2 lesion volume); (ii) 
T2 lesion location (periventricular, juxtacortical, discrete cerebral, infratentorial and 
spinal cord); (iii) lesion activity (gadolinium enhancing lesions) and (iv) tissue 
volumetric measures (grey and white matter fractions (GMF, WMF), brain 
parenchymal fraction (BPF) and ventricular volume).  
 
Stage 2: the significant predictors from analysis within the 4 baseline scan variable 
types were entered together to identify the strongest overall independent predictors on 
the baseline scan.  
 
Stage 3: the 3 month scan was analysed in the same way as Steps 1 and 2 for the 
following variables: (i) new lesion activity (new T2 lesions, gadolinium enhancing 
lesions), (ii) 
1H-MRS measures (N-Acetyl aspartate (NAA), and myo-inositol (Ins) in 
normal appearing white matter (NAWM)), and (iii) MTR measures (NAWM and grey 
matter peak height, peak location and mean).  
 
Stage 4: the significant baseline and 3 month variables were entered together to 
identify the strongest overall independent predictors from both scans.  
 
Number of lesions were categorised into groups for statistical analysis. If there was a 
linear trend across the ordinal categories, and no evidence of non-linearity, the ordinal 
score was entered into the models. For analysis of baseline brain T2 lesion number, 
  133    
patients were grouped by percentiles to ensure similar sized groups (0, 1-4, 5-14 and 
15 or more brain lesions). The number of lesions at each given location and the 
number of active lesions (gadolinium enhancing or new T2 lesions) were analysed as 
(i) binary variable (i.e. presence of 1 or more lesions) and (ii) ordinal variable 
(grouped into 0,1 and 2 or more lesions). The baseline measures location and activity 
were chosen as they are useful in the differential diagnosis of white matter lesions 
[162, 266, 267] but it is less clear whether they affect prognosis.  
 
Volumetric measures (including lesion volumes), MTR and MRS variables were 
analysed as continuous variables. 
 
Age at onset and gender were entered and all models can be considered adjusted for 
these covariates. Where significant their respective hazard ratios (HR) are quoted. 
Disease modifying therapy was not initiated prior to developing CDMS and was not 
adjusted for. 
 
All statistical analysis was performed on Stata 9.2 statistical software (Stata 
Corporation, College Station, Texas, USA). 
 
8.3 Results  
Of 143 ON patients recruited, one was lost to follow-up after the baseline visit (a 
further patient was lost after the 3 month visit and two after both 1 and 3 year visits). 
Therefore 142 ON patients reviewed at least once from baseline were included in the 
Cox regression analysis. Demographic details and MRI findings are summarised in 
table 8.2. 
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Table 8.2: summarising demographic details of the cohort and MRI abnormalities at baseline and 3 
month follow-up and number of patients converting to CDMS, ON: optic neuritis, CDMS: clinically 
definite MS 
Age at ON onset  32 
Gender  46 (32%) male 96 (68%) female 
Median EDSS at baseline  1 (IQR 1-1) 
Median delay from ON onset 
to baseline MRI 
5 weeks (IQR 3-8) 
Median delay from ON onset 
to 3 month MRI 
20 weeks (IQR 13-29) 
Number attending 3 month 
follow-up 
127 (1 patient did not receive contrast) 
Number converting to CDMS 
by final follow-up 
57 (47%) 
 
Number converting to CDMS 
before 3 month follow-up 
8 (6%) 
Median time to CDMS  16 months (IQR 6-36) 
Duration of follow-up  non-converters 62 months (IQR 37-90) 
converters 61 months (57-80) 
No. of patients with:  % converting to CDMS 
with: 
MRI findings 
no lesions  ≥ 1 lesion  no lesions  ≥ 1 lesion 
Brain at baseline  31 (22%)  111 (78%)  10%  49% 
Periventricular at baseline  51 (36%)  91 (64%)  18%  53% 
Juxtacortical at baseline  59 (42%)  83 (58%)  27%  49% 
Discrete at baseline  65 (46%)  77 (54%)  23%  55% 
Infratentorial at baseline  97 (68%)  45 (32%)  34%  53% 
Spinal cord  104 (74%)  37 (26%)  34%  57% 
Brain and/or cord at baseline  28 (20%)  114 (80%)  7%  48% 
Gd enhancing at baseline  105 (74%)  37 (26%)  30%  68% 
New T2 at 3 months  81 (64%)  46 (36%)  22%  74% 
Gd enhancing at 3 months  102 (81%)  24 (19%)  31%  79% 
 
Baseline scan measures 
(i) Brain lesion number 
Abnormal baseline brain MRI per se was associated with a 7 fold increase in hazard 
of CDMS compared to normal brain MRI (HR 7.04 95% CI 2.19-22.56, p<0.001).  
 
Higher numbers of baseline brain T2 lesions were associated with increased 
conversion hazard: HR 1.81 (95% CI 1.40-2.34 p<0.001) was estimated per lesion 
group increase (female gender also associated with a significant increased hazard of 
conversion in this model: HR 2.17 95% CI 1.12-4.21 p=0.043). Linearity of the 
grouping variable was confirmed. For comparison with other studies, Figure 8.1 
depicts the hazard of conversion per baseline T2 lesion grouping category with 
respective hazard ratios (i.e. analysed as categorical rather than ordinal variable). 
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Figure 8.1 Kaplan Meier curve showing probability of converting to CDMS in ON 
patients and how this probability is affected by number of brain lesions on baseline 
MRI  
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.
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HR 4.96, p=0.012
HR 7.61, p=0.001
HR 10.69, p<0.001
 
 
Neither lesion volumetric measures nor the binary variable, abnormal brain MRI, 
contributed further to hazard of CDMS.  
 
(ii) Lesion location (Table 8.3) 
The number of lesions observed separately at each of the 5 possible, mutually 
exclusive locations (periventricular, juxtacortical, discrete cerebral, infratentorial and 
spinal cord) were entered together, while adjusting for total lesion volume, age and 
gender. All 5 locations were significant in univariate analysis.  
 
Periventricular location was significant in the ordinal model (HR 1.83 95% CI 1.21-
2.78 p=0.004), and approached significance in the binary model (HR 2.37 95% CI 
0.99-5.70 p=0.053). After stepwise removal of variables which were contributing 
least to the models, only periventricular location, T2 lesion volume and gender 
remained significant.  
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Table 8.3 showing binary and ordinal models analysing lesion location adjusted for total lesion volume 
after stepwise removal of variables contributing least to the model. 
 Hazard 
ratio 
p 95%  Confidence 
interval 
Binary model 
Presence of periventricular lesion(s)  3.56  0.001  1.71-7.44 
T2 lesion volume  1.09  0.003  1.02-1.16 
Female gender  2.29  0.014  1.18-4.45 
Ordinal model 
Periventricular lesion no. (0,1,≥ 2)  1.91  <0.001  1.34-2.73 
T2 lesion volume  1.08  0.011  1.01-1.15 
Female gender  2.31  0.013  1.19-4.47 
 
(iii) Baseline lesion activity (gadolinium enhancement) 
Gadolinium enhancing lesions were associated with a significant increase in hazard of 
conversion to CDMS whether analysed as binary (HR 3.19, 95% CI 1.88-5.40, 
p<0.001) or ordinal variables (HR 1.94, 95% CI 1.45-2.60, p<0.001) and on 
adjustment for T2 lesion volume, (HR 2.64, 95% CI 1.62-4.29 p<0.001 and 1.82, 
95% CI 1.37-2.41 p<0.001) respectively. Age and gender were not significant in 
analysis of baseline lesion activity. 
 
(iv) Tissue volumetic measures 
No volumetric measures (GMF, WMF, BPF or ventricular volume) were significant 
in Cox proportional hazards regression, even in univariate analysis. 
 
Multivariate analysis of baseline scan measures 
The significant variables from the baseline MRI parameters (gender, brain T2, 
gadolinium enhancing and periventricular lesions) were entered together to determine 
the significant independent predictors of CDMS at this time point.  
 
In the ordinal model, the contribution from brain T2 lesion number was no longer 
significant (HR 1.21 95% CI 0.81-1.82 p=0.350). In the binary model, abnormal brain 
MRI  per se was not significant (HR 2.30, 95% CI 0.65-10.74 p=0.172), and 
periventricular location approached significance (HR 2.30 95% CI 0.97-5.41 
p=0.057). The ordinal variable, brain T2 lesion number, was not significant in the 
binary model if it replaced abnormal brain MRI, (HR 1.28 95% CI 0.88-1.85 
p=0.201), (see Table 8.4). 
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Table 8.4 showing the models with baseline MRI parameters after removal of non-contributing brain 
T2 lesion number. 
  Hazard ratio  p  95% Confidence 
interval 
Binary 
Presence of periventricular lesion(s)  3.50  0.001  1.67-7.33 
Presence of Gd enhancing lesion(s)  2.09  0.008  1.21-3.61 
Female gender  2.00  0.041  1.03-3.89 
Ordinal 
Periventricular lesion no. (0,1,≥ 2)  1.92  <0.001  1.35-2.74 
Gd enhancing lesion no. (0,1,≥ 2)  1.52  0.008  1.12-2.08 
Female gender  2.02  0.039  1.03-3.93 
 
3 month scan measures 
In analysis of gadolinium enhancing and new T2 lesions at 3 months, only the latter 
were significant in binary (HR 6.78 95% CI 3.71-12.39 p<0.001) or ordinal models 
(HR 3.21 95% CI 2.26-4.54 p<0.001) and on exclusion of early converters (HR 6.31 
95% CI 3.34-11.96 p<0.001 and HR 3.09 95% CI 2.11-4.52 p<0.001 respectively).  
 
No MTR measures or metabolite concentrations were significant in univariate 
analysis.  
 
Combining baseline and 3 month scan measures (Table 8.5) 
When the significant variables from the baseline (gender, periventricular and 
gadolinium enhancing lesions) and 3 month analyses (new T2 lesions) were 
combined, baseline gadolinium enhancing lesions did not remain significant. Higher 
HRs were observed for new T2 than for periventricular lesions. The number of 
baseline brain lesions when added later did not contribute to prognosis independently 
of new T2 and periventricular lesions. Gender remained significant only in binary 
models. 
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Table 8.5 showing the final model with the strongest independent predictors of CDMS in ON patients 
from baseline and 3 month follow-up scans, including and excluding the early converters (patients 
converting before the follow-up scan) 
Excluding early converters   Hazard ratio  p  95% Confidence 
interval 
Binary 
Presence of baseline periventricular lesion(s)  2.62  0.029  1.10-6.22 
Presence of new T2 lesion(s) at 3/12  4.52  <0.001  2.29-8.97 
Female gender  2.43  0.026  1.11-5.31 
Ordinal 
Baseline periventricular lesion no. (0,1,≥ 2)  1.58  0.028  1.05-2.39 
No. of new T2 at 3/12 (0,1,≥ 2)  2.56  <0.001  1.71-3.84 
 
 
Including early converters   Hazard ratio  p  95% Confidence 
interval 
Binary 
Presence of baseline periventricular lesion(s)  2.41  0.033  1.07-5.42 
Presence of new T2 lesion(s) at 3/12  4.93  <0.001  2.58-9.41 
Female gender  2.10  0.039  1.04-4.26 
Ordinal 
Baseline periventricular lesion no. (0,1,≥ 2)  1.51  0.037  1.02-2.22 
No. of new T2 at 3/12 (0,1,≥ 2)  2.71  <0.001  1.86-3.93 
 
 
8.4 Discussion 
Effect of lesion number 
In contrast to results from the earliest CIS cohorts, the results from this study show 
that there is an increasing risk of conversion to CDMS with increasing number of 
lesions at baseline. This supports work by Tintore et al [147] who found that the 
number of lesions at presentation differentiated patients’ risk of CDMS. The optic 
neuritis treatment trial (ONTT) [74] found no significant difference in hazard of 
conversion to CDMS at 10 years in groups with 1 brain lesion compared to more than 
1 lesion. A Kaplan-Meier curve suggested differentiation between patients in the 
lesion groups although these appeared to converge over time. Similar findings have 
been reported in the 20 year follow-up from my centre of a mixed CIS cohort with the 
same risk of CDMS in patients with few or many lesions [280].  
 
There are two possible explanations for the different effect of lesion number between 
the earliest and more recent studies. Firstly the earliest studies used less sensitive 
methodology: the 20 year CIS follow-up cohort was scanned in the 1980s at lower 
field strength, and both the CIS and ONTT cohorts scans were acquired without 
contrast at greater slice thickness with spacing. It is possible that the findings of 
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recent studies reflect more sensitive lesion detection because scanning was performed 
at a higher field strength and image resolution. Secondly patients from lower lesion 
load groups may convert to CDMS with longer follow-up: the ONTT follow-up study 
was reported after 10 years and the early CIS cohort has been followed for 20 years. 
Tintore’s and this follow-up study suggest lesion load predicts conversion within a 
range of 5 to 7 years.  However time to CDMS may be important as early conversion 
is reported as a risk factor for disability in some studies [76, 80, 81, 84] and may be 
relevant in considering disease modifying treatments, which delay conversion to 
CDMS [72, 73, 108] and possibly disability [108]. However, the present study also 
showed that lesion location and activity measures were stronger predictors of CDMS 
than lesion load per se.  
 
Effect of lesion location 
Although location is helpful in the differential diagnosis of white matter lesions, it has 
been less clear whether lesion location in CIS patients affects prognosis. This study 
showed, adjusting for total lesion volume, that periventricular lesions increased the 
risk of conversion to CDMS and this variable remained consistently significant in 
subsequent models. This supports the inclusion of periventricular location in several 
diagnostic criteria [160-162, 266]. A reason why periventricular lesions may be more 
predictive of CDMS than other locations is that they occur more frequently (Table 
8.2) and with fewer patients converting in the absence of lesions in this compared to 
other locations. Periventricular lesion number correlated strongly with total T2 brain 
lesion number (Spearmans r=0.88). If the ordinal variable of brain lesion number and 
periventricular lesions were analysed together, neither remained significant due to 
this strong correlation, and because of this total lesion volume was adjusted for in the 
analysis of lesion location. However in the multivariate model of the baseline 
measures, gadolinium enhancing lesions and periventricular lesions remained 
significant but brain lesion number did not, suggesting that the former two measures 
provide sufficient information, one reflecting baseline lesion load and the other lesion 
activity. In effect periventricular lesions may be the best independent marker for 
lesion load. It should be noted that although total lesion volume was accounted for, 
regional volume of lesions was not.  Further analysis could investigate regional lesion 
volume and risk of conversion to CDMS. However, the identification of 
periventricular lesions per se as a predictor for CDMS has practical value as they are 
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readily observed on reading scans in routine clinical practice, whereas measures of 
lesion volume are not. 
 
In some studies cord lesions aid sensitivity of MRI diagnostic criteria [143, 285], but 
these were in cohorts of patients with clinically probable or definite MS many of 
whom had clinical evidence of spinal cord involvement. In this study asymptomatic 
spinal cord lesions, not investigated in the earlier CIS cohorts, were not significant in 
analysis with other baseline location variables, and therefore did not contribute to 
prediction independent of brain lesion measures.  
 
However, in the next chapter, I report an effect of cord lesions on the prognosis for 
disability.  
 
Effect of lesion activity 
When only one baseline scan was considered, gadolinium enhancing lesion(s) were 
an independent predictor of CDMS. However this effect was lost when follow-up 
scans were considered and new T2 lesions emerged as the strongest overall 
independent predictor of CDMS. New T2 lesion(s) are usually permanent, whereas 
gadolinium enhancing lesions are transient, lasting for several weeks on average.  The 
former provides a more sensitive measure of interval disease activity when the 
follow-up scan is performed several months or longer after the baseline study. This 
greater sensitivity probably explains the stronger predictive effect of new T2 lesions. 
The result suggests that there is a prognostic role for repeat imaging in the assessment 
of CIS patients and that non-contrast imaging may suffice at follow-up.  
 
 
Non-lesion MRI measures 
Perhaps disappointingly, none of the non-lesion measures obtained at a single early 
time point – grey matter and white matter tissue volumes, MTR measures and 
NAWM metabolite measures – were predictive of future development of CDMS in 
the present optic neuritis cohort. Abnormalities in the NAWM and grey matter have 
been reported in CIS cohorts including the present cohort [180, 182, 184, 217, 219-
221, 223]. A possible explanation for the lack of predictive effect is that the 
abnormalities in NAWM and grey matter at this very early stage of disease evolution 
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are mild and of themselves unlikely to cause significant clinical manifestations. There 
is evidence from serial studies in MS cohorts that abnormalities in the NAWM and 
grey matter increase over time [175, 187, 188, 193, 200, 211, 212, 218] and may also 
correlate with measures of clinical impairment [175, 187, 211, 218]. There is a 
previous report of increasing grey matter atrophy and ventricular enlargement over a 
period of 1 to 3 years in a subgroup of the present CIS cohort that was associated with 
the development of CDMS [239, 241]. Longitudinal investigation is now required of 
the evolution of non-lesion MR measures of NAWM and grey matter over a longer 
period of time and their relationship to the clinical course. 
 
Age was not significant in any of the analysis whereas the female gender was 
associated with 2 fold increase in hazard of conversion to CDMS in many models. 
Baseline brain MRI was more frequently abnormal in women than men (81% vs 
72%) and this may have contributed to the higher conversion. This is consistent with 
previous reports in patients with ON [273, 274]. 
 
Study limitations 
A limitation of this study was that not all patients had a 3 month follow-up scan and 
therefore the numbers of patients analysed at baseline and 3 months was different 
(142 and 127). Also only a subgroup of patients had MTR (n=89) and spectroscopy 
(n=85) as these were only acquired from 1998 onwards, after a proportion of patients 
had already been recruited and scanned. The smaller numbers may have affected the 
results.  
 
By only including the ON patients, conclusions cannot be drawn about predictors of 
conversion in other CIS patients and further investigation is needed for these other 
presentations. Some studies report lower rate of MRI abnormality and conversion to 
MS in ON compared to non-ON CIS [65, 66, 76, 77, 81, 84, 85]. However, similar 
rates of MRI abnormality in ON and non-ON CIS cohorts have been seen in 
Southeast England cohorts (including this one) followed in the NMR Unit [275, 280]. 
 
8.5 Conclusion 
When two early scans obtained 3 months apart in ON patients were analysed, only 
baseline periventricular lesions and new T2 lesions at follow-up were independent 
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predictors of CDMS. A new T2 lesion on an early follow-up scan was the strongest 
predictor of CDMS.  
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Chapter 9 
Early MRI in optic neuritis. II: the risk for disability  
 
9.1 Introduction 
In the previous chapter I explored the association of characteristic MRI findings in 
optic neuritis (ON) clinically isolated syndrome (CIS) patients and conversion to 
clinically definite (CD)MS and reported the features of lesion location and activity 
independently predicting conversion. In this chapter I investigate how the same MRI 
parameters predict disability at ~6 years. 
 
Of the 38-78% CIS patients converting to clinically definite MS (CDMS) [61, 78, 
147, 156] the subsequent clinical course is very variable. Up to two thirds of patients 
have minimal disability after 10 years [78, 291] whereas up to a half require aid to 
walk after 15 years [61, 292, 293].   
 
Whereas the optic neuritis treatment trial (ONTT) found no correlation between 
baseline MRI findings and disability at 10 years [78], other studies of mixed CIS 
cohorts have found a significant, although modest, association between baseline 
lesion load and disability at up to 20 year follow-up [61, 62, 146, 147].   
 
The relationship of disability with gadolinium enhancement, a marker of disease 
activity, has not been consistently demonstrated in patients with CDMS [150, 152, 
153, 156] and has not been investigated in unselected CIS cohorts [61, 78, 147]. 
Lesion location may also be important for prognosis, with one study concluding two 
or more infratentorial lesions were a significant predictor of disability [156].   
 
Post mortem MS studies have shown abnormalities in the normal appearing white 
matter (NAWM) [38, 39] and cortex [40] and compatible changes [136, 172, 196] 
have been demonstrated in vivo less than a year from CIS onset using non-
conventional MRI [181, 182, 187, 220, 221]. The potential of these non-lesion 
measures to identify CIS patients at greater risk of disability has not yet been 
explored through long-term clinical follow-up.  
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About 80% of the CIS cohort I have been investigating in the NMR Unit presented 
with ON, and some natural history studies report that ON presentation is associated 
with a more benign disease course than other CIS presentations [76, 77, 82] (although 
this was not found in all follow-up studies [61, 72, 276]). As in the previous chapter, I 
limited this follow-up report to ON only, in view of these observations, the small size 
of the non-ON CIS groups in the cohort and the potential difficulty in differentiating 
symptomatic from asymptomatic lesions in brainstem or spinal cord CIS. The aim of 
this study was to identify independent, early MRI predictors of subsequent disability 
after ~6 years in patients who present with isolated ON. Only scans obtained at 
baseline and 3 months later were used in this analysis. 
 
9.2 Methods 
Patients 
Patients aged 16-50 within 3 months of ON onset with no previous neurological 
history suggestive of demyelination or evidence of CNS abnormality outside the optic 
nerves, were consecutively recruited from a Neuroophthalmology clinic at Moorfields 
Eye Hospital between 1995 and 2004 as part of a prospective follow-up study.  All 
patients were reviewed by a single neuroophthalmologist and blood tests were 
performed as required to exclude other causes. Local ethics committee approval was 
obtained prior to starting the study, and informed consent was obtained from patients 
at baseline and each subsequent visit (planned at 3 months, 1, 3 and 5 years from 
baseline). Only patients who had reached the scheduled 5 year time point were 
included in this analysis. Follow-up visits included MRI, history of further events, 
clinical examination and documentation of EDSS. All examinations and EDSS scores 
at 5 years were performed by a single physician. Patients were defined as CDMS 
using the Poser criteria [106]. (The clinical criteria defined by Poser for CDMS, i.e. 
requiring clinical evidence of dissemination in space and time, were used as the aim 
was to investigate early MRI parameters predicting clinical outcome). 
 
MRI acquisition protocols and image analysis 
All images were acquired on a 1.5 Tesla GE scanner and have been described in 
detail in Chapter 4 and where referenced. In this report, MRI findings at baseline and 
3 month follow-up only are considered as the focus is on early imaging predictors. 
MRI acquisition protocols and image analysis are summarized in Table 9.1.  
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Table 9.1 summarising MRI acquisition protocols and image analysis, FOV: field of view, MTI: 
magnetisation transfer imaging, MRS: magnetic resonance spectroscopy, GMF: grey matter fraction, 
WMF: white matter fraction, BPF: brain parenchymal fraction, TIV: total intracranial volume, NAWM 
normal appearing white matter, GM: grey matter 
 Slice 
thickness 
Orientation Matrix  FOV    TR/TE 
(comments) 
Image analysis 
Brain  
post 
contrast, 
baseline and 
3 months  
46x3mm contiguous 
axial slices 
256x256 24cm 3200/15ms   
3200/90ms  
600/14ms 
Number and location of T2, Gd-enhancing, T1-
hypointense  lesions identified by neuroradiologist 
(KAM) and contoured using semi-automated 
thresholding technique to calculate volume [288].  
Ventricular volume measured on T1 weighted 
scans at baseline using MIDAS [239, 289].  
GMF, WMF and BPF calculated from SPM99 
segmented T2-weighted images following lesion 
masking [241]: GMF=GM/TIV, 
WMF=WM+lesion volume/TIV, 
BPF=GM+WM+lesion volume/TIV 
Cord  
post 
contrast, 
baseline  
9x3mm contiguous 
sagittal slices 
512x512 48cm 2500/56ms   
2500/98ms  
500/19ms  
Number of T2, Gd-enhancing lesions identified by 
neuroradiologist (KAM) 
MTI 
[182, 290]  
pre contrast, 
3 months 
28x5mm contiguous 
axial oblique 
slices 
256x128 24cm 1720/30ms 
1720/80ms  
(MT weighted 
with application 
of presaturation 
pulse.) 
Lesion masks created on non-MT images, whole 
brain mask generated and segmented into NAWM 
and GM in SPM99 and applied to calculated MTR 
map determining NAWM and GM pixels. 
Normalised NAWM and GM histograms 
generated.  
1H-MRS 
[221] pre 
contrast, 3 
months 
 single  voxel 
manually 
placed in 
NAWM  
   3000/30ms 
(PRESS 
sequence with 
192 averages 
with optimised 
shimming and 
water 
suppression) 
Metabolite concentrations estimated using 
LCModel and spectra assessed for quality of 
acquisition and processing by observer blinded to 
the clinical data (KTF) 
 
Statistical analysis 
Spearman correlation identified associations with MRI parameters and 5 year EDSS.  
Ordinal logistic regression was performed, with ranked follow-up EDSS as the 
dependent variable (cut-offs chosen to make approximately equal groups: EDSS 0, 1, 
1.5-2, ≥2.5) and MRI parameters as the independent variables. Univariate regression 
analysis identified significant predictors from the parameter types: baseline lesion 
load (T2 lesion number, T2 and T1-hypointense lesion volume), location 
(periventricular, juxtacortical, discrete cerebral, infratentorial and spinal cord), lesion 
activity (gadolinium enhancing lesions), volumetric measures (grey matter, white 
matter and brain parenchymal fractions (GMF, WMF, BPF), ventricular volume); 3 
month follow-up new lesion activity (gadolinium enhancing and new T2 lesions) 
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spectroscopy (N-Acetyl aspartate (NAA), myo-Inositol  (Ins)) and MTR (mean, peak 
height, peak location in NAWM and NAGM) measures.  
 
Multiple regression was performed in three stages.  
 
Stage 1: multiple regression identified the strongest of the significant predictors 
within each variable type, (lesion number, location, volumetric measures, lesion 
activity, spectroscopy and MTR) for each of the 2 time points separately. 
 
Stage 2: the significant predictors of different variable type from stage 1 were entered 
together to identify the strongest independent predictors for each time point scan.  
 
Stage 3: the variables from both time point scans were entered together, to identify 
the strongest overall independent predictors.  
 
Stages 1 to 3 were repeated, firstly excluding the patients whose EDSS had been 
obtained by telephone, and secondly in the subgroup of patients who had converted to 
CDMS by final follow-up. 
 
When variables did not remain significant in multivariate analysis, they were dropped 
stepwise (manually) from the model, and their contribution tested with the likelihood 
ratio (LR) test. When the LR test was borderline significant (p<0.1), the variable was 
maintained in the model, except in the final model where only variables p<0.05 were 
reported.  
 
Number of lesions were categorised into groups for statistical analysis. For analysis 
of baseline brain lesion number, patients were grouped by lesion number according to 
percentiles to ensure similar sized groups (0, 1-4, 5-14 and ≥15 lesions). Other lesion 
measures (location, gadolinium enhancing, new lesions) were grouped into binary (0, 
≥1) and ordinal (0, 1, 2 and ≥3 lesions) variables. If there was no evidence of non-
linearity, the ordinal score was entered into the model. Volumetric measures and non-
conventional MRI parameters were analysed as continuous variables. 
 
  147    
Other covariates (age, gender, baseline EDSS, disease modifying treatment and 
duration of follow-up) were added to the model at the end.  
 
Statistical analysis was performed using Stata 9.2 statistical software (Stata 
Corporation, College Station, Texas, USA). 
 
9.3 Results 
Of 143 ON patients recruited, 106 were recruited at least 5 years earlier, and of these 
100 were successfully followed up at the “5 year” time point (median duration of 
follow-up was actually 6.2 years), and phone EDSS was obtained for 25 patients 
unable to attend for clinical follow-up [248]. Demographic and clinical details are 
summarised in Table 9.2.   
 
Table 9.2 summarising demographic data of the 100 ON patients followed up at the scheduled 5 year 
time point (‘5 years’), median follow-up actually 6 years. 
Median age at CIS onset (IQR)  31.9 (28.2-37.9) 
Gender  33 (33%) ♂: 67 (67) ♀ 
Median time from CIS onset to 
baseline MRI (IQR) 
5 weeks (4-8) 
Median time from CIS onset to follow-
up MRI (IQR) 
20 weeks (18-23) 
Median duration of follow-up (IQR)  6.1 years (5.1 to 7.2) 
Clinical vs phone [248] EDSS  75:25 
Median EDSS in all patients at ‘5 
years’ (range) 
1 (0-8.5) 
Median EDSS in patients remaining 
CIS at ‘5 years’ (IQR) 
1 (0-1) 
Median EDSS in patients CDMS at ‘5 
years’ (IQR) 
2 (1-3) 
0  21 (21%) 
1  40 (40%) 
1.5-2  23 (23%) 
EDSS at  
‘5 years’ 
≥2.5  16 (16%) 
CIS 
RRMS       at ‘5 years’ 
SPMS  
52 (52%) 
43 (43%) 
5 (5%) 
MS by McDonald criteria at 5 years  66 (66%) 
Median time to CDMS (IQR)  17 months (6 to 36) 
 
Baseline and follow-up MRI findings are shown in Table 9.3 and results of univariate 
correlation and regression analysis are shown in Table 9.4. Lesion volume measures 
were not significant in univariate regression, however on exclusion of a single outlier 
both became significant (T2 and T1-hypointense lesion volumes ORs 2.13, p=0.034 
and 1.26 p=0.011 respectively). No brain tissue volume measures were significant.  
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Table 9.3 summarising MRI findings at baseline and 3 months in all patients and in the 5 year EDSS 
subgroups MTR magnetisation transfer ratio, NAWM normal appearing white matter, NAGM normal 
appearing grey  matter.   
  All patients  EDSS 0  EDSS 1  EDSS 1.5-2  EDSS≥2.5 
Baseline:  Median (Interquartile range) 
Brain T2 lesion 
number  
5 (1-16)  0 (0-4)  3 (0-16)  6 (3-16)  15 (6-29)  
Gd lesion 
number  
0 (0-1)  0 (0-0)  0 (0-0)  0 (0-1)  2 (0-6) 
T2 lesion 
volume, mls  
0.46 (0.05-
1.81) 
0 (0-0.34)  0.19 (0-1.67)  0.79 (0.23-
1.81) 
2.08 (0.48-
4.13) 
T1 hypointense 
lesion volume, 
mls  
0 (0-0.15)  0 (0-0)  0 (0-0.15)  0.03 (0-0.25)  0.09 (0-0.54) 
Cord T2 lesion 
number  
0 (0-1)  0 (0-0)  0 (0-0)  0 (0-1)  1 (0-2) 
Number of 
infratentorial 
lesions  
0 (0-1)  0 (0-0)  0 (0-0)  0 (0-2)  1 (0-2) 
Number of 
periventricular 
lesions  
2 (0-7)  0 (0-1)  1 (0-7)  3 (1-8)  7 (2-12) 
Number of 
juxtacortical 
lesions 
1 (0-4)  0 (0-1)  1 (0-3)  1 (0-5)  4 (1-9) 
Number of 
discrete cerebral 
lesions (IQR) 
1 (0-43)  0 (0-0)  0 (0-4)  1 (0-3)  2 (0-5) 
Ventricular 
volume  
6.41 (4.02-
10.13) 
6.27 (4.00-
8.40) 
5.97 (3.27-
10.71) 
6.86 (4.57-
10.76) 
5.98 (4.07-
8.75) 
Grey matter 
fraction  
0.49 (0.47-
0.51) 
0.50 (0.49-
0.51) 
0.49 (0.47-
0.51) 
0.48 (0.48-
0.51) 
0.48 (0.46-
0.50 
White matter 
fraction  
0.37 (0.36-
0.39) 
0.37 (0.36-
0.38) 
0.37 (0.36-
0.39) 
0.37 (0.36-
0.38) 
0.38 (0.36-
0.40) 
Brain 
parenchymal 
fraction  
0.86 (0.85-
0.87) 
0.87 (0.85-
0.88) 
0.86 (0.85-
0.88) 
0.86 (0.85-
0.87) 
0.85 (0.84 – 
0.87) 
3 month follow-up: Median (Interquartile range) 
Number of new 
T2 lesions  
0 (0-1)  0 (0-0)  0 (0-0)  1 (0-1)  2 (1-8) 
Number of Gd 
lesions 
0 (0-0)  0 (0-0)  0 (0-0)  0 (0-1)  1 (0-6) 
N-Acetyl 
Aspartate  
8.16 (7.61-
8.84) 
7.75 (7.37-
9.36) 
8.14 (7.54-
8.73) 
8.56 (8.12-
9.42) 
8.14 (7.26-
8.84) 
Myo-inositol   3.82 (3.06-
4.43) 
4.00 (3.38-
4.64) 
3.82 (2.78-
4.15) 
4.12 (3.31-
4.65) 
3.29 (2.74-
5.01) 
MTR NAWM 
peak height,  
20.88 (19.80-
21.87) 
19.76 (18.92-
21.62) 
20.63 (19.41-
21.41) 
20.78 (19.71-
22.26) 
21.11 (19.87-
22.12) 
MTR NAWM 
peak location,  
38.4 (38.0-
38.7) 
38.4 (38.2-
38.6 
38.4 (38.0-
38.8) 
38.4 (38.0-
38.7) 
38.2 (37.7-
38.5) 
MTR NAWM 
mean 
38.14 (37.84-
38.42) 
38.16 (37.89-
38.28) 
38.14 (37.86-
38.55) 
38.21 (37.89-
38.47) 
38.11 (37.54-
38.39) 
MTR NAGM 
peak height,  
13.05 (12.33-
13.73) 
12.78 (12.46-
13.68) 
13.07 (12.33-
13.72) 
12.52 (11.83-
13.11) 
13.20 (12.12-
14.04) 
MTR NAGM 
peak location,  
33.2 (32.9-
33.5) 
33.1 (32.7-
33.3) 
33.1 (32.9-
33.5) 
33.1 (32.8-
33.6) 
33.4 (32.8-
33.6) 
MTR NAGM 
mean 
32.32 (32.05-
32.61) 
32.05 (31.98-
32.41) 
32.33 (32.11-
32.55) 
31.89 (32.46-
32.63) 
32.26 (32.08-
32.71) 
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Table 9.4 Univariate analysis with spearman rank correlation coefficients and ordinal logistic 
regression derived odds ratios for baseline and follow-up MRI parameters (NB for regression analysis, 
lesion number variables were analysed as  score variables * grouped 0,1,2,≥3 lesions or 
# 0, 1-4, 5-14, 
≥15 lesions). MTR: magnetisation transfer ratio, NAWM: normal appearing white matter, NAGM: 
normal appearing grey matter 
 No.  of 
patients 
Spearman 
correlation 
coefficient 
p 
value 
Odds 
ratio 
p value 
BASELINE 
 
T2 brain lesion number 
#  100 0.425  <0.001  2.068  <0.001 
T2 brain lesion volume   100 0.422  <0.001  1.104 0.108 
T1 hypointense brain lesion volume   100 0.313  0.002  1.575 0.092 
T2 cord number *  100 0.367  <0.001  2.067 0.001 
Infratentorial  lesion number*  100 0.372  <0.001  2.500 <0.001 
Periventricular lesion number*  100 0.387  <0.001  1.809 <0.001 
Juxtacortical  lesion number*  100 0.333  <0.001  1.556 0.002 
Gd lesion number*  100 0.428  <0.001  2.072 <0.001 
Grey matter fraction  100 -0.222  0.027  0.894  0.088 
White matter fraction  100 0.077  0.448  1.040    0.687 
Brain parenchymal fraction  100 -0.178  0.077  0.852  0.058 
Ventricular volume (mls)   100 0.084  0.433  1.027  0.450 
3 MONTH FOLLOW-UP 
Number of new T2 lesions *  87 0.510  <0.001  2.470 <0.001 
Number of Gd lesions *  87 0.383  <0.001  2.514 0.001 
N-Acetyl aspartate  74 0.180  0.427  1.246  0.389 
Myo-inositol   74 -0.049  0.097  0.932  0.743 
MTR NAWM peak height  72 0.163  0.202  1.248 0.167 
MTR NAWM peak location  72 -0.089  0.486  0.848 0.735 
MTR NAWM mean   72 -0.079  0.537  0.883 0.811 
MTR NAGM peak height  72 -0.052  0.684  0.934 0.740 
MTR NAGM peak location  72 0.158  0.216  2.030 0.212 
MTR NAGM mean   72 0.102  0.426  1.493 0.494 
 
 
Logistic regression:  Multivariate analysis of relationship between early MRI 
measures and EDSS at follow-up 
 
1.) Baseline scan measures 
i. Lesion load The ordinal brain lesion variable (subsequently referred to as brain 
lesion number) was the strongest of the lesion load variables and a two-fold increase 
in risk of greater disability was estimated per lesion group increase (HR 2.07 95% CI 
1.47-2.91 p<0.001). T2 and T1-hypointense lesion volumetric measures did not 
contribute independently even on exclusion of the outlier (ORs for brain lesion 
number in analysis with T2 and T1-hypointense lesion volumes 1.78 (95% CI 1.14-
2.80) and 2.00 (95% CI 1.37-2.90, both p<0.001) respectively).  
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ii. Lesion location All 5 possible, mutually exclusive locations were analysed together 
(periventricular, juxtacortical, infratentorial, discrete cerebral, spinal cord), adjusting 
for brain lesion number. In the binary model, only spinal cord lesions remained 
significant, and infratentorial lesions approached significance. In the ordinal model, 
infratentorial and spinal cord lesions were both significant. After stepwise removal of 
non-contributing variables, only infratentorial, spinal cord and brain lesion number 
remained. In the binary model, the contribution from infratentorial lesions borderline 
significant (p=0.064) and was therefore retained. See Models 5a in Table 9.5. 
 
iii. Lesion activity When baseline gadolinium lesion(s) were added to Models 5a, 
brain lesion number no longer remained significant and was therefore dropped. In 
addition, in the binary model, spinal cord lesions did not remain significant, but 
removal showed their contribution to that model was borderline (p=0.087), and was 
therefore retained (see Models 5b in Table 9.5).  
 
iv. Tissue volumetric measures No volumetric measures were significant when added 
to the multivariate Models 5b.  
 
2.) 3 month follow-up scan measures 
i. New lesion activity In analysis of gadolinium enhancing and new T2 lesions at 3 
months, gadolinium enhancing lesions became insignificant leaving new T2 lesion(s) 
with a binary OR of 11.51 (95% CI 3.14-42.21 p<0.001) and ordinal OR of 2.42 
(95% CI 1.23-4.78, p=0.005).  
 
ii. Other variables No spectroscopy or MTR measure at 3 months were significant in 
univariate analysis and were therefore not further investigated.  
 
3.) Multivariate analysis combining baseline and 3 month follow-up scan measures 
Combining the significant baseline (spinal cord, infratentorial locations and 
gadolinium enhancing lesions) and 3 month parameters (new T2 lesions), gadolinium 
enhancing lesions became borderline significant in the ordinal model (p=0.054). 
Infratentorial lesions did not remain significant in the binary analysis. These variables 
were therefore dropped from the final model, see Model 5c in Table 9.5.  
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Table 9.5 showing Models 5a (analysis of 5 possible baseline lesion locations, adjusting for baseline 
lesion number, after removal of variables not contributing significantly to the models), Models 5b 
(analysis of all significant baseline lesion variables, baseline lesion load, location and activity 
measures, after serial removal of variables not contributing to the model) and Models 5c (showing the 
final model in all ON patients with significant lesion variables from baseline and 3 month follow-up 
MRI after serial removal of variables not contributing to the models). 
BINARY MODEL 5a (grouped 0, ≥1) n=100 
 
Location   Odds ratio  95% CI  p 
Infratentorial 2.36  0.95-5.86  0.065 
Spinal cord  2.51  1.02-6.15  0.044 
Grouped brain lesions  1.66  1.15-2.40  0.007 
ORDINAL MODEL 5a (grouped 0, 1, 2, ≥3) n=100 
 
Location   Odds ratio  95% CI  p 
Infratentorial 1.80  1.08-3.03  0.025 
Spinal cord  1.62  1.04-2.51  0.031 
Grouped brain lesions  1.87  1.08-2.29  0.019 
BINARY MODEL 5b (grouped 0, ≥1) n=100 
 
Location /enhancement  Odds ratio  95% CI  p 
Infratentorial 3.37  1.37-8.29  0.008 
Spinal cord  2.18  0.89-5.33  0.088 
Gd enhancing  4.93  2.21-10.98  <0.001 
ORDINAL MODEL 5b (grouped 0, 1,2, ≥3) n=100 
 
Location /enhancement  Odds ratio  95% CI  p 
Infratentorial 2.22  1.34-3.70  0.002 
Spinal cord  1.65  1.07-2.55  0.023 
Gd enhancing  1.84  1.25-2.70  0.002 
BINARY MODEL 5c (grouped 0, ≥1) n=87 
 
Parameter Odds  ratio 95%  CI  p 
Baseline 
Spinal cord  3.30  1.26-8.68  0.015 
Gd enhancing  2.78  1.02-7.59  0.045 
3 months 
New T2 3months  7.12  2.64-19.18  <0.001 
ORDINAL MODEL 5c (grouped 0,1,2, ≥3) n=87 
 
Parameter Odds  ratio 95%  CI  p 
Baseline 
Infratentorial 1.82  1.06-3.11  0.030 
Spinal cord  1.94  1.23-3.06  0.004 
3 months 
New T2 3months  2.06  1.34-3.18  0.001 
 
Other covariates 
Age, gender, baseline EDSS, disease modifying therapy and time between symptom 
onset and 5 year follow-up inserted into the models individually were not significant.  
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Excluding phone-EDSS patients 
Similar results were obtained at all 3 stages if we repeated the analysis excluding 
patients whose EDSS had been obtained over the phone rather than in person (n=75 at 
baseline and 69 at 3 months follow-up). The final binary and ordinal models 
contained only baseline spinal cord (OR’s 4.41, 95% CI 1.47-13.24, p=0.008, and OR 
2.35, 95% CI 1.35-4.07, p=0.002) and new T2 lesions at 3 months (OR’s 6.89, 95% 
CI 2.44-19.47, p<0.001 and 1.87, 95% CI 1.19-2.93, p=0.007). 
 
CDMS patients only 
If only those ON patients converting to CDMS by 6 years are investigated (n=48), no 
measures of baseline brain lesion load, location or activity were significant in 
univariate analysis. Only baseline cord lesions, GMF and BPF were significant in 
univariate analysis, however the volumetric measures did not remain significant after 
adjusting for age, leaving just cord lesions (ordinal OR 1.92, 95% CI 1.14-3.26, 
p=0.015, binary OR 5.07, 95% CI 1.60-16.11, p=0.006). No variable from the 3 
month follow-up visit remained significant in the patients who had converted to 
CDMS at 6 years.  
 
No other covariates were significant in the analysis of CDMS patients. 
 
 
9.4 Discussion 
In the previous chapter, the strongest independent predictor of conversion to CDMS 
was new T2 lesion(s), with periventricular lesions also being significant predictors, 
potentially acting as a surrogate marker of baseline lesion load. Brain lesion number 
was not significant in analysis with these other MRI measures. Similarly, in this 
study, early independent MRI predictors of disability in ON patients were measures 
of lesion location (spinal cord and infratentorial lesions) and activity (baseline 
gadolinium-enhancement and new T2 lesions at follow-up) rather than lesion load.  
 
Effect of baseline lesion load  
In this ON cohort, lesion number was a significant predictor of the 6 year EDSS in 
univariate analysis in agreement with the recently reported mixed CIS cohorts 
followed up at 7 and 20 years [61, 62, 146, 147]. However an important new finding 
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in the present cohort is that baseline lesion number was no longer significant in 
analysis including other MRI lesion location and activity parameters, which were not 
investigated in these other studies. Analysis of the NMR Unit’s earlier mixed CIS 
cohort also found brain lesion load at 5 years, cross-sectional and increase from 
baseline, correlated more strongly with EDSS at 14 and 20 years than did baseline 
measures [61, 62].  It may be that lesion increase over time is more predictive than 
one baseline measure and the significant effect of new T2 lesions at 3 months in the 
present study supports this idea: investigation of longer term changes in T2 number 
and volume in the present cohort will be of interest.  
 
Due to the presence of a single outlier, the continuous variable lesion volume was 
significant in spearman correlation (sensitive to values’ rank) but not in logistic 
regression (sensitive to values’ magnitude) where lesion number, analysed as an 
ordinal variable, was significant.  
 
The significant association between baseline brain lesion number and 6 year disability 
did not remain so in analysis of the patients converting to CDMS. Although still 
significant in the Unit’s earlier CIS cohort, the correlation between baseline T2 lesion 
volume and 20 year EDSS was weaker in the CDMS subgroup [62]. The Barcelona 
CIS study does not report this subgroup analysis [147]. The overall findings – in my 
and the Unit’s earlier CIS cohorts – suggest that baseline brain lesion load per se is a 
better predictor of conversion to CDMS than disability. That brain lesion load did not 
remain significant in the analyses including measures of lesion location and activity 
suggests that the latter lesion measures are more important with respect to disability 
than overall lesion load  per se.  
 
Lesion location and the effect of spinal cord and infratentorial lesions 
The spinal cord is considered a characteristic location for demyelination. 
Asymptomatic cord lesions, were seen in 26% of my ON cohort, and were reported at 
an earlier stage of study recruitment in 27% and 42% of CIS patients from the same 
cohort at presentation [141, 142].  Whether cord lesions add independent prognostic 
information in patients with brain lesions has not been clear and the previous chapter 
did not reveal any independent influence of cord lesions on the risk for CDMS. 
However this study shows the presence of asymptomatic cord lesion(s) at ON 
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presentation significantly increased the odds of higher disability at 6 years and in this 
effect was independent of and stronger than brain lesion load; there may therefore be 
a role for cord MRI in ON patients in considering the risk for future disability.   
 
Infratentorial lesions were significant in ordinal but not binary analysis, suggesting 
the number of infratentorial lesions influences the risk for disability. This study is 
concordant with the findings from a Dutch CIS cohort that 2 or more baseline 
infratentorial lesions in CIS patients were significant predictors of time to EDSS≥3 
[156]. Asymptomatic infratentorial lesions are found in CIS patients on MRI. An 
early study found brainstem and cerebellar lesions in 14% and 11% of ON CIS 
patients respectively [138]. Brainstem or cerebellar lesions were found in 31% of my 
ON cohort, and the increase in detection may be due to improvement in imaging 
technology. A role for infratentorial lesions in disability was supported by a study in 
which patients with progressive MS had similar numbers of supratentorial lesions but 
higher numbers of infratentorial lesions than age-, sex- and disease duration-matched 
patients with benign MS [294].   
 
Lesions in the spinal cord or brainstem are more likely to affect a clinically strategic 
pathway than supratentorial lesions. Although not always clinically eloquent at 
presentation, they may result in delayed symptoms through secondary degeneration or 
when subject to further episodes of inflammatory demyelination. The presence of 
such lesions at presentation may indicate a propensity for further lesions in the same 
region which themselves cause symptoms and subsequent sustained disability. In the 
supratentorial compartment there is potential for compensatory mechanisms and 
reorganisation of functional pathways; this potential may be less in the spinal cord 
and infratentorial regions where the threshold of axonal damage needed before 
clinical deficits develops may be lower.  
 
The lesion locations investigated were relatively large areas of the CNS rather than 
specific pathways that have immediate functional relevance. For example, lesions in 
specific tracts such as the internal capsule may have significant effects on later 
disability, and were not investigated in this study. 
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Effect of lesion activity measures 
MRI evidence of lesion activity added significant prognostic information with regards 
to disability in the whole CIS cohort, with both gadolinium-enhancing lesions at 
baseline and (more consistently) new T2 lesions on the follow-up scan being 
independent predictors of disability in the final model (Models 5c). However, neither 
of these remained significant predictors of disability when analysis was confined to 
the subgroup who converted to CDMS.  In the previous chapter, new T2 lesions were 
strongly significant in the final model predicting CDMS per se. These findings 
suggest that the lesion activity variables may be predicting conversion to CDMS 
rather than disability per se. This idea is supported by other studies which have found 
gadolinium lesions predict relapse occurrence but not later disability [152, 153].  
 
Non-lesion measures 
In the previous chapter, MTR and MRS parameters obtained 20 weeks from CIS 
onset were not significantly associated with conversion to CDMS in the ON cohort. 
Similarly there was no association with disability at 6 years. Although changes in 
MTR and MRS have been detected in CIS patients compared to controls, including 
this cohort, [181, 182, 187, 221], it is possible that the abnormalities in the NAWM 
and grey matter are mild at such an early stage of disease and unlikely to manifest 
clinically.  Longitudinal studies of CDMS patients have demonstrated changes in 
MTR [187] and MRS [211] over time, some of which correlated with clinical 
impairment [187, 211].  Further longitudinal investigation of CIS cohorts is required 
of the evolution of non-lesion MR measures and their relationship to the clinical 
course.   
 
In this study, baseline GMF was an independent significant predictor of disability in 
the subgroup of patients who converted to CDMS, but was confounded by age. 
Longitudinal atrophy measures were associated with the concurrent development of 
CDMS in this CIS cohort [239, 241]. Future analysis should investigate the 
relationship between longitudinal atrophy with later disability.  
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Study limitations 
The study has several limitations. Firstly, tissue volumetric measures were generated 
from 2D acquisitions as 3D acquisitions were not available in the patients recruited 
before 1998.    
 
Secondly, only about three-quarters of patients had MRS or MTR due to quality of 
acquisition or processing and lack of availability before 1998. Nevertheless, it seems 
likely that had there been a clear predictive effect of these MR measures an effect 
should have been apparent. 
 
Thirdly, this study was limited to the ON subgroup and is not necessarily applicable 
to non-ON presentations; some [76, 77, 82] but not all [61, 72, 276] studies have 
suggested that ON has a better long-term prognosis than non-ON presentations. When 
investigating the predictive role of lesion location in patients with brainstem and 
spinal cord CIS, special care will be needed to identify clinically silent infratentorial 
and spinal cord lesions. 
 
Fourthly, EDSS has been criticised for its emphasis on ambulation, which may 
explain the association with spinal cord lesions. MSFC was not used due to ceiling 
effects in a relatively unimpaired cohort. Also EDSS was obtained over the phone in 
25% of my cohort. Although clinical examination would have been preferable, in 
these patients it was impractical. Reassuringly similar results were obtained on their 
exclusion. 
 
Finally, only 12% of my cohort had EDSS≥3 at ~6 years and the median EDSS of the 
CDMS patients was 2. In the Unit’s earlier CIS cohort the median EDSS of the 
CDMS group was 3.25 and 4.0 after 14 and 20 years respectively [61, 62]. More 
prolonged follow-up is needed to determine whether the early predictors identified in 
this study are still relevant in the cohort as more disability emerges.   
 
 
9.5 Conclusion 
Several MRI lesion measures on scans obtained within 6 months of ON onset - 
number of baseline spinal cord and infratentorial lesions, baseline gadolinium lesions 
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and new T2 lesions after 3 months - predicted disability after 6 years; only spinal cord 
lesions were predictive of disability in those developing CDMS.   
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Chapter 10 Summary 
This thesis explores the diagnostic and prognostic roles of MRI at the earliest 
clinically manifest stage of relapse-onset MS, the clinically isolated syndrome (CIS). 
To be able to distinguish the patients at greatest risk of developing CDMS and, 
possibly more importantly, disability would help counsel patients and direct current 
and emerging disease modifying therapies.  
 
MRI has aided diagnosis of MS by detecting characteristic lesions on brain and cord 
images which help distinguish demyelination from other conditions. This has allowed 
incorporation of MRI findings into diagnostic criteria [161, 162, 167, 266, 267], with 
MRI evidence of dissemination in time and space replacing the need for clinical 
evidence, thus leading to earlier diagnosis, and potentially to therapeutic intervention. 
Trials have shown early treatment with disease modifying drugs delay subsequent 
clinical episodes and disability [72, 276] although the long-term benefit of these 
agents is still under investigation. In addition to the therapeutic benefits of early 
diagnosis, access to MS specialist clinics and personnel is equally important. 
 
MRI findings however are not the same around the world, with frequency of 
abnormalities at CIS presentation varying in a similar way to the variation in MS 
prevalence (Chapter 5). This has implications on the use of MRI in diagnosis and 
prognosis globally, as criteria evaluated in one region may not be as accurate in 
regions with different frequencies of MRI abnormalities. 
 
10.1 Diagnosis 
The results from Chapters 6 and 7 of this thesis show that sensitivity and accuracy of 
diagnostic criteria can be improved whilst maintaining high specificity. The criteria 
proposed in this thesis are also simpler than the current McDonald criteria [167, 266], 
requiring just 2 lesions in separate but characteristic locations for DIS and a new T2 
lesion as evidence of DIT, irrespective of timing of the baseline scan. In the 
preliminary study where the criteria were tested in my London CIS cohort, the 
sensitivity increased to 77% compared to 46% for the McDonald criteria, with 
specificity high at 92% (vs 94% for the McDonald criteria [266]). It was noted 
however that the criteria performed less well in the (small) non-ON subgroup.  
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Further evaluation of the MRI criteria was performed in a multicentre European CIS 
cohort, important in light of the observation that the frequency of MRI abnormalities 
in CIS patients varies in reports of other CIS and ON cohorts. It was also hoped to 
increase the proportion of non-ON presentations for better evaluation in that 
subgroup.  
 
Several points have come to light from these studies. Firstly the proposed simplified 
criteria performed well against the McDonald 2001 [266] and recently modified 
McDonald 2005 criteria [167]. The simplified criteria were the most sensitive at 
detecting cases of MS in the first year of CIS follow-up (72% vs. 47% and 60% for 
the 2001 and 2005 McDonald criteria respectively) whilst maintaining high 
specificity (87% for the simplified criteria, 91% and 88% for the 2001 and 2005 
McDonald criteria), thus being effective in excluding patients who do not develop 
CDMS. Secondly all DIT criteria were more specific than DIS criteria supporting a 
role for repeat imaging. Thirdly, spinal cord imaging only marginally increased the 
specificity and sensitivity of the criteria, suggesting it is of limited value in non-spinal 
cord syndromes. Fourthly, not all CIS presentations carried the same risk of CDMS. 
As highlighted in the preliminary study, in which the criteria performed less well in 
the non-ON subgroup, Cox regression analysis showed that CIS presentation was an 
independent risk factor for CDMS, with non-ON presentations having increased risk 
of conversion compared to ON patients. Finally conversion was lower in Barcelona 
than the other centres, where MS prevalence was also lowest [253]. However even on 
adjustment for these covariates in the survival analysis, the clear effect of the MRI 
diagnostic criteria on risk for CDMS was retained, and most strongly for the 
simplified criteria.  
 
Concern has been raised as to the timing of the baseline scan. To be confident that 
subsequent new lesions were disseminated in time from the initial clinical episode, 
the McDonald 2005 criteria stipulated that the baseline scan must be more than 30 
days from CIS onset, comparable to the clinical requirement for DIT. My results 
show that in these characteristic CIS presentations, (95% unifocal disease in the age 
range 16-50) the criteria were equally specific whether applied to cases with baseline 
imaging performed less or more than 30 days from CIS onset.  
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Therefore the proposed MRI criteria are more sensitive, accurate and simpler than the 
current McDonald 2005 criteria, whilst maintaining high specificity. 
 
10.2 Prognosis 
Whether MRI findings considered characteristic for demyelination affect prognosis 
was explored in the ON subgroup of my CIS cohort in Chapters 8 and 9. This was 
divided into risk of converting to CDMS and risk of disability. Analysis was 
restricted to the MRI parameters acquired at baseline and 3 months follow-up as the 
focus was on early predictors of clinical outcome.  
 
Our investigation of MRI parameters estimated hazard of conversion to CDMS and 
disability doubled with each increase in lesion group, supporting the findings by 
Tintore et al, where risk of conversion and disability increased with lesion number 
[147]. Long-term follow-up of two other CIS cohorts at 10 and 20 years found 
baseline lesion load did not predict conversion to CDMS [78, 280], as patients with a 
single lesion and multiple lesions had the same risk of CDMS. A modest correlation 
between baseline lesion load and disability at 20 years was found in the mixed CIS 
cohort [280]. The discrepancy between earlier and more recent studies may be due to 
differences in scan quality, with the recent studies being acquired at higher field 
strengths and/or resolution. Also it is likely that patients with lower lesion loads 
convert to CDMS with longer follow-up, and this is supported by the apparent 
convergence of curves in the Cox regression analysis in the ONTT by 10 years [78]. 
However as early conversion is reported as a risk factor for disability in some studies 
[80, 81, 84], distinguishing such patients may help with counselling and potentially 
directing disease modifying therapy. Therefore these results suggest number of 
lesions detected on scans of today’s image resolution and field strength influence risk 
of conversion to CDMS and development of disability. 
 
However, the prognostic studies in this thesis suggest that MRI lesion characteristics 
other than the total number, not investigated in the earlier studies, are better 
independent predictors in ON CIS. Although baseline brain lesion number was 
significant in univariate analysis predicting conversion to CDMS or disability at 5 
years, it did not remain so in analysis with MRI parameters of lesion location and 
activity.  
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Lesion activity was a significant risk factor, and new T2 lesions were the strongest 
predictors of CDMS and disability. For the most part gadolinium-enhancing lesions 
did not contribute independently of new T2 lesions, although were strong predictors if 
only baseline imaging was considered. Gadolinium enhancing lesions are transient 
whereas new T2 lesions are usually permanent and are therefore a more sensitive 
measure of new disease activity. As neither new T2 lesions nor gadolinium enhancing 
lesions remained significant in analysis predicting disability in the subgroup who 
converted to CDMS, the lesion activity variables may be predicting conversion to 
CDMS rather than disability per se as subsequent clinical episodes are required to 
develop disability. Just as we concluded in the evaluation of MRI diagnostic criteria, 
repeat imaging is helpful in the assessment of CIS patients. Although risk of CDMS 
increases with increasing baseline brain lesion load, this becomes insignificant in 
analysis with new T2 lesions. Thus specificities are improved with addition of DIT 
criteria.  
 
Investigation of lesion location in the ON CIS group revealed that independent of 
total lesion load periventricular location was consistently associated with an increased 
risk of conversion to CDMS and seemed to act as a surrogate measure of baseline 
lesion load. Just as spinal cord lesions added little to the performance of MRI criteria, 
they did not independently predict conversion to CDMS. However, spinal cord 
lesions were consistently associated with increased disability, and in the CDMS 
subgroup were the only predictor. Therefore there is a potential role for spinal 
imaging in non-spinal cord presentations. 
 
Disappointingly none of the non-lesion measures were significant in predicting 
CDMS or disability. Although MTR and spectroscopy data was not available for all 
patients, it was for the majority and if they had had a clear predictive effect this 
should have been apparent. Changes have been detected in NAWM and grey matter 
in CIS patients compared to controls [180, 182, 184, 217, 219-221, 223], but this 
study suggests they are too mild at this early stage to cause clinical manifestations. 
Just as lesions accumulate over time, so too do changes in non-lesion brain tissue 
[175, 187, 188, 200, 211, 218] which have been shown to correlate with measures of 
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clinical impairment [175, 187, 211, 218]. Longitudinal studies are required to assess 
their relationship with outcome. 
 
10.3 Future questions 
Our observational study of global MS prevalence suggested an association with MRI 
abnormalities in ON patients at presentation. It would be useful to take this 
hypothesis further with a prospective study as the accuracy of MRI in diagnosis and 
prognosis will vary globally depending on the strength of this association.   
 
Regarding diagnosis, the studies in this thesis were performed retrospectively on 
cohorts of patients presenting with a clinical syndrome characteristic of 
demyelination on scans acquired at 1.5T. Future work should evaluate the diagnostic 
criteria in a new, prospectively recruited CIS cohort, ideally in another multicentre 
study. This could be an opportunity to compare the accuracy of the criteria at 1.5T 
and higher field strengths. As these are becoming increasingly available their 
increased sensitivity to white matter lesions will require re-evaluation of the criteria 
[295, 296]. The non-ON CIS subgroup remained a small proportion of the multicentre 
analysis of the diagnostic criteria, and ideally future prospective cohorts would have a 
better balance of CIS topography. Also it is important to assess how the criteria 
perform in a clinically mixed cohort, and whether they can distinguish demyelination 
from other multifocal white matter conditions. Longer follow-up will be important to 
assess whether the specificity of the criteria falls as patients with lower lesion loads 
and slower lesion accrual convert with time increasing the number of false negatives. 
As newer imaging techniques become available, such as double inversion recovery 
which has higher sensitivity to cortical lesions [168], the incorporation of such 
findings into diagnostic criteria will be of interest. Lastly, investigating whether the 
presence of oligoclonal bands in the CSF allows reduction of the DIS or DIT criteria 
to maintain accuracy would be important. 
 
Regarding the role of MRI in prognosis, both studies were limited to ON 
presentations and may not extrapolate to non-ON CIS. Further investigation of a 
mixed CIS cohort would be of interest. It would be interesting to investigate whether 
the clinically silent spinal cord and infratentorial lesions predict disability through 
secondary degeneration or by representing a predisposition to inflammation in these 
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locations giving rise to brainstem or spinal cord syndromes. That is, can sustained 
disability arise from initially clinically silent lesions or must they manifest clinically? 
In light of recent work on the association between neuromyelitis optica and anti-
aquaporin 4 antibody [297], it would be interesting to investigate the antibody’s 
presence in the sera of the ON cohort and determine whether it is associated with 
those presenting with spinal cord lesions and/or developing disability.   
 
Longer follow-up would help determine whether the MRI parameters highlighted in 
this thesis as being important for predicting conversion to CDMS continue to be so as 
more patients with lower lesion loads convert. Also only 12% of my cohort had 
EDSS≥3 at ~6 years. With time a more disabled cohort with potentially greater spread 
of disability may emerge, and it is important to investigate whether the significant 
early MRI predictors of disability remain so. This thesis concentrated on early MRI 
parameters, only looking at the scans obtained at baseline and 3 month follow-up. 
The timing of the second scan was not investigated and as new T2 lesions were the 
strongest predictor of CDMS it would be useful to know the optimum time for a 
repeat scan. It seems likely that earlier repeat imaging lowers the sensitivity but 
increases the specificity and vice versa. Early non-lesion measures did not contribute 
to prognosis in this study, although differences have been detected in CIS patients at 
this early stage. Longitudinal study of these quantitative variables will be important to 
elicit the stage when they become important for prognosis, which may be as the 
association between T2 visible lesions and disability plateaus. The disadvantage of 
longitudinal quantitative measures is the inherent delay in obtaining them and 
sensitivity to change in hardware. 
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